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1 Introduction 
1.1 Transition Metal-Catalyzed C−H Bond Functionalization 
In the past decades, transition metal-catalyzed cross-coupling reactions have been considered as one 
of the most powerful and reliable methods for chemo- and site-selective construction of 
carbon−carbon (C−C) or carbon−heteroatom (C−Het) bonds.1-4 Besides academia, these reactions 
have also been widely employed in pharmaceutical, agrochemical, and fine chemical industries.5,6 For 
their magnificent contribution for palladium-catalyzed cross-coupling reactions, R. F. Heck, E. Negishi 
and A. Suzuki were awarded the Nobel Prize in chemistry in 2010.7-9 The generally accepted 
mechanisms for these palladium-catalyzed cross-coupling transformations are illustrated in Scheme 
1.1. In both types of coupling reactions, first step is the oxidative addition of the aryl halide (or 
pseudohalide) to the catalytically active palladium(0) species which initiates the catalytic cycle. At 
this stage the processes diverge. In the Mizoroki-Heck10,11 reaction, the reaction progresses by 
coordination of an alkene to the palladium(II) species followed by syn-migratory insertion and 
syn-β-hydride elimination to form the substituted alkene product, and subsequently base-assisted 
elimination to regenerate the active palladium(0). In the Negishi12 and Suzuki-Miyaura13 
cross-coupling reactions, the oxidative addition is followed by transmetalation of an organometallic 
or main group element species to generate a Palladium(II) intermediate. Subsequent reductive 
elimination results in C−C bond formation with the regeneration of palladium(0) species to complete 






































Scheme 1.1: General catalytic cycles for Mizoroki–Heck, Negishi, and Suzuki–Miyaura reactions 
 
Despite the various applications of these reactions, the use of pre-functionalized starting materials 
and generation of stoichiometric amount of undesired byproducts remain major disadvantages. As a 
more atom- and step-economical14,15 alternative, C−H functionalization has recently emerged as a 
valuable tool allowing the transformation of otherwise unreactive C−H bonds (Scheme 1.2).16-24 
Furthermore, the direct construction of C−C bonds by functionalizing two C−H bonds including 
C(sp3)−H bonds, which was termed as cross-dehydrogenative coupling (CDC),25 has been extensively 
studied.26,27 
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Scheme 1.2: Strategies for C−C and C−Het bond formation 
 
Depending on the nature of the transition metal M and the ligand set Ln, the elementary step of C−H 
bond metalation was proposed to proceed via different pathways. Ackermann as well as Eisenstein 



















































Scheme 1.3: Different mechanisms for C−H metalation 
 
Oxidative addition is a common mechanism in which a C−H bond first coordinates to the metal 
vacant site and is then cleaved to form a M−H bond and a M−C bond (Scheme 1.3a). This process 
often occurs for electron-rich, low-valent late transition metals (Re, Fe, Ru, Os, Ir and Pt). However, 
early group 3 and 4 transition metals as well as lanthanides (d0 configuration) usually do not undergo 
oxidative addition. Therefore, for these metals σ-bond metathesis (SBM) is more common (Scheme 
1.3b). Similar reactivity is observed for late- or post-transition metals (Pd2+, Pt2+, Pt4+, Hg2+) in strongly 
polar medium, electrophilic attack of the metal occurs in which the metal largely acts as a Lewis acid 
and thus classified as electrophilic substitution (Scheme 1.3c). C−H bond activation can also proceed 
via 1,2-addition to unsaturated M−X bonds (Scheme 1.3d). 
 
In the early 1970s, work by Shaw and Gaunt highlighted the importance of stoichiometric amounts of 
NaOAc for successful cyclometalation of N,N-dimethylaminomethylferrocene (1) (Scheme 1.4).29 
Subsequently, Reutov and co-workers found that carboxylic acids are competent additives for the 
same transformation and furnished products with moderate enantiomeric excess.30 More 
importantly, a transition state of concerted carboxylate-assisted intermolecular deprotonation17 was 
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Scheme 1.4: Base-assisted cyclometalation and proposed transition state 3 
 
In this context, theoretical calculations have offered new insight into the mechanism of base-assisted 
C−H metalation. Based on computational studies, Davies and Macgregor described such reaction as 
ambiphilic metal-ligand activation (AMLA),31 whereas Fagnou used the term 
concerted-metalation-deprotonation (CMD).32 Both proposals favor a similar six-membered transition 
state, however, Davies and Macgregor suggested an agostic interaction between metal center and 




















Scheme 1.5: Proposed transition state for base-assisted C−H activation 
 
The groups of Oxgaard and Goddard reported detailed experimental and computational studies on 
C−H bond activation of benzene by iridium complexes. Herein, a four-membered transition state was 
proposed and described as internal electrophilic substitution (IES).33 
1.2 Site-Selectivity in C−H Bond Functionalization  
C−H bonds are ubiquitous in nature, a characteristic which on one hand facilitates their usage as 
starting material for elaboration of more complex structures. However, on the other hand, this makes 
controlling the site-selectivity of C−H functionalization a great challenge. In electrophilic aromatic 
substitution, it has been well established that electron-donating substituents direct incoming 
electrophiles to the ortho- (6) and para-positions (7), whereas electron-withdrawing substituents lead 
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Scheme 1.6: Site-selectivity in electrophilic aromatic substitution 
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In spite of the synthetic importance of this classic selectivity pattern, accessing the isomers which are 
not anticipated by these rules remained a challenge. Over the last few decades, C−H functionalization 
involving the use of directing groups (DGs) has become the most common approach that allows 
access to ortho-functionalized aromatic compounds through chelation-assisted cyclometalation34,35 or 
weak coordination.20 A directing group usually bears a heteroatom of which the lone pair of electrons 




Scheme 1.7: Coordination mode of a DG in transition metal-catalyzed C−H functionalization 
 
The same principle has previously been utilized in the stoichiometric directed ortho-metalation 
(DoM), discovered independently by Gilman36 and Wittig37 in the late 1930s. In this approach, an 
aryllithium intermediate is formed by ortho-deprotonation following the chelation of lithium by the 
direct metalation group (DMG). Subsequent attack by an electrophile delivers the 
ortho-functionalized product. Scheme 1.8a shows a recent example of preparing ortho-substituted 
naphthalenes 9 and 10 via carbamate assisted DoM.38 It is worth noting that the DoM strategy can be 
employed for the preparation of meta-substituted products as well. For example, the group of Brown 
demonstrated that utilizing removable sulfoxide group as DMG smoothly gave rise to 
































Scheme 1.8: Examples of site-selective DoMs 
 
Although the DoM strategy usually exhibits high reactivity and efficiency, there remain certain 
drawbacks. First, the necessity of using stoichiometric amounts of strong base inevitably produces 
stoichiometric amounts of salt waste. Second, employing very reactive strong base largely limits the 
potential substrate scope in terms of functional group tolerance. 
 
Besides using directing groups, the site-selectivity can also be controlled by employing electronically 
activated substrates.40 For example, the group of Yu developed palladium-catalyzed C−H olefination 
of electron-deficient arenes 14,41 wherein the most acidic meta-C−H bond is predominately 
functionalized (Scheme 1.9). Systematic theoretical study of this reaction has been performed. It was 
calculated that the initial C−H activation step proceeds via concerted metalation-deprotonation (CMD) 
pathway.42  
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 O2 (1 atm)
  Ac2O (1.0 equiv)
Ligand (20 mol % )









Scheme 1.9: meta-Selective C−H alkenylation of electron-deficient arene 14 
 
Palladium-catalyzed norbornene-mediated ortho-selective C−H functionalization of iodobezene 
derivatives 18, which is also known as the Catellani reaction, allows for the facile construction of up 
to three C−C bonds in a site-selective fashion.43 Given its unique site-selectivity, considerable 
attention has been drawn in extending the synthetic utility of this transformation over the last 
decade.44,45 Recently, the group of Dong developed an elegant example of employing Catellani 
reaction for site-selective C−H amination of arenes 18.46 Comparing to the well-known 
Buchwald-Hartwig amination,47 this novel approach provided amination products exclusively at 
ortho-position (19) rather than ipso-position (20) (Scheme 1.10). More importantly, this method 
offers broad implications for developing various dual functionalizations of arenes that involve 



































Scheme 1.10: Different selectivity patterns in palladium-catalyzed aminations 
 
Based on their previous work of using carboxylic acids as directing groups for formal meta-selective 
direct arylation of phenols,48 in 2014, Larrosa and co-workers modified their methodology by 
installing carboxylic acid as a traceless directing group in situ which enabled palladium-catalyzed 
ortho-selective arylation and can be cleaved under the same reaction conditions (Scheme 1.11). This 
improved method avoided the pre-functionalized phenols (21) and the overall meta-arylation process 
proceeded in a one-pot fashion.49,50 
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21, KOH (3 equiv), 50 °C, 10 min; then
CO2 (25 atm), 100 °C, 2 h; then
22, PEPPSI-IPr (2 mol %), Ag2CO3 (0.5 equiv)






















Scheme 1.11: One-pot direct meta-arylation of phenol 21 
 
In spite of the above mentioned approaches for achieving meta- or formal meta-selective C−H bond 
functionalizations, developing more general methods to directly access meta- or para-positions of 
aromatic compounds with high site-selectivity remains a challenge.51-53 
 
One major breakthrough was achieved by the groups of Smith54 and Hartwig.55 They have reported 
one-pot iridium-catalyzed C−H borylation and sequential functionalization of 1,3-disubstituted arenes 
at C-5 position. Most recently, Hartwig and co-workers disclosed rhodium-catalyzed meta-selective 
C−H silylation of unactivated arenes (26).56,57 The resulted silylarene products 27 are very useful 
building blocks for organic synthesis (Scheme 1.12). In this type of transformations, regio-selectivity 
was proposed to be governed by a combination of the steric bulkiness around the catalyst and the 
substituents on the arenes.58 
[Rh(coe)2OH]2 (1.0 mol %)
Ligand (2.2 mol %)
[Si]-H (2 equiv)
cyclohexane (2 equiv)















Scheme 1.12: Rhodium-catalyzed meta-selective C−H silylation 
 
A second breakthrough in achieving meta-selectivity is through coordination of transition metal 
catalyst to a rational designed template which facilitates the approach of the catalyst to the remote 
meta-C−H bond. This novel method, in which the first palladium-catalyzed meta-selective 
alkenylation assisted by a removable nitrile-containing directing group in substrates 29 via a highly 
strained, tricyclic-cyclophane-type palladated intermediate was achieved (Scheme 1.13), was 
developed by the group of Yu in 2012.59  
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15a29a (R = Me)
29b (R = F)
30a (R = Me): 86% (m:others = 94 : 6)
30b (R = F): 52% (m:others = 75 : 25)  
Scheme 1.13: Palladium-catalyzed meta-selective C−H alkenylation 
 
Subsequently, Yu and co-workers developed other nitrile-containing directing groups based on the 
same strategy (Scheme 1.14). These directing groups successfully promoted meta-selective arylation, 
methylation and alkenylation of phenylpropanoic acid 31 and phenolic derivatives,60 meta-selective 
olefination and acetoxylation of anilines and tetrahydroquinolines 32,61 meta-selective olefination, 
arylation, and acetoxylation of indolines 33,62 and, most recently, meta-selective olefination of 
phenylacetic acid derivatives 34.63 The group of Tan slightly modified the Yu template by using a 
silicon atom for attachment in substrate 35, allowing for a facile introduction and deprotection 































31 32 33 34 35
 
Scheme 1.14: Directing groups for palladium-catalyzed meta-C−H functionalization 
 
As an alternative approach, Gaunt and co-workers reported copper-catalyzed meta-selective C−H 
arylation of anilides 3665,66 and subsequently α-aryl carbonyl compounds (Scheme 1.15).67 Regarding 
the mechanism of this remarkable transformation, the authors initially proposed a copper 
intermediate. However, at slightly elevated temperature, this transformation took place smoothly in 
the absence of any copper catalyst. 
NHO
R1
cat. Cu(OTf)2 or cat. HOTf
Ph2IOTf (2 equiv)







Scheme 1.15: meta-selective C−H arylation of anilides 36 
 
Subsequently the same group described copper-catalyzed para-selective direct arylation of aniline 
and phenol derivatives.68 Again, reaction occurred in the absence of copper and ortho-arylation was 
observed when the para-position of aniline was blocked. This selectivity pattern is consistent with a 
classical electrophilic aromatic substitution. However, copper improved the reactivity of this 
transformation presumably by inducing dissociation of the triflate anion to form an activated 
aryliodonium species. 
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In 2011, Frost and co-coworkers discovered that in contrast to palladium,56 ruthenium led to 
completely different site-selectivity in direct C−H sulfonylation of 2-phenylpyridine derivatives (38a) 
(Scheme 1.16).69-71 In this novel approach, a cyclometalated ruthenium complex containing a Ru-Caryl 
σ-bond was initially formed, and then the ruthenium center itself became a directing group,72,73 thus 
directing the electrophilic attack to the para-position with respect to the ruthenium by inductive and 








[RuCl2(p-cymene)]2 (5 mol %)
K2CO3 (2 equiv)









Pd(Ch3CN)2Cl2 (10 mol %)
K2CO3 (2 equiv), 4 Å MS














Scheme 1.16: Different selectivity pattern in transition metal-catalyzed C−H sulfonylation 
 
1.3 Transition Metal-Catalyzed Alkylation with Alkyl Halides 
 
Friedel-Crafts Alkylation 
Ever since Friedel and Crafts reported the first AlCl3-mediated electrophilic aromatic substitution of 
benzene (41a) with alkyl chlorides 42 in 1877 (Scheme 1.17),74 the Friedel-Crafts alkylation has been 
one of the most powerful C−C bond forming processes in organic synthesis. However, it took more 
than a century for asymmetric catalytic versions of this transformation to be developed.75 Meanwhile, 









Scheme 1.17: Electrophilic aromatic alkylation as reported by Friedel and Crafts 
 
Despite the fact that research towards developing new strategies for catalytic, stereoselective,76 
enantioselective and environmentally benign77 Friedel-Crafts alkylation is still active, many innate 
limitations hinder the broader application of these methods. First, acid-labile functional groups are 
not tolerated. Second, the electrophiles often undergo rearrangements, thus limiting the utility for 
n-alkylations. Third, chemo- or regioselectivity is not perfect, and the electron-deficient arenes are 
much less reactive than the electron-rich ones. At last, the electronic effects prevent formation of 
products with alkyl group located meta- to electron-donating groups. 
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Transition Metal-Catalyzed Cross-Coupling 
In conventional cross-coupling chemistry, alkyl electrophiles bearing β-hydrogen atoms had been 
considered unsuitable substrates for mainly two reasons. First, the oxidative addition of alkyl C−Hal 
bonds to a metal center is more difficult than aryl−Hal and alkenyl−Hal ones due to their electron-rich 
nature. Second, the thus formed alkyl metal species are substantially less stable owing to a lack of π 
electrons which can interact with empty d orbitals of the metal. This instability easily gives rise to 
undesired side reactions, most prominently β-hydride eliminations.78 
 
However, since the pioneering work of Kochi79 and Suzuki,80 a wide range of transition metals can 
readily catalyze the coupling of primary alkyl halides and organometallic regents.81,82 Compared with 
primary alkyl halides, secondary alkyl halides are more difficult to couple in conventional 
cross-coupling chemistry due to the increased energy barrier towards oxidative addition, which 
results from the increased steric hindrance. Nevertheless, tremendous progress has been made in 
coupling secondary alkyl halides during the past decade.83 
 
In 2003, the group of Fu reported the first nickel-catalyzed Negishi coupling of secondary alkyl 
bromides 44 and iodides (Scheme 1.18a). This transformation proceeded smoothly in the presence of 
various functional groups, such as sulfon amides, ethers, acetals, esters, and amides.84 Shortly 
thereafter, the same group reported an asymmetric nickel-catalyzed Negishi coupling of secondary 
electrophiles (Scheme 1.18b).85 Coupling of racemic α-bromoamides (47) under the catalysis with 
NiCl2 and iPr-Pybox led to a variety of functionalized α-substituted amides (49) in good yields and 







[Ni(cod)2] (4 mol %)
s-Bu-Pybox (8 mol %)








NiCl2·diglyme (10 mol %)
(R)-(i-Pr)-Pybox (13 mol %)












47 48 49  
Scheme 1.18: Nickel-catalyzed Negishi coupling of secondary alkyl halides 
 
Besides Negishi coupling, nickel-catalyzed Suzuki-,86 Hiyama-,87 Kumada-,88 and Sonogashira-type 
coupling89 were also reported in an enantioselective fashion, with major contribution from the Fu 
group. Although nickel has been proven to be the most versatile metal for cross-coupling of alkyl 
halides,90 other transition metals, such as copper,91 iron,92 cobalt93 and palladium94 are also 
competent.  
 
Although huge progress has been made towards coupling secondary alkyl halides in the past decade, 
until now, there are only a few publications concerning transition metal-catalyzed C−C bond 
formation with unactivated tertiary alkyl halides. In 2013, Fu and Zultanski reported the first 
nickel-catalyzed Suzuki coupling of tertiary alkyl halides (50).95 
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NiCl2·diglyme (10 mol %)











Scheme 1.19: Nickel-catalyzed Suzuki coupling of tertiary alkyl halides 50 
 
The mechanism of nickel-catalyzed Negishi alkyl-alkyl cross-coupling has been studied independently 
by the groups of Vicic96 and Phillips.97 Recently, Fu and coworkers also examined the pathway for 
Negishi arylation of secondary propargylic bromides.98 Both studies proposed catalytic cycles 
involving the transmetalation of organozinc regents and the reductive elimination to yield the 
products and most importantly, activation of the alkyl halides by single electron transfer (SET)99 to 
form free alkyl radicals. However, Vicic found that nickel(II) species were inactive in the alkyl-alkyl 
coupling and thus proposed transmetalation as the first step (Scheme 1.20a), while in Fu’s 























Scheme 1.20: Proposed mechanisms for nickel-catalyzed Negishi coupling: a) alky-alkyl coupling; b) 
aryl-propargyl coupling 
 
Transition Metal-Catalyzed Direct C−H Alkylation 
An innate disadvantage of conventional cross-coupling of alkyl halides is the usage of 
pre-functionalized nucleophilic substrates which are often not commercially available. Preparation of 
these nucleophiles as well as the cross-couplings themselves potentially produces undesired 
byproducts. Thus, direct C−H bond alkylation represents an economically attractive alternative. 
Indeed, during the last few years, tremendous progress has been achieved in the field of direct C−H 
bond alkylation of (hetero)arenes, and different transition metals proved to be competent.100 
 
Intramolecular Direct C−H Alkylation 
One of the early examples of transition metal-catalyzed intramolecular C−H benzylation was 
developed by the group of Wong.101 Initial intermolecular Suzuki−Miyaura cross-coupling afforded 
intermediate 57, which set the stage for a palladium-catalyzed intramolecular direct benzylation 
(Scheme 1.21). 
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[Pd(PPh3)4] (10 mol %)
aq. Na2CO3 (2 M)
MeOH/PhMe (2:3)












Scheme 1.21: Palladium-catalyzed direct intramolecular benzylation 
 
In 2003, Buchwald and co-workers disclosed palladium-catalyzed oxindoles synthesis through 
intramolecular alkylation of α-chloroacetanilides 58 (Scheme 1.22a).102 ortho- or meta-Substituted 
α-chloroacetanilides delivered oxindoles 59 of which the less hindered ortho-positions were 
selectively alkylated. Subsequently, the group of Chang also reported synthesis of pyrroloindoles 61 
via palladium-catalyzed intramolecular benzylation of pyrroles 60 under similar reaction conditions 
(Scheme 1.22b).103 Pyrroles bearing electron-withdrawing substituents were observed to react faster 





Pd(OAc)2 (1−3 mol %)
NEt3, PhMe
80 °C, 2.5−6 h









Pd(OAc)2 (5 mol %)
NEt3, PhH
100 °C, 1−12 h




Pd(OAc)2 (2 mol %)
DME, 100 °C, 12 h















Scheme 1.22: Palladium-catalyzed direct intramolecular cyclizations 
 
In a follow-up work, Chang and co-workers demonstrated that simple arenes 62 could also be cyclized 
with an optimized palladium/BINAP system (Scheme 1.22c).104 It is noteworthy that in all these 
intramolecular reactions described above, the halides were activated and thus underwent facile 
oxidative addition. 
 
Direct C−H Alkylation of Heteroarenes 
Besides arenes, heteroarenes were demonstrated as suitable substrates for transition metal-catalyzed 
direct C−H alkylation as well. In 2009, Hoarau and co-workers developed one of the earliest examples 
of palladium-catalyzed alkylation and benzylation of oxazoles 66 (Scheme 1.23a).105 The scope of 
heteroarenes for this transformation was significantly expanded by the group of Fagnou; various 
five-membered heteroarenes were functionalized at the most acidic C−H bond (Scheme 1.23b).106 
Addition of pivalic acid turned out to be beneficial for the overall efficiency, which indicated a 
CMD-type mechanism. 
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Pd(OAc)2 (5 mol %)
P(biphenyl-2-yl)Cy2 (10 mol %)
Cs2CO3




Pd(OPiv)2 (2 mol %)
2-Ph2P-2'-(Me2N)biphenyl (4 mol %)
Cs2CO3











Scheme 1.23: Palladium-catalyzed direct alkylations of heteroarenes 
 
Shortly thereafter, Hu and co-workers demonstrated that nickel complexes are also capable of 
promoting direct alkylation of heteroarenes.107 Interestingly, addition of cocatalytic amounts of CuI 
proved to be essential for achieving high yields (Scheme 1.24a). The groups of Miura108 and 
Ackermann109 independently showed that user-friendly [(Diglyme)NiBr2] also allowed for the 




Precatalyst 74 (5 mol %)
CuI (7.5 mol %)
t-BuOLi








[NiBr2·diglyme] (5 mol %)
terpyridine (5 mol %)
t-BuOLi
















Scheme 1.24: Nickel-catalyzed direct alkylation of heteroarenes 
 
Furthermore, in 2012, Hu and co-workers showed that not only primary alkyl halides, but also 
secondary alkyl halides 44 are suitable substrates for copper-catalyzed direct alkylation of 
heteroarenes 70 (Scheme 1.25a).110 Reactions with radical scavengers and other mechanistic studies 
suggested a radical mechanism. Recently, palladium-catalyzed direct alkylation of pyridine N-oxides 
76 and other heteroarenes with unactivated secondary alkyl halides were also independently 
reported by the groups of Fu111 and Wu112 (Scheme 1.25b,c). 
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78 (10 mol %)
NaOt-Bu
















Br Pd(OAc)2·dppf  (5 mol %)
Cs2CO3








[Pd(PPh3)4] (5 mol %)
Cs2CO3

















Scheme 1.25: Palladium or copper-catalyzed direct alkylation with secondary alkyl halides 44 
 
Norbornene-Mediated Direct C−H Alkylation 
While the electron-rich C3-position of indoles 79 can be easily alkylated by Friedel-Crafts alkylation, 
regioselective direct alkylation at C2-position of free N-H indoles is not straightforward. As already 
discussed in Chapter 1.2, Catellani reaction displays unique site-selectivity via manipulation of 
norbornene. Thus, Bach and co-workers took advantage of this strategy and achieved for the first 




PdCl2(MeCN)2 (10 mol %)
norbornene (2 equiv)






Scheme 1.26: Norbornene-mediated direct C2 alkylation of free N-H indoles 79 
 
The C2-alkylation process was originally assumed to initiate by the well-established C3-palladation. 
However, after comprehensive mechanistic study, Bach and co-workers proposed N-palladation of 
indole to be the first step.114 The synthetic utility of this protocol for 2-alkylation of indoles was also 
demonstrated by its application in the total synthesis of Aspidosperma alkaloids. 
 
Monodentate Directing Group Assisted Direct C−H Alkylation  
With respect to directing group-assisted C−H alkylation, Tremont and co-workers discovered that 
stoichiometrically palladated acetanilides reacted smoothly with alkyl iodides.115 Further investigation 
achieved a catalytic version of this transformation, albeit with a low turnover number of 1.5 (TON) 
(Scheme 1.27).  
H
N
Ac Pd(OAc)2 (25 mol %)







42f36a 81  
Scheme 1.27: Palladium-catalyzed direct alkylation of acetanilide 36b 
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In 2009, Yu and co-workers disclosed palladium-catalyzed direct alkylation of benzoic acids 82 with 
either 1,2-dichloroethane or dibromomethane (Scheme 1.28).116 Mechanistic studies showed that 
ortho-selective alkylation took place first and subsequent intramolecular SN2 cyclization delivered 
desired lactones 83. Using alkyl bromides and chlorides instead of iodides allowed the catalytic cycle 
to be closed without using stoichiometric amounts of AgOAc. 
OH
O Pd(OAc)2 (10 mol %)
K2HPO4






Scheme 1.28: Palladium-catalyzed direct alkylation of benzoic acids 82 
 
Besides palladium catalysts, the group of Nakamura developed a cobalt-catalyzed direct alkylation of 
secondary benzamides 84, an important functional group and structure motif which can be further 
transformed (Scheme 1.29).117 Inexpensive DMPU was used as ligand and the reaction proceeded 




MePhCo(acac)2 (10 mol %)
DMPU (12 equiv)
CyMgCl (3 equiv)







81%84a 42g 85  
Scheme 1.29: Nickel-catalyzed direct alkylation of secondary benzamide 84a 
 
In 2013, the groups of Ackermann and Yoshikai reported cobalt/N-heterocyclic carbene catalytic 
systems for the ortho-alkylation of arenes 38 and 86 with both primary and secondary alkyl chlorides 
and bromides, independently (Scheme 1.30).118-120 A radical mechanism was proposed based on the 
fact that both trans- and cis-isomers of 1-(tert-butyl)-4-cyclohexane afforded products with the same 





Br CoBr2  (10 mol %)
Ligand (10 mol %)
t-BuCH2MgBr








Scheme 1.30: Cobalt-catalyzed direct alkylation with secondary alkyl bromide 44c 
 
Recently, Yu and co-workers achieved palladium-catalyzed direct C(sp3)−H alkylation of 
electron-deficient secondary benzamides 89a with pyridine- and quinoline-based ligands 91 as crucial 
promoters (Scheme 1.31).121 Furthermore, this protocol allowed for the preparation of unnatural 
amino acids as well. 
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Pd(TFA)2 (10 mol %)
Ligand (20 mol %)
AgOPiv (3 equiv)
DCE (0.2 M)













Ar = (4-CF3)C6F4  
Scheme 1.31: Palladium-catalyzed direct alkylation of C(sp3)−H bond 
 
Bidentate Directing Group-Assisted Direct C−H Alkylation  
Ever since Daugulis and co-workers’ work on utilizing 8-aminoquinoline (Q) and picolinamides (PA) as 
bidentate directing groups for promoting palladium-catalyzed C(sp3)−H and C(sp2)−H arylation of 
amides,122 many research groups have been intensively exploring the potential of this strategy in 
transition metal-catalyzed C−H bond functionalization.123,124 
 
In 2010, the group of Daugulis reported several examples of palladium-catalyzed C(sp3)−H alkylation 
of amides 92 assisted by 8-aminoquinoline (Scheme 1.32a).125 Shortly thereafter, Chen and 
co-workers extended the scope of palladium-catalyzed C(sp2)−H alkylation by picolinamide assistance 
in substrate 94, various primary alkyl iodides were tolerated and the directing group could easily be 
cleaved (Scheme 1.32b).126 In 2012, Daugulis and co-workers published another method for unnatural 





Q Me + i-BuI
Pd(OAc)2 (5 mol %)



































Pd(OAc)2 (11 mol %)
Cs3PO4, CsOPiv











Scheme 1.32: Bidentate DG-assisted palladium-catalyzed direct alkylations 
 
Following their previous publication of direct C(sp2)−H alkylation, Chen and co-workers disclosed 
efficient palladium catalyst for the alkylation of C(sp3)−H bonds of aliphatic amine substrates 97 via 
picolinamide assistance.128 Ag2CO3 and dibenzyl phosphate (BnO)2PO2H were determinant 
promoters of this reaction (Scheme 1.33a). This research group also succeeded in optimizing Daugulis’ 
work on unnatural amino acids synthesis under essentially the same conditions (Scheme 1.33b). This 
approach provided a convenient and powerful solution to site-selective incorporation of isotopically 
labeled moieties into the carbon scaffolds of amino acids.129 Similar transformations were also 
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Pd(OAc)2 (5 mol %)
(BnO)2PO2H (20 mol %)
Ag2CO3, NaI
PhMe/t-AmOH (9:1)
Ar, 110 °C, 2−20 h
Pd(OAc)2 (10 mol %)






92b 42k 96b 100
t-AmOH, 110 °C, 6−24 h
 
Scheme 1.33: Bidentate DG-assisted palladium-catalyzed direct alkylation of C(sp3)−H bond 
 
Besides palladium, Chatani and co-workers reported the first example of bidentate directing 
group-assisted nickel-catalyzed C−H alkylation of benzamide derivatives 101 (Scheme 1.34a).132 A 
variety of functionalized primary alkyl bromides 42 were applicable in the alkylation reaction. Shortly 
thereafter, the group of Ackermann successfully utilized challenging secondary alkyl bromides 44 and 
trifluoroethyl iodide (42l) in this reaction (Scheme 1.34a).133 Furthermore, Ge and co-workers 
achieved nickel-catalyzed direct alkylation of unactivated C(sp3)−H bonds with the assistance of 
8-aminoquinoline (Scheme 1.34b).134 The reaction favored the C−H bonds of methyl groups over the 
methylene C−H bonds and tolerated various functional groups. It should be mentioned that 
inexpensive iron catalysts were also demonstrated to be competent in promoting bidentate directing 
group-assisted direct C−H alkylation of C(sp2)−H bonds with both primary and secondary alkyl 






Ni(OTf)2 (10 mol %)
PPh3 (20 mol %)
Na2CO3






[(DME)NiCl2] (10 mol %)
BDMAE (40 mol %)
LiOt-Bu














Ni(acac)2 (10 mol %)






























92c 42m 96c  
Scheme 1.34: Bidentate DG-assisted nickel-catalyzed direct alkylation 
 
Ruthenium(II)-Catalyzed Direct C−H Alkylation 
Based on their research on carboxylate-assisted ruthenium(II)-catalyzed direct arylations,138,139 
Ackermann and co-workers successfully extended this catalytic system to unprecedented 
ruthenium(II)-catalyzed direct C−H alkylation and benzylation of 2-phenylpyridines 38.140,141 Among 
various screened carboxylates, sterically bulky 1-AdCO2H proved to be the most efficient. Primary 
Introduction 
- 17 - 
 
alkyl iodides, bromides, chlorides served as viable substrates, while alkyl bromides 42e provided the 
best yields (Scheme 1.35a). 
N
+
[RuCl2(p-cymene)]2 (2.5 mol %)
K2CO3
NMP, 60 °C, 20 h
N





1) [RuCl2(p-cymene)]2 (2.5 mol %)
K2CO3, m-xylene
120 °C, 20 h
1-AdCO2H (30 mol %)
2) NaBH3CN, ZnCl2

















Scheme 1.35: Ruthenium(II)-catalyzed direct alkylation with primary alkyl halide 42e 
 
Furthermore, aromatic ketimines 86 could also be efficiently alkylated, which was exploited for the 
synthesis of secondary amines 104 through a sustainable one-pot-process (Scheme 1.35b). Further 
investigation by performing this direct alkylation in water yielded meta-alkylated by-product 105a 
(Scheme 1.36),142 This meta-alkylation took place under solvent-free reaction conditions as well, 
albeit in low yields.  
N
+
[RuCl2(p-cymene)]2 (2.5 mol %)
K2CO3
H2O, 100°C, 20 h
N






38b 42e 103b: 45% 105a: 7%  
Scheme 1.36: Preliminary observation of ruthenium(II)-catalyzed direct meta-alkylation 
 
Based on the mechanistic studies, a catalytic cycle proposed by Ackermann and co-workers is shown below 
in Scheme 1.37. This catalytic cycle initiated with the formation of a ruthenium(II) carboxylate complex 106, 
which reversibly activated the ortho-C−H bond through carboxylate-assisted deprotonation (109) to 
form cyclometalated intermediate 108. Thereafter, complex 108 reacted with primary alkyl halides 42 
via formal oxidative addition to yield intermediate 109. Finally, reductive elimination regioselectively 
gave rise to the alkylated arene 110, and thereby regenerated the active catalyst 106. 
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Scheme 1.37: Proposed catalytic cycle for ruthenium(II)-catalyzed direct alkylation 
 
However, shortly thereafter, Ackermann and Hofmann demonstrated that meta-alkylation products 
can be isolated in high yields by using secondary alkyl halides 44.143 The direct alkylations occurred 
under mild conditions with ample scope and tolerated valuable functional groups (Scheme 1.35). 
N
+
[RuCl2(p-cymene)]2 (2.5 mol %)










1,4-dioxane, 100°C, 20 h
 
Scheme 1.38: Ruthenium(II)-catalyzed direct meta-alkylation with secondary alkyl halide 44d 
 
Concerning the mechanism, the authors proposed that cyclometalation activated the arene for a 
SEAr-type alkylation with the secondary alkyl halides through the strong directing group effect of the 
Ru−C σ-bond, thus leading to a functionalization in the para- or ortho-position with respect to the 
Ru−C bond. The detailed mechanism will be discussed in Chapter 3.1. 
 
1.4 Transition Metal-Catalyzed Oxidative C−H Alkenylation 
Encouraged by the need for green and sustainable chemistry,144 synthetic chemists are constantly 
seeking more efficient ways to construct C−C bonds, the essential link in all organic molecules. In the 
early 1970s, Mizoroki10 and Heck11 disclosed palladium-catalyzed C−C bond forming reaction between 
an aryl halide and an alkene (see above). In fact, before achieving insertion of palladium into Ar−X 
bond under catalytic condition, Heck also performed in situ synthesis of ArPdX complexes from 
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palladium salts and aryl-metal complexes in the late 1960s.145,146 However, both methods produce 
stoichiometric amounts of byproducts. In consideration of the atom economy principle,147 direct C−C 
bond formation from two C−H bonds would be the most promising approach. 
 
In this context, in 1967 Fujiwara and Moritani achieved the synthesis of stilbene employing the 
reaction of the styrene-PdCl2 complex with benzene148 and, in 1968, the oxidative coupling between 
styrene 15 and benzene 41 with two turnovers of palladium.149 Shortly thereafter, they reported a 




AcOH, 110 °C, 8 h
R2
R1
15 41 112  
Scheme 1.39: Palladium-catalyzed Fujiwara−Moritani reaction 
 
Since Fujiwara and Moritani’s seminal work, enormous efforts have been devoted to optimizing and 
extending the scope of this reaction.26,151 In 2002, the groups of de Vries and van Leeuwen reported 
an exceptionally mild Fujiwara-Moritani reaction which employed anilide directing groups to control 
reactivity and site-selectivity (Scheme 1.40). The addition of TsOH played an important role in 
improving the reactivity, which was believed to increase the electrophilicity of the palladium catalyst 



















Scheme 1.40: Palladium-catalyzed direct alkenylation of anilide 36b 
 
In 2010, Yu and co-workers disclosed the oxidative coupling between phenylacetic acid derivatives 
114 and alkenes 15 (Scheme 1.41).153 Weak coordination between C=O bond of the carboxylate and 
Pd(OAc)2 was proposed to facilitate the ortho-C−H functionalization. Notably, introducing 
mono-protected amino acids (MPAAs) 116 as ligands enhanced both site-selectivity and reactivity. 





Pd(OAc)2 (5 mol %)
BQ (5 mol%)












Scheme 1.41: Palladium-catalyzed direct alkenylation of phenylacetic acid 114a 
 
Moreover, MPAAs 116 are not only limited to enhance the reaction rate and regioselectivity, but can 
also function as chiral ligand to control enantioselectivity.154,155 Yu and coworkers demonstrated that 
alkenylation of diphenylacetate sodium salt 114b was accompanied by desymmetrization to afford 
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product 115b with modest to excellent enantioselectivities (Scheme 1.42). 
CO2Na
Me Ph+
Pd(OAc)2 (5 mol %)
BQ (5 mol %)
t-AmOH, 90 °C, 48 h







73% yield, 97% ee114b 15c 115b  
Scheme 1.42: Enantioselective palladium-catalyzed oxidative C−H alkenylation 
 
Subsequently, Yu and co-workers achieved the challenging C(sp3)−H bond alkenylation of aliphatic 
secondary amides 89 (Scheme 1.43).156 As regards the mechanism, initial formation of a 
five-membered palladacycle assisted by amide directing group was proposed. LiCl served as a source 
of chloride anions which stabilized palladium(0) and facilitated the formation of chloride-bridged 



























89b 15b 117  
Scheme 1.43: Palladium-catalyzed direct alkenylation of C(sp3)−H bond 
 
Besides palladium, other transition metal catalysts have been reported for enabling the oxidative 
C−H alkenylation reactions as well. In recent years, great effort has been devoted to 
rhodium-catalyzed oxidative C−H alkenylation.157,158 Despite the relatively high cost of rhodium 
catalysts, it is still of major interests owing to the high efficiency, reactivity, and functional group 
tolerance.  
 
An early contribution by Matsumoto, Yoshida, and coworkers achieved rhodium-catalyzed oxidative 
C−H olefination of benzene with ethylene.159 In 2007, Satoh and Miura reported an example of 
rhodium-catalyzed C(sp2)−H bond alkenylation (Scheme 1.44).160 At low catalyst loadings, the 
olefination of benzoic acid 82a resulted in ortho-alkenylated lactone 118a, which arose from 




[RhCp*Cl2]2 (1.0 mol %)
Cu(OAc)2·H2O (5.0 mol%)
under air, 





82a 15a 118a  
Scheme 1.44: Rhodium-catalyzed C−H alkenylation of benzoic acid (82a) 
 
Patureau and Glorius reported a related rhodium-catalyzed ortho-alkenylation of anilides 36 using an 
in-situ generated cationic rhodium complex (Scheme 1.45).161 Comparing to palladium catalysts, 
lower catalyst loadings, good functional group tolerance and higher reactivity of electron-neutral 
olefins were realized. Under elevated pressure, ethylene reacted to yield the corresponding 
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[RhCp*Cl2]2 (1.0 mol %)
Cu(OAc)2·H2O (2.1 equiv)
t-AmOH, 120 °C, 16 h
AgSbF6 (2 mol %)
80%36a 15c 119a  
Scheme 1.45: Rhodium-catalyzed C−H alkenylation of anilide 36a 
 
In contrast, significantly less expensive, yet highly reactive ruthenium catalysts have only recently 
been developed for facilitating oxidative C−H bond alkenylations on arenes.162 In 2001, Milstein and 
co-workers reported an example of synthesizing styrene derivatives (112a) via ruthenium-catalyzed 
oxidative coupling of arenes (41a) with olefins (Scheme 1.46).163 Whereas a range of ruthenium 
complexes, such as RuCl3·H2O, [Ru(CO)3Cl2]2, [(η6-C6H6)RuCl2]2, Ru(NO)Cl3·5H2O and 
Ru(F3CCOCHCOCF3)3, enabled similar catalytic reactivities, yet Ru3(CO)12 exhibited low efficiency. 
Carbon monoxide was proposed to stabilize a cationic ruthenium species, and a value of KIE ≈ 2 was 
established with substrates C6H6 (41a) and C6D6, indicating the C−H bond metalation to be the 
rate-determining step. Unfortunately, low reactivity of the simple alkenes as well as the low 
regioselectivity limited this approach for practical application. Furthermore, this strategy was limited 
by the high temperature and high pressure of molecular oxygen and carbon monoxide. 
 
CO2Et+
CO2Et[RuCl3·3H2O] (0.4 mol %)
O2 (2 bar), CO (6.1 bar)
180 °C, 48 h
35%41a 15a 112a  
Scheme 1.46: Ruthenium-catalyzed C−H alkenylation of simple arene 41a 
 
Fortunately, this limitation of low selectivity observed in alkenylations of simple arenes was 
successfully addressed by employing substrates with directing groups for chelating assistance. In 2010, 
the group of Yi reported on oxidative C−H alkenylation of benzamide derivatives 120 with unactivated 
alkenes (15d) enabled by cationic ruthenium hydride complex [(η6-C6H6)(PCy3)(CO)RuH]+BF4− (123) 
(Scheme 1.47).164 In contrast to previous work of the Milstein group, a negligible KIE of 1.1 was 
observed for the competition reaction between C6H5C(O)NEt2 (120a) and its deuterated analogue 
C6D5C(O)NEt2, thus suggesting a reversible arene C−H bond metalation step. In the absence of an 
external oxidant, an excess of alkene 15 as well as the alkenylated product 121 served as the 
hydrogen scavenger. Unfortunately, participation of 121 led to a mixture of the products 121 and 122. 
 
+
CH2Cl2 or PhCl, 80 °C, 5 h










120a 15d 121a 122  
Scheme 1.47: Ruthenium-catalyzed C−H alkenylation of benzamide 120a 
 
In 2011, Ackermann and Pospech disclosed the lactone synthesis via ruthenium(II)-catalyzed oxidative 
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C−H bond alkenylation of benzoic acids 82 with acrylates or acrylonitrile (15e) in water (Scheme 
1.48a).165 With stoichiometric amounts of Cu(OAc)2·H2O as the oxidant, the reaction proceeded 
smoothly under mild reaction conditions. The ortho-alkenylated intermediate underwent immediate 
intramolecular oxa-Michael reaction and delivered lactone derivatives 118 in good yields. 
+
Cu(OAc)2·H2O 
H2O, 80 °C, 16−24 h
O OH











o-xylene, 110 °C, 16 h










15b84b 124a  
Scheme 1.48: Ruthenium(II)-catalyzed C−H alkenylation of benzoic acid (82b) and benzanilide (84b) 
 
A similar phenomenon was observed by the groups of Satoh/Miura and Ackermann in the 
ruthenium(II)-catalyzed oxidative alkenylation of benzanilide (84b) (Scheme 1.48b).166 Indeed, the 
initially formed alkenylated derivative underwent intramolecular Michael reaction to give bicyclic 
benzamide 124a. 
 
Subsequently, ruthenium(II)-catalyzed oxidative alkenylation of various amide derivatives were 
studied (Scheme 1.49). Satoh, Miura and co-workers demonstrated the oxidative alkenylation of 
N,N-dimethylbenzamide (120c) in the presence of co-catalytic AgSbF6, [RuCl2(p-cymene)]2 and 
Cu(OAc)2·H2O.167 Notably, no reaction would occur in the absence of the silver salt. Li and co-workers 
achieved alkenylation of cyclic N-protected isoquinolones 120b under similar reaction conditions.168 
The Ackermann group showed that the use of less expensive KPF6 instead of AgSbF6 enabled 
olefination of N-monosubstituted benzamides 84c using environmentally benign water as solvent.169 
Moreover, this approach was not limited to aromatic amides. Ruthenium(II)-catalyzed oxidative 
alkenylation of acrylamines (125a) was also developed by Zhang and Loh,170 and moderate to good 
yields and excellent site-selectivity were obtained.  
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84, 120, 125 15 126
120c120b84c 125a
126c126b126a 126d
Scheme 1.49: Ruthenium(II)-catalyzed C−H alkenylation of benzamide derivatives 
 
Alternatively, ruthenium(II)-catalyzed C−H alkenylation of benzamides could be realized without 
external oxidant. Pre-functionalized starting materials bearing an internal oxidizing directing groups 
such as N-methoxybenzamide (127a)171 and N-hydroxybenzamides172 smoothly delivered olefinated 







[RuCl2(p-cymene)]2 (5.0 mol %)
MeOH, 60 °C, 4−24 h
NaOAc (30 mol %)+
87%127a 15b 128  
Scheme 1.50: Ruthenium(II)-catalyzed C−H alkenylation of N-methoxybenzamide (127a) 
 
In addition to chelation-assisted olefination of benzamides, the groups of Ackermann and 
Jeganmohan independently studied ruthenium(II)-catalyzed oxidative alkenylation of readily available, 
yet weakly coordinating21 esters,173,174 and phenones.175 Thus, a catalytic system consisting of 
[RuCl2(p-cymene)]2, AgSbF6, and co-catalytic amounts of Cu(OAc)2·H2O utilizing air as terminal 
oxidant allowed for efficient aerobic C−H bond alkenylations of aryl esters, phenones 129 (R2 = OAlk, 
Alk, respectively) utilizing air as a terminal oxidant (Scheme 1.51). Most recently, Loh and coworkers 
disclosed ruthenium(II)-catalyzed oxidative cross-coupling of acrylates. This protocol offered a 
straightforward and atom-economical synthesis of functionalized (Z,E)-muconate derivatives with 





R1 DCE, 100 °C, 12
−16 h
[RuCl2(p-cymene)]2 (2.0−5.0 mol %)
AgSbF6 (10−40 mol %)






R2 = OAlk, Alk129 15 130  
Scheme 1.51: Ruthenium(II)-catalyzed C−H alkenylation of esters, phenones and aldehydes 129 
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Moreover, not only arenes bearing electron-withdrawing groups, but also electron-rich substrates 
could undergo facile alkenylation under ruthenium(II) catalysts. In 2012, Ackermann and co-workers 
reported on the first ruthenium(II)-catalyzed oxidative alkenylation of anilides 36 with alkenes 15 in 
water (Scheme 1.52).169 Intramolecular competition experiments with N-benzoyl anilides delivered 




[RuCl2(p-cymene)]2 (5.0 mol %)
Cu(OAc)2·H2O (1 equiv)
H2O, 120 °C, 20 h






62%36c 15a 119b  
Scheme 1.52: Ruthenium(II)-catalyzed C−H alkenylation of anilide 36c 
 
Ruthenium(II)-catalyzed oxidative alkenylation of arenes also proved viable by utilizing heterocyclic 
directing groups (Scheme 1.53). N-Arylpyrazoles 131,166,177 2-arylimidazoles 132167 were 
demonstrated to be suitable substrates by the groups of Dixneuf, Bolm, Satoh and Miura. It should be 
mentioned that Ackermann and Ma reported on the ruthenium(II)-catalyzed oxidative olefination of 
phenol derivatives 133 bearing a pyridine directing group which can easily be removed.178 Recently, 
the groups of Liu and Ackermann disclosed ruthenium(II)-catalyzed oxidative alkenylation of arenes 
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Scheme 1.53: Ruthenium(II)-catalyzed C−H alkenylations directed by heterocyclic DGs 
 
Ruthenium(II)-catalyzed oxidative alkenylations of heterocyclic compounds were achieved with 
assistance of various directing groups employing the catalytic system described above, albeit with 
different catalytic efficacies. Thus, Satoh, Miura and co-workers disclosed carboxylic acid-directed 
ruthenium(II)-catalyzed oxidative alkenylation of thiophenes, benzothiophenes, benzofurans, pyrroles, 
and indoles.182 Subsequently, the groups of Prabhu and Wang reported on the 
ruthenium(II)-catalyzed C-2 alkenylation of indoles using either N-benzoyl183 or N-carbamoyl (79a)184 
moiety as a directing group, respectively (Scheme 1.54). 
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1,4-dioxane, 100 °C, 24 h
[RuCl2(p-cymene)]2 (2.5 mol %)






88%79a 15c 141  
Scheme 1.54: Ruthenium(II)-catalyzed C−H alkenylation of N-carbamoylindole 79a 
 
Most recently, novel and synthetically useful directing groups have been utilized for 
ruthenium(II)-catalyzed oxidative alkenylations (Scheme 1.55). For instance, Ackermann and 
co-workers achieved direct C−H olefination of amidines 142185 and of sulfonic acids 143.186 The group 
of Satoh and Miura disclosed free amino group-directed ortho-alkenylation and successive cyclization 
to produce (isoindol-1-yl)acetic acid derivatives 150.187 Azoxybenzenes 145 also underwent smooth 
oxidative alkenylation under ruthenium(II) catalysis.188 The group of Greaney reported on the cascade 
C−H bond functionalization based on ruthenium(II)-catalyzed oxidative alkenylation.189 1-Indanones 
152, indeno-indenes, and indeno-furanones became accessible via this approach. Moreover, 
Jeganmohan and co-workers demonstrated a highly regio- and stereoselective synthesis of 
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148 149 150 151 152 153
15
 Scheme 1.55: Recent examples of ruthenium(II)-catalyzed oxidative C−H alkenylation 
 
1.5 Transition Metal-Catalyzed Alkyne Annulations by C−H/Het−H Functionalizations 
 
Aromatic heterocycles represent structural motifs which can be found in a great number of 
biologically active natural and synthetic compounds, pharmaceuticals, and agrochemicals.191 
Moreover, aromatic heterocycles are widely used for synthesis of polymeric materials and dyes of 
high value. Chemists have been making great effort towards preparation of these heterocyclic 
compounds for decades. Among a variety of new synthetic methodologies, transition metal-catalyzed 
reactions are of particular interests for direct constructions of complex structures from readily 
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accessible starting materials.192-194 Inspired by the traditional cross-coupling chemistry, 
palladium-catalyzed processes have emerged as a powerful tool in heterocycle synthesis,195,196 among 
which, the Larock indole-synthesis is extremely versatile and can be utilized in preparing a variety of 
indole derivatives 79 (Scheme 1.56).197 However, the same as in the traditional cross-coupling 
chemistry requirement of prefunctionalized starting materials, discussed above in Chapter 1.1, 

















Scheme 1.56: Larock indole synthesis 
 
Along with the rapid development of various transition metal-catalyzed C−H bond functionalization 
methods, more attention have been drawn to apply these methodologies into synthesis of natural 
products and pharmaceuticals.198-200 
 
In this context, the group of Miura and Satoh reported the rhodium-catalyzed annulation of benzoic 
acids 82 with internal alkynes 155, a variety of isocoumarin derivatives 156 were prepared using this 
method (Scheme 1.57).160,201 
CO2H
+
[RhCp*Cl2]2 (1.0 mol %)
Cu(OAc)2·H2O (5.0 mol %)
under air







82a 155a 156a  
Scheme 1.57: Rhodium-catalyzed oxidative annulation with benzoic acid (82a) 
 
Shortly thereafter, Fagnou and co-workers published a rhodium-catalyzed indole synthesis through 
C−H/N−H bond functionalizations (Scheme 1.58).202 Acetanilides 36 underwent insertion of internal 
alkynes 155 through initial C−H bond activation followed by oxidative annulation to produce 
substituted indoles 79. Subsequently, heterocycle synthesis employing rhodium catalysis has been 







[RhCp*Cl2]2 (2.5 mol %)
Cu(OAc)2·H2O (2.1 equiv)










Scheme 1.58: Rhodium-catalyzed indole synthesis via C−H/N−H bond functionalizations 
 
Encouraged by their success in carboxylate-assisted ruthenium(II)-catalyzed alkylation and arylation 
reactions,17,205 Ackermann and co-workers set out to study annulations by using less expensive 
ruthenium(II) catalysts.206 Thus, in 2011, they reported on the first ruthenium(II)-catalyzed alkyne 
annulations by C−H/Het−H bonds functionalization (Scheme 1.59). 207 This isoquinolone 157a 
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synthesis proceeded smoothly with [RuCl2(p-cymene)]2 as the catalyst and stoichiometric amounts of 









t-AmOH, 100 °C, 22 h





76%84c 155a 157a  
Scheme 1.59: Ruthenium(II)-catalyzed isoquinolone synthesis via C−H/N−H bonds functionalizations 
 
Experiments with isotopically labeled starting materials disclosed a KIE of 2.6, which indicated a 
kinetically relevant C−H activation step. Based on mechanistic studies, the reaction was proposed to 
proceed by an initial ruthenation via acetate-assisted C−H bond cleavage followed by migratory 
insertion of the alkyne, subsequent C−N bond-forming reductive elimination and final reoxidation to 
























































Scheme 1.60: Proposed catalytic cycle for ruthenium(II)-catalyzed oxidative annulation 
 
Dixneuf and Wang carried out detailed mechanistic study regarding the C−H bond ruthenation and 
the alkyne insertion.208,209 The structures of isolated key intermediates were in line with the 
mechanism proposed in Scheme 1.60. 
 
Encouraged by the initial success, the groups of Ackermann and others made efforts to extend the 
scope of ruthenium(II)-catalyzed oxidative alkyne annulations through C−H/Het−H bond 
functionalization. In this context, various substituted heterocycles such as 2-pyridones 164,210 indoles 
79,211 isocumarins (156),212,213 annulated pyrans (167),214 isochromenes (175),215 pyrroles (171),216 
phosphaisocoumarins 172,217 quinolinones 173,218 isoquinolones 157219 and isoquinolines 174a185,220 
were prepared in the last few years. 5-Aryl-1H-pyrazoles 162,221 2-arylpyrroles and 2-arylindoles 79222 
also underwent smooth annulation with alkynes under ruthenium(II) catalyst (Scheme 1.61) 
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Product:
 Scheme 1.61: Recent examples of ruthenium(II)-catalyzed oxidative annulation 
 
In 2012, Lam and co-workers developed ruthenium(II)-catalyzed oxidative alkyne annulations by 
2-aryl-1,3-dicarbonyl compounds 176 involving formal functionalization of C(sp3)−H and C(sp2)−H 
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Scheme 1.62: Ruthenium(II)-catalyzed oxidative annulation via C(sp3)−H/C(sp2)−H functionalization 
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The group of Luan also reported on a similar ruthenium(II)-catalyzed cyclization reaction of 
1-aryl-2-naphthols 179.224 Dearomatized spirocyclic molecules bearing an all-carbon quaternary 
stereocenter could be obtained by this novel method with good yields and excellent site-selectivity 
(Scheme 1.62b).  
 
However, due to the oxidative character of the reactions discussed above, stoichiometric amounts of 
external oxidants were required to regenerate the active catalyst. Very recently, Ackermann and 
co-workers developed unprecedented ruthenium(II)-catalyzed oxidative alkyne annulations with 






































































Scheme 1.63: Ruthenium(II)-catalyzed aerobic alkyne annulations and proposed catalytic cycle 
 
This novel method prevented the use of copper or silver salts and thus generated water as the only 
byproduct. Moreover, a ruthenium(0) sandwich complex 184 was identified as a key intermediate of 
the catalytic cycle. Compound 184 was reoxidized by molecular oxygen to regenerate the active 
catalytic species 106a.  
 
Alternatively, a recently emerged strategy of using directing/oxidizing groups as internal oxidant 
represented itself as an important alternative in C−H functionalization.226 Fagnou and co-workers 
reported pioneering work of using internal oxidants for alkyne annulations involving C−H/N−O bond 
cleavages in 2010.227 Hydroxamic acid esters 127 were employed as substrates for the 
rhodium-catalyzed annulation. The only byproduct of this reaction is methanol, and the reaction 
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[RhCp*Cl2]2 (2.5 mol %)
MeOH, 60 °C, 16 h










Scheme 1.64: Rhodium-catalyzed isoquinolone synthesis via C−H/N−O bond functionalizations 
 
In 2011, the same strategy was independently applied in ruthenium(II)-catalyzed redox-neutral 
isoquinolone synthesis by the groups of Ackermann,228 Li and Wang.229 Ackermann and co-workers 
also showed that free hydroxamic acids (127b) were competent substrates, and the reaction 
proceeded smoothly in water (Scheme 1.65).172 
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Scheme 1.65: Ruthenium(II)-catalyzed isoquinolone synthesis via C−H/N−O bond functionalizations 
 
Most recently, Huang and co-workers reported the first ruthenium(II)-catalyzed redox-neutral 
annulation via N−N bond cleavage (Scheme 1.66).230 In this case, pyrazolidin-3-one moiety in 
substrate 185 was demonstrated to operate as an internal oxidizing directing group. It’s noteworthy 
that terminal alkynes, such as 155c, which were previously mostly incompetent in 
ruthenium(II)-catalyzed cyclizations, reacted smoothly and delivered indole products 186 as a single 
regioisomer. 
[RuCl2(p-cymene)]2 (2.5 mol %)
+
H










155c185 186  
Scheme 1.66: Ruthenium(II)-catalyzed annulation via C−H/N−N bond functionalizations 
 
Objectives 




In recent years, transition metal-catalyzed C–H bond functionalizations have become an indispensable 
tool for chemo-, site- and enantioselective direct construction of C–C and C–Het bonds. In particular, 
Ackermann and coworkers focused on developing new strategies for C–H functionalizations 
employing significantly less expensive, yet highly reactive ruthenium(II) catalysts. In this context, 
carboxylate assistance was found to be crucial for promoting the efficiency of the C–H activation step. 
 
Ackermann and coworkers have disclosed ruthenium(II)-catalyzed C–H alkylation of arenes with both 
primary and secondary alkyl halides. More importantly, direct alkylation with secondary alkyl 
bromides exhibited unique meta-selectivity. Despite the progress of employing secondary alkyl 
halides in traditional cross-coupling reactions, tertiary alkyl halides were less studied in either 
cross-coupling or C–H bond functionalization. Thus, one major emphasis of this thesis is on 
developing ruthenium(II)-catalyzed direct alkylation reactions with tertiary alkyl halides 50. At the 
outset of this project, chelation-assisting heterocycles were employed as directing groups (107). 
Furthermore, given the significant advantages of monoprotected amino acid (MPAA) 116 as ligands in 
promoting palladium-catalyzed C–H bond activation, we were also interested in testing their behavior 




















Scheme 2.1: Ruthenium(II)-catalyzed direct alkylation with tertiary alkyl halides 
 
In addition, considering the synthetically usefulness of this novel transformation, we were interested 
in extending its scope to arenes bearing directing groups which can be readily removed or further 
functionalized. Thus, we probed ketimine derivatives 188 for ruthenium(II)-catalyzed direct alkylation 
with both tertiary and secondary alkyl halides 50 and 44. Although transition metal-catalyzed 
ortho-selective C–H alkylation of ketimines was known, direct meta-alkylation with tertiary or 
secondary alkyl halides proved elusive. More importantly, simple one-pot hydrolysis could yield 























Scheme 2.2: Ruthenium(II)-catalyzed direct alkylation of ketimines 188 
 
Moreover, besides electron-deficient arenes, we were also interested in ruthenium(II)-catalyzed 
direct alkylation of the electron-rich ones. Thus, N-(pyrimidyl-2-yl)anilines 161 were also examined as 
substrates for this direct meta-alkylation. Tertiary, secondary as well as primary alkyl bromides were 
probed in this reaction. Importantly, the pyrimidyl directing group could easily be cleaved under 
acidic conditions to furnish a range of meta-alkylated anilines 191. 
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Scheme 2.3: Ruthenium(II)-catalyzed direct alkylation of N-(pyrimidyl-2-yl)anilines 161 
 
Despite the rapid development of ruthenium(II)-catalyzed Fujiwara-Moritani reactions, direct 
oxidative alkenylation of electron-rich arenes were underdeveloped. Consequently, we were 
interested in developing the first ruthenium(II)-catalyzed oxidative C–H alkenylation of phenol 
derivatives. Herein, we chose readily cleavable carbamates as directing groups in substrate 192 and 



















Scheme 2.4: Ruthenium(II)-catalyzed oxidative C–H alkenylation of phenol carbamates 192 
 
Another project was to extend the scope of oximes for the ruthenium(II)-catalyzed redox-neutral 
alkyne annulations of alkynes 155 with oximes 194 via C–H/N–O bonds functionalization. Moreover, 
well-defined cationic ruthenium(II) complex was examined as a catalyst for this transformation. A 
variety of symmetrically as well as unsymmetrically substituted alkynes 155 were tested with this 






























Ruthenium(II)-Catalyzed meta-Selective C─H Alkylations 
- 33 - 
 
3 Ruthenium(II)-Catalyzed meta-Selective C–H Alkylations 
 
As indicated in Chapter 1.3, transition metal-catalyzed C–H alkylation with unactivated alkyl halides 
has emerged as an economical alternative for the construction of C(sp2)–C(sp3) bonds. Ackermann 
and coworkers have demonstrated that, among a variety of transition metals, relatively cheap 
ruthenium(II) complexes showed excellent catalytic capability for highly site-selective direct 
alkylations under mild reaction conditions.140,142 More importantly, unique meta-selectivity was 
observed when unactivated secondary alkyl halides were employed as the electrophiles (Chapter 
1.2).143 In spite of the recent success in applying secondary alkyl halides in cross-coupling and C–H 
functionalization,95 unactivated tertiary alkyl halides were very rarely explored. Therefore, we set out 
to develop the first example of ruthenium(II)-catalyzed direct C–H alkylation with unactivated tertiary 
alkyl halides. 
3.1 Ruthenium(II)-Catalyzed meta-Selective C–H Alkylations by Heterocycle 
Assistance with Tertiary Alkyl Bromides  
3.1.1 Optimization Studies 
 
At the outset of our studies, we adopted the reaction conditions for the ruthenium(II)-catalyzed 
direct meta-alkylation with secondary alkyl bromides,143 using 2-phenylpridine (38b) as the standard 
substrate for this challenging alkylation with t-butyl bromide (50a) (Table 3.1). To our delight, the 
desired meta-alkylated product 187ba was obtained in 59% isolated yield (entry 1). Several other 
carboxylate co-catalysts also successfully delivered the target product, albeit in moderate yields 
(entries 2–5). While no reaction occurred in the absence of an additive (entry 6), high yield was 
obtained when Piv-Val-OH (116a) was introduced as a co-catalytic additive (entry 7). Although 
ruthenium(II)-amino acid complexes have been known for decades,231,232 they have been employed as 
catalysts for direct C–H functionalizations only very recently.233 Decreasing the loading of 
[RuCl2(p-cymene)]2 to 1.0 mol % led to a slightly lower yield (entry 8). A ruthenium(II)-amino acid 
complex 195 was independently prepared and showed excellent catalytic activity, furnishing desired 
product 187ba in even higher yield comparing to the in situ generated catalytic system (entry 9). Not 
surprisingly, this novel type of tertiary alkylation did not take place in the absence of ruthenium(II) 
catalyst or employing a Lewis acid catalyst, such as AlCl3 (entries 10–11). Palladium or rhodium 
catalyst could not promote this transformation under otherwise identical reaction conditions (entries 
12–14). Other ruthenium catalysts were also tested, whereas [RuCl2(PPh3)3] delivered only 10% of 
GC-conversion, Ru3(CO)12 showed no reactivity (entries 15–16). Encouraged by the excellent 
efficiency promoted by the Piv-Val-OH co-catalyst, we went on examining different MPAA ligands 116. 
Among selected amino acids, valine derivatives proved to be optimal (entries 17–19). Unprotected 
valine delivered coumpound 187ba only in low yield, thus highlighting the importance of a protecting 
group on the nitrogen; other N-protected MPAAs afforded the meta-alkylated product 187ba in 
moderate yields (entries 20–25). Furthermore, among a variety of different solvents, 1,4-dioxane 
proved to be the solvent of choice (entries 26–31). Using stoichiometric quantities of acetates as 
bases in the absence of any co-catalyst gave product 187ba in only unsatisfying low yields (entries 
32–35).  
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catalyst 2.5 mol %
base
solvent, 100 °C, 20 h




38b 50a 187ba  
Entry Catalyst Additive Base Solvent Yield (%) 
1 [RuCl2(p-cymene)]2 MesCO2H K2CO3 1,4-dioxane 59 
2 [RuCl2(p-cymene)]2 1-AdCO2H K2CO3 1,4-dioxane 58 
3 [RuCl2(p-cymene)]2 NaOAc K2CO3 1,4-dioxane 38 
4 [RuCl2(p-cymene)]2 KOAc K2CO3 1,4-dioxane 50 
5 [RuCl2(p-cymene)]2 CsOAc K2CO3 1,4-dioxane 51 
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K2CO3 1,4-dioxane 53 
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Ruthenium(II)-Catalyzed meta-Selective C─H Alkylations 


























32 [RuCl2(p-cymene)]2 -- KOAc 1,4-dioxane 37 
33 [RuCl2(p-cymene)]2 -- NaOAc DME 49 
34 [RuCl2(p-cymene)]2 -- CsOPiv DME 41 
35 [RuCl2(p-cymene)]2 -- CsOPiv 1,4-dioxane 33 
a Reaction conditions: 38b (0.5 mmol), 50a (1.5 mmol), catalyst (2.5 mol %), additive (30 mol %), base (1.0 mmol), 
solvent (2 mL), 100 °C, 20 h, under N2; isolated yields. 
b 1.0 mol % catalyst. c 5.0 mol % catalyst. d GC-conversion. 
 
3.1.2 meta-C–H Alkylation with Tertiary Alkyl Bromides: Scope and Limitations 
 
With the optimized conditions in hand, we subsequently explored the scope and limitations of this 
meta-selective alkylation. Various unactivated tertiary alkyl bromides 50 were tested with both in-situ 
generated ruthenium(II) catalyst and the single-component complex 195. In most cases, these two 
systems delivered comparable yields (Table 3.2). Thus, 1-methylcyclohexyl bromide (50b) gave the 
alkylated product 187bb in 78% and 75% yield, respectively (entry 1). Sterically more congested 
tertiary alkyl bromides also afforded desired products in moderate yields (entries 2–4). More 
importantly, tertiary alkyl bromides bearing functional groups, such as ether (50f), olefin (50g), 
chloride (50h) and phenyl groups (50i and 50j), were well tolerated (entries 5–9). Interestingly, 
despite the well-established method of ruthenium(II)-catalyzed alkylation with primary alkyl chlorides, 
compound 187bh was not contaminated with any primary alkylated byproduct (entry 7). 
 














cat. A: [RuCl2(p-cymene)]2 (2.5 mol %)
            Piv-Val-OH (30 mol %)
cat. B: [RuCl(O-Val-Piv)(p-cymene)] (5 mol %)
K2CO3
1,4-dioxane,100 °C, 20 h
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a Reaction conditions: cat. A: [RuCl2(p-cymene)]2 (2.5 mol %), Piv-Val-OH (30 mol %) or cat B: 
[RuCl(O-Val-Piv)(p-cymene)] (5.0 mol %); 38b (0.5 mmol), 50 (1.5 mmol), K2CO3 (1.0 mmol), 1,4-dioxane (2 mL), 
100 °C, 20 h, under N2; isolated yields. 
b [RuCl2(p-cymene)]2 (5.0 mol %). 
 
Subsequently, the influence of electron-donating and electron-withdrawing substituents on the aryl 
moiety upon the efficiency of the alkylation was examined (Table 3.3). Unsubstituted 
2-phenylpyridine (38a) was smoothly converted in good yield under both conditions (entry 1). 
Phenylpyridines bearing electron-withdrawing fluoro (38c), acetyl (38d) and ester (38e) groups in the 
para-position (entries 2–4) as well as p-tolylpyridine 38f (entry 5) selectively delivered meta-selective 
products in moderate to good yields. It is noteworthy that these functional groups could be valuable 
for further functionalization. However, surprisingly low yields were observed for electron-deficient 
trifluoromethyl- or cyano-substituted substrates 38g and 38h, respectively (entries 6 and 7). The 
same held true for the vinyl-containing substrate 38i (entry 8). Substituents in the 3-, 4-, or 5- position 
on the pyridine moiety in substrates 38 generally did not significantly affect the reaction outcome, 
affording the meta-alkylated products in moderate to good yields (entries 9–15). 
 













cat. A: [RuCl2(p-cymene)]2 (2.5 mol %)
            Piv-Val-OH (30 mol %)
cat. B: [RuCl(O-Val-Piv)(p-cymene)] (5 mol %)
K2CO3
1,4-dioxane,100 °C, 20 h
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a Reaction conditions: cat. A: [RuCl2(p-cymene)]2 (2.5 mol %), Piv-Val-OH (30 mol %) or cat B: 
[RuCl(O-Val-Piv)(p-cymene)] (5.0 mol %); 38 (0.5 mmol), 50a (1.5 mmol), K2CO3 (1.0 mmol), 1,4-dioxane (2 mL), 
100 °C, 20 h, under N2; isolated yields. 
b 10 mol % [Ru]. 
 
Summarizing the results of alkylations of ortho- and meta-substituted 2-phenylpyridines 38 (Table 
3.4), it is particularly noteworthy that ortho-substituted arene 38q furnished the products 187 being 
substituted exclusively at the sterically more congested meta-position (entries 1 and 2). 
meta-Methoxy substituted arene 38r selectively furnished the product 187rb alkylated in 
meta-position, with respect to both methoxy and pyridyl substituents, although with lower efficacy 
(entry 3). Furthermore, meta-selective alkylation of naphthalene derivative 38s gave rise to 
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1,4-dioxane, 100 °C, 20 h
[RuCl2(p-cymene)]2
(5.0 mol %)
Piv-Val-OH (30 mol %)
187  








































































Reaction conditions: 38 (0.5 mmol), 50 (1.5 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), Piv-Val-OH (30 mol %), K2CO3 (1.0 
mmol), 1,4-dioxane (2 mL), 100 °C, 20 h, under N2; isolated yields. 
 
Taking the importance of heteroarenes as key motifs in various bioactive compounds into 
consideration, we were delighted to observe alkylation of substituted thiophene 38t in a 




1,4-dioxane,100 °C, 20 h
(5.0 mol %)










38t 50a 187ta  
Scheme 3.1: Direct meta-alkylation of 2-(thiophen-3-yl)pyridine (37t) 
 
Besides pyridine, synthetically useful the pyrazole heteroarene could serve as a directing group for 
the ruthenium(II)-catalyzed meta-alkylation as well (Table 3.5). 1-Phenylpyrazole derivatives 131 
bearing either electron-donating or electron-withdrawing groups could be smoothly meta-alkylated 
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with a range of tertiary alkyl bromides (entries 1─4). However, moderate to low yields were observed 
when electron-neutral 1-phenylpyrazole (131c) (entries 5─6) or electron-deficient one 131d (entries 7 
and 9) were subjected to the optimized reaction condition. In accordance with the reactivity of 
ortho-substituted 2-phenylpyridines 38 discussed above, direct alkylation of ortho-substituted 
1-phenylpyrazole 131e only took place at the sterically more congested meta-C─H bond (entries 9).  
 















cat. A: [RuCl2(p-cymene)]2 (5.0 mol %)
            Piv-Val-OH (30 mol %)
cat. B: [RuCl(O-Val-Piv)(p-cymene)] (10 mol %)
K2CO3
1,4-dioxane,100 °C, 20 h
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a Reaction conditions: A: [RuCl2(p-cymene)]2 (5.0 mol %), Piv-Val-OH (30 mol %); B: [RuCl(O-Val-Piv)(p-cymene)] (195) 
(10 mol %); 131 (0.5 mmol), 50 (1.5 mmol), K2CO3 (1.0 mmol), 1,4-dioxane (2 mL), 100 °C, 20 h, under N2; isolated 
yields. 
 
Moreover, 2-phenylpyrimidine derivatives 197 appeared to be suitable substrates for the 
ruthenium(II)-catalyzed meta-selective direct alkylation as well (Table 3.6). Both the in situ formed 
catalytic system and the ruthenium(II) complex 195 were applicable. Unsubstituted arene 197a 
smoothly delivered meta-alkylated product 198aa in moderate yields (entry 1). While electron-rich 
arene 197b showed lower efficacy (entry 2), high yield was obtained for electron-deficient arene 197c 
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cat. A: [RuCl2(p-cymene)]2 (5.0 mol %)
            Piv-Val-OH (30 mol %)
cat. B: [RuCl(O-Val-Piv)(p-cymene)] (10 mol %)
K2CO3
1,4-dioxane,100 °C, 20 h
 





































a Reaction conditions: cat. A: [RuCl2(p-cymene)]2 (5.0 mol %), Piv-Val-OH (30 mol %) or cat B: 
[RuCl(O-Val-Piv)(p-cymene)] (10 mol %); 197 (0.5 mmol), 50a (1.5 mmol), K2CO3 (1.0 mmol), 1,4-dioxane (2 mL), 
100 °C, 20 h, under N2; isolated yields. 
 
3.1.3 Mechanistic Studies 
 
Given the unique meta-selectivity of our ruthenium(II)-catalyzed direct alkylation, we performed 
detailed mechanistic studies to delineate its mode of action. To this end, we conducted 
intermolecular competition experiments and experiments with isotopically labeled starting materials. 
 
3.1.3.1 Intermolecular Competition Experiments 
 
Intermolecular competition experiments between para-substituted 2-phenylpyridines (38) were 
performed, in which a 1.25 fold excess of both substrates was treated with bromide 50a as the 
limiting reagent under otherwise identical optimized reaction conditions. The ratio of products was 
determined by 1H-NMR after aqueous workup. 
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[RuCl2(p-cymene)]2





























































































Piv-Val-OH (15 mol %)
(2.5 mol %)
K2CO3




Piv-Val-OH (18.6 mol %)
(3.1 mol %)
K2CO3




Scheme 3.2: Intermolecular competition experiments between substituted 2-phenylpyridines 38 
 
Experiment A showed electron-rich substrate 38f to be more reactive in comparison to its 
trifluoromethyl-substituted analogue 38g. Similar result could be observed in experiment B, in which 
arene 38b with electronically more donating substituent reacted more rapidly than methyl-containing 
compound 38f. Interesting results were obtained from experiments C and D. Thus, electron-deficient 
fluoro-substituted arene 38c was found to be more reactive than both methoxy substituted 38b and 
unsubstituted 38a. This phenomenon could be rationalized as the result of ortho-orienting effect of 
the fluorine substituent.234 
 
Subsequently, we performed competition experiments between tertiary alkyl bromide 50b and 
primary alkyl bromide 42e as well as between 50f and secondary alkyl bromide 44d. These results 
showed no special preference of either reaction. The reaction rates appeared to be comparable and 
still conserving the individual regioselectivity mode for each electrophile. 
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Scheme 3.3: Intermolecular competition experiments between alkyl bromides 42e, 44d and 50b, 50f 
 
3.1.3.2 Experiments with Deuterium-Labeled Substrates 
 
As shown in Scheme 3.4, upon alkylation of deuterated 2-phenylpyridine [D5]-38a under the 
optimized reaction conditions, significant D/H exchanges in the ortho-positions of both substrate and 
product were observed. We found 81% and 58% hydrogen incorporation in the product [Dn]-187aa as 
well as 57% hydrogen incorporation in the recovered starting material [Dn]-38a. This result provided 
strong support for the C−H bond metalation step to proceed initially in the ortho-position of the 
arene. Moreover, the D/H-exchange caused by adventitious water in the stoichiometric base and by 
the acid moiety in the co-catalytic additive Piv-Val-OH indicated the ortho C−H bond metalation to be 





























Piv-Val-OH (30 mol %)
[Dn]-187aa: 54% [Dn]-38a: 19%
t-BuBr
 
Scheme 3.4: D/H exchange during direct meta-alkylation of [D5]-phenylpyridine 38a 
 
We also performed our standard reaction in the presence of small amounts of D2O (Scheme 3.5). In 
accordance with our previously discussed reaction of [D5]-38a (Scheme 3.4), a significant amount of 


















1,4-dioxane, 100 °C, 20 h
[RuCl2(p-cymene)]2 
(2.5 mol %)
Piv-Val-OH (30 mol %)




Scheme 3.5: Direct meta-alkylation of arene 38b in the presence of D2O 
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To probe the mechanism of the cleavage of the meta-C−H bond and the formation of the C−C bond, 
[D3]-38a was also subjected to the optimized reaction conditions. The reaction smoothly delivered 
meta-alkylated product [D2]-187aa in 46% isolated yield together with 32% of recovered substrate 
[D3]-38a (Scheme 3.6). Detailed 1H NMR studies showed no hydrogen incorporation in any 
meta-positions neither of the product nor of the recovered starting material, thus indicating the 
















[D3]-38a [D3]-38a: 32%[D2]-187aa: 46%
K2CO3
1,4-dioxane, 100 °C, 20 h
[RuCl2(p-cymene)]2 
(2.5 mol %)




Scheme 3.6: Direct meta-alkylation of (trideuteriophenyl)pyridine [D3]-37a 
 
Moreover, we performed an intermolecular competition experiment between equimolar amounts of 
2-phenylpyridines 38a and [D3]-38a under the optimized reaction conditions. On the average of 2 















[D0]-187aa : [D2]-187aa = 1.44
average of 2 runs38a [D3]-38a [Dn]-38a: 38%[Dn]-187aa: 12%
K2CO3
1,4-dioxane, 100 °C, 20 h
[RuCl2(p-cymene)]2 
(2.5 mol %)




Scheme 3.7: KIE study through competition between arenes [D0]-37a and [D3]-37a 
 
3.1.3.3 Experiments in the Presence of Radical Scavengers  
 
In order to gain some understanding about the C−C bond formation, we performed reactions in the 
presence of different radical scavengers 199 to see, if any kind of alkyl radical was formed in this 
novel transformation (Table 3.7). Stoichiometric amounts of TEMPO (199a) completely inhibited the 
reaction. However, this observation could not finally confirm a radical mechanism. For instance, it is 
known that ruthenium hydride smoothly react with TEMPO to form a ruthenium-TEMPO complex.235 
On the contrary, other representative scavengers such as BHT (199b) and E-stilbene (199d) did not 
affect the reaction outcome, furnishing product 187ba in comparable yields. When 
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Piv-Val-OH (30 mol %)
 























Reaction conditions: 38b (0.5 mmol), 50a (1.5 mmol), radical scavenger 199 (1.5 mmol), [RuCl2(p-cymene)]2 
(5.0 mol %), Piv-Val-OH (30 mol %), K2CO3 (1.0 mmol), 1,4-dioxane (2 mL), 100 °C, 20 h, under N2; isolated yields. 
 
3.1.3.4 Proposed Catalytic Cycle 
 
Based on the experimental studies summarized above and taken into account the studies of 
ruthenium(II)-catalyzed meta-alkylation with secondary alkyl halides143 and ruthenium(II)-catalyzed 
meta-sulfonylation,70 we propose a plausible catalytic cycle which is shown in Scheme 3.8. 
 
Initially, the ruthenium(II)-MPAA complex 195 undergoes ligand exchange with substrate 38a and is 
coordinated by the nitrogen atom of the pyridine directing group to form complex 200. Subsequently, 
the amino acid enables the reversible cyclometalation via transition state 201, thus forming a 
five-membered ruthenacycle 202. The strong directing group effect of the Ru−C(sp2) σ-bond 
introduces the irreversible tert-alkylation predominantly in the remote para-position.73 However, the 
exact pathway for the C−C bond forming step is still not understood, and tertiary alkyl cation or 
radical could be involved as well. Finally, the proto-demetalation step delivers the meta-alkylated 
product 187aa and regenerating the catalytically active species 195.  
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Scheme 3.8: Proposed catalytic cycle for the ruthenium(II)-catalyzed direct meta-alkylation with 
bromide 50a 
 
Moreover, Houk, Yu and Wu have investigated the role of N-acyl amino acid in palladium-catalyzed 
remote C−H activation of tethered arenes.236 Computational studies suggested the MPAA ligand not 
only to stabilize the monomeric palladium complex but also to serve as the internal base for proton 
abstraction. Hence, a similar transition state 205 for the ruthenium(II)-catalyzed meta-alkylation 













Scheme 3.9: Possible transition state 205 for the ruthenium(II)-catalyzed direct meta-alkylation 
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3.2 Ruthenium(II)-Catalyzed meta-Selective C–H Alkylations of Ketimines with 
Secondary and Tertiary Alkyl Bromides 
 
Inspired by the success of our ruthenium(II)-catalyzed direct meta-alkylation reactions of 
2-phenylpyridines 38, 1-phenylpyrazoles 131 and 2-phenylpyrimidines 197 described above, we 
became intrigued to enlarge the synthetically usefulness of this unprecedented meta-selective 
tertiary alkylation by modifying the directing group from heterocycles to those which can be readily 
manipulated. Since the Ackermann group reported on the ruthenium(II)-catalyzed ortho-alkylation of 
ketimines with primary alkyl bromides and given the versatile application of ketimines,142 we set out 
to develop ruthenium(II)-catalyzed direct meta-alkylation of ketimines 188 with both tertiary and 
secondary alkyl bromides. 
 
3.2.1 Optimization Studies 
 
Preliminary studies by N. Hoffmann on the ruthenium(II)-catalyzed secondary alkylation of ketimines 
showed that ketimine 188a bearing electron-withdrawing substituent could be meta-alkylated with 
both cyclic and acyclic secondary alkyl bromides.237 Although only unsatisfactory low yields were 
obtained, it was a proof of principle that ketimines are suitable substrates for this transformation. At 
the outset of our studies, we subjected substituted ketimine 188aa to our standard reaction 
conditions for the meta-alkylation of 2-phenylpyridines; the results are summarized in Table 3.8. To 
our delight, the desired meta-alkylated acetophenone 189ab was obtained in 22% yield after one-pot 
hydrolysis (entry 1). Whereas MesCO2H provided only 26% NMR conversion, the desired product 
189ab was obtained in 50% yield when using 1-AdCO2H as an additive (entries 2 and 3). Decreasing 
the reaction temperature to 100 °C completely shut down the reaction. Moreover, elevating the 
reaction temperature to 140 °C led to lower yields (entries 4 and 5). Among several solvents screened, 
toluene and o-xylene could give comparable results (entries 6–9). Using Cs2CO3 as a base instead of 
K2CO3 could also deliver the product in comparable 49% yield. On the contrary, Na2CO3 and Ag2CO3 
proved to be unsuitable bases (entries 10–12). Furthermore, stoichiometric amount of base in the 
absence of co-catalyst only led to unsatisfactory low yields (entries 13 and 14). Subsequently, we 
tested different protecting groups on the imine moiety, among which 3,4,5-trimethoxyphenyl (TMP) 
proved to be the most efficient one (entries 16–21). As shown in entry 18, although a high 
GC-conversion was determined in this transformation, only 66% NMR conversion and 52% isolated 
product was obtained, which indicated an unsatisfactory mass balance. Generally, a pale spot could 
always be observed on the baseline of the TLC analysis in these reactions. However, attempts on 








Ruthenium(II)-Catalyzed meta-Selective C─H Alkylations 
- 51 - 
 






additive 30 mol %
base
solvent, temp, 20 h









Entry PG Additive Base Solvent Temp(°C) Yield (%) 
1 PMP (188aa) Piv-Val-OH K2CO3 1,4-dioxane 120 22 
2 PMP MesCO2H K2CO3 1,4-dioxane 120 26
b
 
3 PMP 1-AdCO2H K2CO3 1,4-dioxane 120 50 
4 PMP 1-AdCO2H K2CO3 1,4-dioxane 100 0 
5 PMP 1-AdCO2H K2CO3 1,4-dioxane 140 47 
6 PMP 1-AdCO2H K2CO3 NMP 120 0 
7 PMP 1-AdCO2H K2CO3 o-xylene 120 49 
8 PMP 1-AdCO2H K2CO3 DME 120 36 
9 PMP 1-AdCO2H K2CO3 PhMe 120 52 
10 PMP 1-AdCO2H Na2CO3 PhMe 120 <5 
11 PMP 1-AdCO2H Cs2CO3 PhMe 120 49 
12 PMP 1-AdCO2H Ag2CO3 PhMe 120 0 
13 PMP - KOAc PhMe 120 30b 
14 PMP - NaOAc PhMe 120 <5 
15 PMP Piv-Val-OH K2CO3 PhMe 120 30
b
 







1-AdCO2H K2CO3 PhMe 120 58 















1-AdCO2H K2CO3 PhMe 120 50
b
 
a Reaction conditions: 188a (0.5 mmol), 50b (1.5 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), additive (30 mol %), base 
(1.0 mmol), solvent (2 mL), 20 h, under N2; yield of isolated products. 
b NMR yield with CH2Br2 as internal standard.   
c GC-conversion. 
 
3.2.2 Direct meta-Alkylation with Tertiary Alkyl Bromides: Scope and Limitations 
 
With the optimized reaction conditions in hand, we subsequently explored the scope and limitations 
of the meta-selective alkylation in terms of differently substituted ketimines 188 and tertiary alkyl 
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bromides 50 (Table 3.9). The parent t-BuBr (50a) smoothly delivered the desired product 189aa in 59% 
yield (entry 1). Sterically more hindered tertiary alkyl bromides also afforded the corresponding 
products in moderate yields (entries 2–6). It should be emphasized that tertiary alkyl bromide 50h 
bearing the chlorine substituent was well tolerated (entry 4). Unsubstituted ketimines were also 
examined under the standard reaction conditions. Thus, meta-alkylated acetophenone 189ba and 
propiophenone 189ca were obtained in 54% and 55% yield, respectively (entries 7 and 8). When 
arenes 188 bearing electron-donating groups were tested, switching solvent from toluene to 
1,4-dioxane was necessary to prevent the undesired benzylation. Both alkylations afforded products 
189da and 189eb in 47% yield (entries 9 and 10). Electron-deficient propiophenone-derived ketimine 
188f was tolerated in this transformation as well (entry 11). 
 
Table 3.9: Direct meta-alkylation of ketimines 188 with tertiary alkyl bromides 50 
+
 [RuCl2(p-cymene)]2
1-AdCO2H (30 mol %)















23 °C, 3 h
H+
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a Reaction conditions: 188 (0.5 mmol), 50 (1.5 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), 1-AdCO2H (30 mol %), K2CO3 
(1.0 mmol), PhMe (2 mL), 120 °C, 20 h, under N2; yield of isolated products. 
b 1,4-dioxane (2 mL) as the solvent. 
 
3.2.3 Direct meta-Alkylation with Secondary Bromides: Scope and Limitations 
 
Besides tertiary alkyl bromides 50, we were pleased to find that secondary alkyl bromides 44 could 
also serve as electrophiles in the meta-C–H alkylation reactions. Differently substituted ketimines 188 
were tested under the optimized reaction conditions with bromocycloheptane (44e) (Table 3.10). A 
generally broader scope of ketimines was observed compared to the tertiary alkyl bromides 50. 
Transformation of unsubstituted ketimines to the desired products 206 proceeded smoothly (entries 
1 and 8). Ketimines bearing both electron-donating and electron-withdrawing groups were well 
tolerated and delivered meta-alkylated products in moderate to good yields (entries 2–7). It is worth 
noting that naphthalene derivative 188i selectively furnished meta-substituted product 206ie under 
the optimized reaction conditions (entry 9).  
 
Table 3.10: Direct meta-C–H alkylation of ketimines 188 with secondary alkyl bromide 44e 
+
 [RuCl2(p-cymene)]2
1-AdCO2H (30 mol %)







23 °C, 3 h
H+
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a Reaction conditions: 188 (0.5 mmol), 44e (1.5 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), 1-AdCO2H (30 mol %), K2CO3 
(1.0 mmol), PhMe (2 mL), 120 °C, 20 h, under N2; yield of isolated products. 
b 1,4-Dioxane (2 mL) as the solvent. 
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Subsequently, we continued to explore the scope of acyclic secondary alkyl bromides 44 (Table 3.11). 
In contrast to the monoalkylation of ketimine 188a with cyclic secondary alkyl bromides 44, the 
reaction with the acyclic secondary bromide 44f led to the formation of dialkylated product in large 
amounts, whereas the monoalkylated product 206af was isolated in low yield (entry 1). Unfortunately, 
the dialkylated products which could be observed on GC-MS analysis were difficult to isolate as pure 
compounds. To our delight, in the case of the 2-substituted naphthalene derivative 188i with its 
single meta-position, products 206i were obtained in excellent yields (entries 4–7). 
 
Table 3.11: Direct meta-C–H alkylation of ketimines 188 with acyclic secondary alkyl bromides 44 
+
 [RuCl2(p-cymene)]2
1-AdCO2H (30 mol %)











23 °C, 3 h
H+
 


























































a Reaction conditions: 188 (0.5 mmol), 44 (1.5 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), 1-AdCO2H (30 mol %), K2CO3 
(1.0 mmol), PhMe (2 mL), 120 °C, 20 h, under N2; yield of isolated products. 
b 44 (0.75 mmol). 
 
Furthermore, given the importance of amines as structural motifs in organic synthesis, we performed 
a one-pot reduction of the meta-alkylated ketimine products 188. Not surprisingly, both 
unsubstituted ketimine 188b and para-fluoroacetophenone imine 188a afforded secondary amines in 
good yields (Scheme 3.10). 
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1-AdCO2H (30 mol %)




R = H   188b








R = H   207be: 52%
R = F   207ae: 61%  
Scheme 3.10: One-pot synthesis of meta-alkylated secondary amines 207 
 
3.2.4 Direct meta- versus ortho-Alkylation with Cyclic Secondary Alkyl Bromides 
 
Besides bromocycloheptane (44e), we explored the reaction scope with different cyclic secondary 
alkyl bromides as well (Table 3.12). Unfortunately, bromocyclopropane (44i) proved unsuitable for 
this reaction (entry 1). However, cyclic alkyl bromides with ring sizes varying from 4 to 8 could be 
smoothly converted and gave alkylated product 206 in moderate yields (entries 2–5). Surprisingly, 
ruthenium(II)-catalyzed alkylation with bromocyclobutane (44j) turned out to exclusively yield 
ortho-functionalized product 206aj in 50% yield (entry 2) ), as was disclosed by 2D NMR data for 
selected products. 
  
Table 3.12: Direct alkylation of ketimines 188 with cyclic secondary alkyl bromides 44 
+
 [RuCl2(p-cymene)]2
1-AdCO2H (30 mol %)








23 °C, 3 h
H+
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a Reaction conditions: 188a (0.5 mmol), 44 (1.5 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), 1-AdCO2H (30 mol %), K2CO3 
(1.0 mmol), PhMe (2 mL), 120 °C, 20 h, under N2; yield of isolated products. 
 
In order to test the universality of this phenomenon, we chose 2-phenylpyridine derivative 38b for 
the alkylation with cyclic secondary alkyl bromides 44 under the conditions optimized for the 
alkylation with tertiary bromides (Table 3.13). As above, we found no product formation in the 
reaction with bromocyclopropane 44i (entry 1). Furthermore, the ortho-selectivity pattern was 
observed for the alkylation with bromocyclobutane 44j, however, in this case resulting in the 
dialkylation to furnish product 208bj (entry 2). Bromocyclopentane 44k again smoothly delivered 
meta-alkylated product 208bk in good yield (entry 3). 
 






1,4-dioxane,100 °C, 20 h
(2.5 mol %)
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a Reaction conditions: 37b (0.5 mmol), 44 (1.5 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), Piv-Val-OH (30 mol %), K2CO3 
(1.0 mmol), 1,4-dioxane (2 mL), 100 °C, 20 h, under N2; yield of isolated products. 
 
Intermolecular competition reaction between bromocyclobutane (44j) and bromocyclopentane (44k) 
was performed under the standard reaction conditions (Scheme 3.11). As expected, ortho-alkylated 
compound 206aj was isolated as a pure product. However, we also obtained the 
ortho,meta-dialkylated ketone 209 which should result from either a sequential 
ruthenium(II)-catalyzed ortho-alkylation of meta-alkylated product 206ak or meta-alkylation of 
ortho-alkylated compound 206aj. Thus, no particular difference in reaction rates was found between 
these two cyclic alkyl bromides. More importantly, each alkyl bromide gave rise to the corresponding 













Isolated yield: 33% 27% not isolated
 [RuCl2(p-cymene)]2
1-AdCO2H (30 mol %)





44j 44k 206aj 206ak209






Scheme 3.11: Intermolecular competition experiment between cyclic alkyl bromides 44j and 44k 
 
Ruthenium(II)-catalyzed direct alkylation with exo-bromonorbornane (44m) led to interesting results 
as well (Scheme 3.12). Both ortho- and meta-alkylated products exo-206im and exo-206im’ were 
isolated in a ratio of 2.4 : 1 with retention of the thermodynamically more stable exo-configuration of 











1-AdCO2H (30 mol %)
PhMe, 120 °C, 20 h
K2CO3
(5.0 mol %)
188i exo-44m exo-206im: 46% exo-206im':19%
23 °C, 3 h
H+
 
Scheme 3.12: Ruthenium(II)-catalyzed direct norbornylation of ketimine 188i 
 
3.2.5 Intramolecular Competition Experiments 
 
Importantly, alkylation of ketimine 188j could be considered as an intramolecular competition 
reaction, the result of which showed that the arene bearing the fluorine substituent was selectively 
converted (Scheme 3.13). 
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1-AdCO2H (30 mol %)
PhMe, 120 °C, 20 h
K2CO3
(5.0 mol %)






188j 206je62%  
Scheme 3.13: Intramolecular competition experiments of ketimine 188j 
 
3.2.6 Intermolecular Competition Experiments 
 
Intermolecular competition experiments between substituted ketimines 188, during which a 1.25 
fold excess of both substrates 188 was treated with bromocycloheptane (44e) as the limiting reagent 
under otherwise identical reaction conditions, were performed (Scheme 3.14). The ratio of products 




1-AdCO2H (38.5 mol %)




































23 °C, 3 h
H+
 
Scheme 3.14: Intermolecular competition experiments between ketimines 188 
 
Experiment A showed electron-deficient fluoro-substituted arene 188a to be more reactive than the 
unsubstituted ketimine 188b. This could be accounted for by the ortho-orienting effect of the fluorine 
substituent. However, the trifluoromethyl-bearing substrate 188h was more reactive than the methyl 
substituted 188d as well, presumably due to the increased acidity of the C─H bond in the neighboring 
position. This observation contrasts with the previous one made for meta-alkylation of 
2-phenylpyridines 38 (Scheme 3.2), but in line with the effects observed in ruthenium(II)-catalyzed 
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3.3 Ruthenium(II)-Catalyzed meta-Selective C–H Alkylations of Aniline Derivatives 
with Unactivated Alkyl Bromides 
 
N-(Pyrimidine-2-yl)anilines 161 are important structural motifs in biologically active and naturally 
occurring compounds and pharmacologically active substances (Scheme 3.15). Among them, Imatinib 
(210) and Nilotinib (211) are in the list of the top-selling drugs. Therefore, it is of particular interest to 
synthesize aniline derivatives via C─H bond functionalization. Ackermann and co-workers have 
reported ruthenium(II)-211 or nickel-catalyzed238 C─H/N─H bond functionalization of 
N-(pyrimidine-2-yl)anilines 161 where the pyrimidyl group served as a removable directing group. 
However, direct alkylations of arenes 161 have thus far proved elusive. Herein, we wish to extend our 
scope of ruthenium(II)-catalyzed direct meta-alkylation to N-(pyrimidine-2-yl)aniline derivatives 161. 
More importantly, the pyrimidyl moiety can readily be cleaved, thus providing access to 


















































Scheme 3.15: N-2-Pyrimidyl anilines 161 in drugs and bioactive compounds 
 
3.3.1 Optimization Studies 
 
At the outset of our studies, we adopted the reaction conditions optimized for the 
ruthenium(II)-catalyzed meta-alkylation of 2-phenylpyridines 38 (Table 3.14). To our delight, the 
desired product 215aa was isolated in 66% yield (entry 1). Other MPAAs as well as different 
N-protecting groups showed lower efficiency (entries 2─8). Unprotected valine (116e) was also 
capable to promote this transformation, albeit with lower efficacy (entry 9). Among a variety of 
solvents, 1,4-dioxane proved to be most efficient (entries 10─14). However, 1H NMR only showed a 
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solvent, 100 °C, 16 h
MPAA 30 mol %
[RuCl2(p-cymene)]2
161a 50a 215aa  















































































































Ruthenium(II)-Catalyzed meta-Selective C─H Alkylations 
































a Reaction conditions: 161a (0.5 mmol), 50a (1.5 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), MPAA 116 (30 mol %), K2CO3 
(1.0 mmol), solvent (2 mL), 100 °C, 16 h, under N2; isolated yields. 
b GC-conversion. 
 
3.3.2 Effect of Directing Groups 
 
Furthermore, we probed the effect of the different directing group for this ruthenium(II)-catalyzed 
direct meta-alkylation (Scheme 3.16). Switching the pyrimidyl group to the pyridyl one under 
otherwise identical reaction conditions resulted in a 30% lower isolated yield of the product 217, 
indicating pyridyl to be the less efficient directing group in this transformation. A simple phenyl 
substitution failed to yield any product 218. This observation clearly showed the necessity of a 
chelating heteroatom in the directing group for this reaction. Moreover, this indirectly proved this 
reaction not to be a simple electrophilic aromatic substitution, in which the ruthenium(II) complex 
functioned only as a Lewis acid. Besides, electron-donating amines are well-known ortho- and 
para-directing groups. Thus, this mechanism could cause an alternative to meta-selective 














1,4-dioxane, 100 °C, 16 h
Piv-Val-OH (30 mol %)
[RuCl2(p-cymene)]2
F F
X = Y = N         215aa : 66%
X = CH, Y = N  217     : 36%
X = Y = CH       218     :  0%
X = Y = N            161a
X = CH, Y = N     216b  
X = Y= CH           216c
50a
 
Scheme 3.16: Directing group effect in the direct meta-alkylation of aniline derivatives 
 
3.3.3 Direct meta-Alkylation with Tertiary Alkyl Bromides: Scope and Limitations 
 
With the optimized reaction conditions in hand, we subsequently explored the scope and limitations 
of the meta-selective alkylation with a range of tertiary alkyl bromides 50 (Table 3.15). Cyclic tertiary 
bromide 50b delivered the desired product 212ab in 60% yield (entry 1). Sterically hindered tertiary 
alkyl bromides 50 also afforded the corresponding products in moderate yields (entries 2─3). It 
should be emphasized that alkyl bromide 50h with a chlorine substituent was well tolerated (entry 4). 
Moreover, alkenyl- (50g) and phenylsubstituted bromides 50i could smoothly be converted as well 
(entries 5 and 6). 
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Piv-Val-OH (30 mol %)
[RuCl2(p-cymene)]2
161a 50 215  
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a Reaction conditions: 161a (0.5 mmol), 50 (1.5 mmol), [RuCl2(p-cymene)]2 (2.5 mol %), Piv-Val-OH (30 mol %), K2CO3 
(1.0 mmol), 1,4-dioxane (2 mL), 120 °C, 20 h, under N2; isolated yields. 
 
Thereafter, we explored the scope of substituted N-(pyrimidine-2-yl)anilines 161 for the direct 
meta-selective alkylation (Table 3.16). To our delight, arenes bearing bromine (161b) and chlorine 
(161c) substituents were smoothly converted, giving the meta-alkylated products 215ba and 215ca in 
moderate yields (entries 1 and 2). Likewise, electron-neutral as well as electron-rich arenes delivered 
the target compounds 215da and 215ea in good yields as well (entries 3 and 4). Notably, switching 
the ligand to Ad-Ile-OH enabled the direct meta-alkylation of challenging ortho-substituted substrates. 
Aniline derivate 161f and 161g furnished alkylation products exclusively at the sterically more 
congested meta-C─H bond (entries 5 and 6). 2,4-Substituted aniline 161h was smoothly alkylated at 
the 3-position, highlighting the excellent site-selectivity of this approach (entry 7). 
 
 













1,4-dioxane, 100 °C, 16 h
(5.0 mol %)
Piv-Val-OH (30 mol %)
[RuCl2(p-cymene)]2
161 50a 215  
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a Reaction conditions: 161 (0.5 mmol), 50a (1.5 mmol), [RuCl2(p-cymene)]2 (5 mol %), Piv-Val-OH (30 mol %), K2CO3 
(1.0 mmol), 1,4-dioxane (2 mL), 100 °C, 20 h, under N2; isolated yields; 
b 120 °C. c Ad-Ile-OH instead of Piv-Val-OH. 
 
3.3.4 Direct Alkylation with Primary and Secondary Alkyl Bromides 
 
Furthermore, we probed if this optimized catalytic system could be applied for the alkylation with 
primary and secondary alkyl bromides (Scheme 3.17). However, only trace quantity of the product 
219 was detected when 1-bromohexane (42e) was employed. Bromocycloheptane (44e) was able to 
deliver the desired product under standard conditions, albeit only in a unsatisfactory low yield. 
Replacing MPAA ligand by 1-AdCO2H could improve the yield to 45%, unfortunately, the yield could 
not be further improved by raising the reaction temperature. 
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Piv-Val-OH:                      28%
1-AdCO2H:                       45%







1,4-dioxane, 100 °C, 16 h
(5.0 mol %)
Piv-Val-OH (30 mol %)
[RuCl2(p-cymene)]2
(5.0 mol %)





Scheme 3.17: Direct alkylations with primary and secondary alkyl bromides 42e and 44e 
 
Given the fact that N-(pyrimidine-2-yl)anilines containing the piperidine moiety are important 
constituents in antitumor reagents and kinase inhibitors, we were interested in preparing these 
analogues employing our ruthenium(II)-catalyzed meta-selective direct alkylation strategy (Table 
3.17). We chose fluoro-substituted aniline 161f as the standard substrate, N-Boc-protected piperidine 
44n as the alkylating reagent. Under the optimized reaction conditions, the desired product 220 could 
be obtained in 32% isolated yield (entry 1). However, other carboxylates as well as MPAAs provided 
only low conversions (entries 2−4). Subsequently, we tested different protecting groups on the 
piperidine nitrogen. However, alkylation with neither pivaloyl- nor tosyl-protected piperidine 44 
allowed to improve the yield (entries 5−6). 
 


















161f 44 220  
Entry PG Additive Yield (%) 
1 Boc (44n) 1-AdCO2H 32 
2 Boc (44n) MesCO2H <5 
3 Boc (44n) Piv-Val-OH <5 
4 Boc (44n) Ad-Ile-OH <5 
5 Piv (44o) 1-AdCO2H 20 
6 Ts (44a) 1-AdCO2H <5 
a Reaction conditions: 161f (0.25 mmol), 44 (0.75 mmol), [RuCl2(p-cymene)]2 (5 mol %), additive (30 mol %), K2CO3 
(0.75 mmol), 1,4-dioxane (2 mL), 120 °C, 18 h, under N2; isolated yields. 
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3.3.5 Removal of the Directing Group 
 
Importantly, the pyrimidyl directing group could readily be cleaved under acidic conditions, providing 
meta-alkylated aniline derivative 191 in high yield (Scheme 3.18). Thus, our new methodology 










mw. 150 oC, 1 h
84%
191215aa  
Scheme 3.18: Removal of the directing group 
 
3.3.6 H/D Exchange  
 
In order to gain insight into the reaction mechanism of the ruthenium(II)-catalyzed meta-selective 
direct alkylation of aniline derivatives 161, we performed an experiment in the presence of D2O 
under the optimized reaction conditions. As shown in Scheme 3.18, a significant H/D exchange was 
observed in the ortho-position of both the product [Dn]-215aa and the recovered starting material 













44% D 15% D
[RuCl2(p-cymene)]2 
(5 mol %)
Piv-Val-OH (30 mol %)
t-BuBr








Scheme 3.19: Direct meta-alkylation of aniline 161a in the presence of D2O 
 
Most probably, the mechanism of these meta-alkylation corresponds to those discussed above 
(Scheme 3.9). 
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4 Ruthenium(II)-Catalyzed Oxidative C–H Alkenylation of Aryl 
Carbamates 
As discussed above in Chapter 1.4, significant progress has been accomplished in 
ruthenium(II)-catalyzed environmentally benign twofold C–H bond alkenylations. In contrast, the use 
of air- and moisture stable ruthenium(II) complexes for challenging oxidative C–H bond alkenylations 
with widely accessible phenol derivatives has unfortunately proven to be elusive until recently.178 In 
the course of our continuing efforts in step-economical C–H bond functionalizations, we devised 
reaction conditions for ruthenium(II)-catalyzed cross-dehydrogenative alkenylations of aryl 
carbamates bearing removable directing groups.239-241 Importantly, aryl carbamates are key 
intermediates in organic synthesis, and serve as versatile organic electrophiles in transition metal 
catalysis.242,243 
 
4.1 Optimization Studies 
At the outset of our studies, we optimized reaction conditions for the oxidative alkenylation of aryl 
carbamate 192a (Table 4.1). Preliminary studies with a naphthyl carbamate indicated that the desired 
oxidative alkenylation was not viable with CsOAc or KPF6 as the co-catalytic additive. However, 
satisfactory results were gratifyingly achieved when employing 10 mol% of AgSbF6. The desired 
olefination did not occur in the absence of the ruthenium complex [RuCl2(p-cymene)]2 (entry 1). 
Among a set of representative solvents, DME turned out to be the optimal one (entries 2–6), and the 
catalytic system was found to be air-stable (entry 7). The use of a combination of CuBr2 and NaOAc as 
terminal oxidant failed to deliver the desired product (entry 8). Notably, the cross-dehydrogenative 
alkenylation failed to proceed in the absence of AgSbF6 as the co-catalyst (entry 9), thus being 
suggestive of the formation of a cationic ruthenium(II) catalyst. Yet, the preformed cationic complex 
[Ru2Cl3(p-cymene)2][PF6] bearing the PF6– counteranion did not deliver the desired product under 
otherwise identical reaction conditions (entry 10). 
 
Table 4.1: Optimization of oxidative alkenylation with carbamate 192a 
+ CO2Et oxidant
[Ru] (2.5 mol %)
solvent, 110 °C, 24 h
O NMe2
O








192a 15a 193aa  
Entry Catalyst Oxidant Solvent Yield (%) 
1 --- Cu(OAc)2·H2O DME 0 
2 [RuCl2(p-cymene)]2 Cu(OAc)2·H2O DMF 0 
3 [RuCl2(p-cymene)]2 Cu(OAc)2·H2O PhMe 0 
4 [RuCl2(p-cymene)]2 Cu(OAc)2·H2O DCE 40 
5 [RuCl2(p-cymene)]2 Cu(OAc)2·H2O DME 84 
6 [RuCl2(p-cymene)]2 Cu(OAc)2·H2O t-AmOH 48 
7 [RuCl2(p-cymene)]2 Cu(OAc)2·H2O DME 84
b 
8 [RuCl2(p-cymene)]2 CuBr2/NaOAc DME 0
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9 [RuCl2(p-cymene)]2 Cu(OAc)2·H2O DME 0
c 
10 [Ru2Cl3(p-cymene)2][PF6] Cu(OAc)2·H2O DME 0
c 
a Reaction conditions: 192a (0.5 mmol), 15a (1.0 mmol), catalyst (2.5 mol %), oxidant (1.0 mmol), solvent (3 mL); 
isolated yields. b Under air. c Without AgSbF6. 
 
4.2 Effect of Directing Groups 
With the optimized catalytic system in hand, we tested the influence of the N-substituents of the 
phenyl carbamates on the reaction efficacy (Scheme 4.1). Thus, N,N-dialkyl-substituted carbamates 
192 and 221 furnished the desired products 193 and 222 in high yields, with atom-economical 
N,N-dimethyl derivative 192b providing the best results. Mono N-substituted carbamate 221d as well 
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Scheme 4.1 Effect of N-substituents on C–H bond alkenylation of cabarmates 
 
4.3 Scope and Limitations 
Subsequently, we probed the scope of the optimized catalyst in the twofold C–H bond 
functionalizations with moisture-stable phenol derivatives 192 (Table 4.2). The cationic ruthenium(II) 
catalyst proved to be broadly applicable. Thus, substrates bearing ortho- and para-substituents were 
efficiently converted into the corresponding monoalkenylated products 193 (entries 1–13). Notably, 
valuable functional groups, such as aryl and alkyl fluorides (entries 5 and 11), chlorides (entries 7 and 
16) or bromides (entries 12, 18 and 20), were well tolerated and therefore provide a handle for 
further elaborations. Furthermore, we observed that intramolecular competition experiments with 
meta-substituted substrates proceeded with high site-selectivities, furnishing alkenylated carbamates 
193 as the sole products (entries 14–24). 
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2 R = Ph (192d) 193da 77 
3 R = i-Pr (192e) 193ea 78 
4 R = OMe (192f) 193fa 65 
5 R = F (192g) 193ga 73 
6 R = CF3 (192h) 193ha 65 













9 R = Ph (192k) 193ka 59 
10 R = OMe (192l) 193la 65 
11 R = F (192m) 193ma 61 
12 R = Br (192n) 193na 60 
13 
        




























15 R= OMe (192q) 193qa 68b 

























20 R = Br (192v) 193va 59 
21 R = I (192w) 193wa 53 
22 
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a Reaction conditions: 192 (0.5 mmol), 15a (1.0 mmol), [RuCl2(p-cymene)]2 (2.5 mol %), AgSbF6 (10 mol %), 
Cu(OAc)2·H2O (1.0 mmol), DME (3 mL), 110 °C, 24 h, under N2; isolated yields. 
b [RuCl2(p-cymene)]2 (5.0 mol %), 
AgSbF6 (20 mol %). 
 
Importantly, the double C–H bond functionalization was not limited to the use of stoichiometric 
amounts of Cu(OAc)2·H2O. Indeed, aerobic oxidative alkenylations proved to be viable with 
















































Scheme 4.2: Aerobic oxidative C–H bond alkenylations 
 
Unfortunately, the cationic ruthenium(II) catalyst provided only rather low conversions in 
alkenylations with acrylonitrile (15e), styrene (15c), 4-bromostyrene (15f) and methyl vinyl ketone 
(15g) (Table 4.3). 
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a Reaction Conditions: 192a (0.5 mmol), 15 (1.0 mmol), [RuCl2(p-cymene)]2 (2.5 mol %), AgSbF6 (10 mol %), 
Cu(OAc)2·H2O (1.0 mmol), DME (3 mL), 110 °C, 24 h, under N2; GC-conversion. 
 
4.4 Removal of Directing Group 
Importantly, compounds 193 are of great synthetic value, as the carbamate directing groups can 
easily be cleaved under basic conditions, thus leading to o-coumaric acid derivative 223 in high yield 











223: 74%193aa  
Scheme 4.3: Removal of directing group 
 
The latter play an important role in chemistry of naturally occurring compounds. For example, as 
intermediates in phenylanine metabolism in enzymatic reactions catalyzed with 2-coumarate 
reductase.244 
 
4.5 Mechanistic Studies 
4.5.1 Intermolecular Competition Experiments 
 
Considering the remarkable activity and high selectivity of the cationic ruthenium(II) catalyst, we 
became interested in probing its mode of action. To this end, we conducted intermolecular 
competition experiments with differently substituted arenes 192, which revealed electron-rich 
substrates to be preferentially converted (Scheme 4.4). This result indicated an electrophilic 
activation manifold. 
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(2.0 equiv) 193fa: 55%
Cu(OAc)2·H2O
[RuCl2(p-cymene)]2
DME, 110 °C, 24 h

























 (2.0 equiv) 193la: 81% 193a'a: 17%
CO2Et
Scheme 4.4: Intermolecular competition experiments between carbamates 192 
 
4.5.2 Reaction with Isotopically Labelled Substrate 
 
Subsequently, we performed a reaction with deuterated labeled substrate [D5]-221b under the  
standard reaction conditions (Scheme 4.5). A significant D/H scrambling on the remaining 
ortho-position of the alkenylated product [D5]-222ba was observed. This finding clearly indicated the 







DME, 110 °C, 7 h

















[D5]-221b 15a [Dn]-222ba  
Scheme 4.5: Ruthenium(II)-catalyzed oxidative alkenylation of carbamate [D5]-221b 
 
4.5.3 Proposed Catalytic Cycle 
 
Based on these mechanistic studies as well as on our previous findings with cationic ruthenium(II) 
catalysts, we proposed the catalytic cycle which began with an initial base-assisted, reversible 
cycloruthenation (Scheme 4.6). Thereafter, migratory insertion of alkene and β-hydride elimination 
deliver product 191, while reductive elimination and reoxidation by Cu(OAc)2·H2O regenerate the 
active cationic catalyst. 
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Scheme 4.6: Proposed mechanism for ruthenium(II)-catalyzed oxidative alkenylation 
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5 Cationic Ruthenium(II) Catalysts for C−H/N−O Functionalizations of 
Oximes 
 
Transition metal-catalyzed annulations of alkynes that involve sequential C–H and Het–H bond 
cleavages have become an important tool for the regioselective synthesis of decorated heterocycles 
(Chapter 1.5). Since the pioneering work of Ackermann and coworkers which employed less 
expensive ruthenium(II) catalysts for the oxidative annulation of alkynes by benzamides,207 several 
publications on ruthenium(II)-catalyzed oxidative annulation reactions have appeared during the last 
four years.206 Unfortunately, these transformations are restricted to the use of external oxidants. 
Hence, developing novel methods which employ internal oxidants continues to be of importance. For 
example, a redox-neutral approach for the preparation of isoquinolones has been reported by 
dehydrogenative  annulations of alkynes with free hydroxamic acids.228 On this basis, C. Kornhaaß 








KPF6 (30 mol %)







81%194a 155a 176aa  
Scheme 5.1: Redox-neutral annulation with oximes as optimized by C. Kornhaaß 
 
The optimized reaction conditions employed a catalytic system consisting of [RuCl2(p-cymene)]2 as 
the precatalyst and KPF6 as a co-catalytic additive. Since this dehydrogenative annulation is 
redox-neutral in nature, no external oxidant is needed, while MeOH proved to be the solvent of 
choice affording the isoquinoline 176aa in 81% yield under these conditions (Scheme 5.1). During the 
course of this transformation, a cationic ruthenium(II) species was most likely formed through 
abstraction of a chlorine atom from the precatalyst with a non-coordinating [PF6]– anion. In order to 
support this concept, the presynthesized cationic complex [Ru2Cl3(p-cymene)2][PF6] was tested as 
















194a 155a 176aa  
Scheme 5.2: Redox-neutral annulation using cationic ruthenium(II) complex 
 
Under the optimized reaction conditions, a variety of differently substituted isoquinolines 194 
bearing valuable electrophilic functional groups was chemoselectively accessed (Table 5.1). As shown 
in entry 1, a tetralone oxime derivative 194b can be converted into the corresponding isoquinoline 
176ba in excellent yield. Elongation of the aliphatic chain in the oximes had no negative effect on the 
reaction outcome, smoothly delivering the desired products in high yields (entries 2 and 3). However, 
oximes containing isopropyl, cyclopropyl, cyclohexyl and benzyl groups demanded elevated reaction 
temperatures and additional molecular sieve to obtain high yields (entries 4–7). Oxime 194b with a 
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para-bromide substituent, which is valuable for post-synthetic elaboration, could also be converted in 
moderate yield (entry 8). In addition, indole derivative 194j also proved to be a suitable substrate, 
although the reaction resulted in a lower yield (entry 9). 
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a Reaction conditions: 194 (0.5 mmol), 55a (1.0 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), KPF6 (30 mol %), MeOH (2 
mL), 60 °C, 24 h, under N2; isolated yields. 
b 4 Å Mol-sieves (100 mg per 0.5 mmol 194), 80 °C. c 4 Å Mol-sieves, 100 °C. 
 
Given the remarkable efficacy of the in-situ generated ruthenium(II) catalyst, we subsequently 
probed the efficacy of presynthesized cationic complex [Ru2Cl3(p-cymene)2][PF6]. Importantly, this 
well-defined complex displayed an activity as well as chemo-, regio- and siteselectivity being 
comparable to the one demonstrated by the in-situ formed catalytic system (Table 5.2, entries 1 and 
2). Electron-rich methyl- (194k) as well as electron-deficient fluoro- (194l) and 
trifluoromethyl-containing (194m) oximes could all be converted to the desired isoquinolines in 
moderate to good yields (entries 3–5). Interestingly, when meta-substituted oximes were subjected 
to the reaction conditions, different regioselectivities were observed for the substrates with diverse 
electronic properties. Indeed, whereas m-methylacetophenone oxime (194o) only delivered the 
sterically less hindered product 176oa (entry 7), annulation with oxime 194n containing a fused 
dioxolane-moiety took place at the sterically more congested C−H bond (entry 6). This finding could 
be explained a secondary chelation effect caused by the oxygen atom in 3-position, which served as a 
secondary directing group through lone pair donation to the metal center. Such secondary directing 
group effect has recently been reported also for ruthenium(II)-catalyzed hydroarylation of olefins.246 
Furthermore, this cationic ruthenium(II)-catalyzed annulation was not limited to the use of 
diphenylacetylene. Symmetrically substituted dialkylacetylene as well as unsymmetrical alkynes 
bearing both alkyl and aryl substituents also furnished the target products in moderate to good yield 
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MeOH, 60 °C, 24 h
(5.0 mol %)
194 155 176  
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a Reaction conditions: 192 (0.5 mmol), 155 (1.0 mmol), [Ru2Cl3(p-cymene)2][PF6]  (5.0 mol %), MeOH (2 mL), 60 °C, 24 
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6 Summary and Outlook 
Ruthenium(II)-catalyzed C−H functionalizations have recently emerged as a reliable tool for the 
efficient chemo- and site-selective construction of C−C and C−Het bonds. Within this thesis, efforts 
have been devoted to developing new synthetic methods employing versatile ruthenium(II) catalysts. 
 
In the first project, a novel catalytic system consisting of [RuCl2(p-cymene)]2 and MPAAs as the 
ligands was elaborated and exhibited excellent activity and regioselectivity in unprecedented direct 
meta-alkylation with tertiary alkyl bromides 50. A broad substrate scope of 2-phenylpyridines 187 as 
well as tertiary alkyl halides 50 were found under the optimized reaction conditions. Various 
functional groups, including chloro, ether and ester were well tolerated (Scheme 6.1). Moreover, 
other N-containing heterocycles, such as pyrimidine and pyrazole, served as competent directing 
groups for promoting this transformation in arenes 197 and 131, respectively. Interestingly, 
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Scheme 6.1: Ruthenium(II)-catalyzed direct meta-alkylation with tertiary alkyl bromides 50 
 
Importantly, ruthenium(II) catalysis also allowed for the facile direct meta-alkylation of ketimines 188. 
Electron-deficient ketimines 188 were favorably converted comparing to their election-rich analogues. 
Sterically hindered tertiary alkyl bromides 50 smoothly gave rise to the desired meta-alkylated 
products 189. The auxiliary from the alkylated products can easily be removed within a one-pot 
hydrolysis, thus yielding a wide range of meta-functionalized aryl ketones 189 (Scheme 6.2). 
Futhermore, the imine double bond in the meta-alkylated ketimines underwent one-pot reduction, 
furnishing secondary amines 207 in good yields. Although the yields of these alkylations were 
moderate comparing to the case of heterocycle-directed reactions, compounds 189 and 207 are 
generally more useful building blocks in organic synthesis. 
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K2CO3, PhMe 
































189aa: 59% 189ah: 50% 189ba: 54% 189fb: 62% 189eb: 47%  
Scheme 6.2: Ruthenium(II)-catalyzed direct meta-alkylation of ketimines 188 
 
Not only tertiary alkyl bromides 50, but also secondary alkyl bromides 44, both cyclic and acyclic, 
were competent electrophiles for this novel transformation (scheme 6.3). Electron-rich as well 
electron-deficient ketimines 188 were smoothly converted. The intermolecular competition 
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206be: 58% 206ge: 60%206ae: 60% 206je: 62% 206ih: 62%  
Scheme 6.3: Ruthenium(II)-catalyzed direct meta-alkylation with secondary alkyl bromides 44 
 
Further investigation of this approach realized the ruthenium(II)-catalyzed direct alkylation of 
N-(pyrimidyl-2-yl)anilines 161 (Scheme 6.4). Again, the ruthenium(II)-MPAA catalytic system proved 
to be the most efficient. The direct alkylation smoothly took place at the meta-position of an 
electron-donating directing group, which in not anticipated by classical electrophilic aromatic 
substation. Another important aspect of this reaction is the N-pyrimidyl could readily be cleaved, thus 
leading to meta-alkylated aniline 191. Moreover, excellent site-electivity was achieved when ortho- or 
even di-substituted anilines 161 were employed, furnishing selectively the meta-functionalized 
products in good yields. 
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a Ad-Ile-OH as additive
HCl (conc.)
mw, 150 °C, 1 h
 
Scheme 6.4: Ruthenium(II)-catalyzed direct meta-alkylation of aniline derivatives 161 
 
Future investigations of the ruthenium(II)-catalyzed direct meta-alkylation should be performed 
addressing three major issues. First of all, meta-alkylations accomplished in this thesis were realized 
via cyclometalation assisted by N-containing directing group. Extending the substrate scope to readily 
available, weakly-coordinating directing groups including ketones or esters is of major interest. 
Secondly, since research directed towards enantioselective cross-coupling of secondary alkyl halides 
is active nowadays, developing transition metal-catalyzed enatioselective direct alkylation reactions 
should be an important goal. At last, despite the preliminary understanding of the reaction 
mechanism, detailed explanation of how the elementary steps of activation of the tertiary halide and 
C−C bond formation take place remain unclear and need further elucidation. Better insight of the 
reaction mechanism is crucial for further development of ruthenium(II)-catalyzed meta-selective C−H 
functionalization. 
 
Within the second project, a ruthenium(II)-catalyzed cross-dehydrogenative coupling of aryl 
carbamates 192 with acrylates 15a was achieved (Scheme 6.5). The cationic ruthenium(II) catalyst 
enabled the highly efficient olefination of electron-rich arenes 192 with high site-selectivity. 
Carbamates bearing ortho-, meta-, or para-substitutions underwent facile alkenylation, delivering a 
broad range of protected phenols 193. Importantly, the weakly-coordinating cabarmate group could 
easily be removed, thus providing a practical method for the preparation of o-coumaric acids which 
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Scheme 6.5: Ruthenium(II)-catalyzed oxidative alkenylation of carbamate 192 
 
The third project focused on redox-neutral annulations of alkynes 155 via ruthenium(II)-catalyzed 
C−H/N−O bond functionalization of oximes 194. A well-defined cationic ruthenium(II)-catalyst 
allowed the synthesis of highly substituted isoquinolines 176 (Scheme 6.6). Electron-rich as well as 
electron-deficient oximes could be efficiently converted. Unsymmetrical aryl-alkyl-alkynes 155 









































176da: 86% 176na: 86% 176oa: 77% 176af: 72% 176ae: 77%  
Scheme 6.6: Well-defined ruthenium(II) complex-catalyzed alkyne annulation 
 
However, only poor yields were obtained with terminal alkynes in most of the ruthenium(II)-catalyzed 
annulation reactions. Presumably this is the result of dimerization of the terminal alkyne. Interestingly, 
in a recent published work, this shortage was successfully overcome via ruthenium(II)-catalyzed 
C−H/N−N bond functionalization.230 This offered broad implications for future developments of 
ruthenium(II)-catalyzed alkyne annulations for more functionalized heterocycle synthesis.  
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7 Experimental Section 
7.1 General Remarks 
Unless otherwise noticed, all reactions were performed under a N2 atmosphere using pre-dried 
glassware and standard Schlenk techniques. 
 
Solvents 
All solvents for reactions involving moisture-sensitive reagents were dried, distilled and stored under 
inert atmosphere (Ar or N2) according to the following standard procedures. tert-Amylalcohol 
(t-AmOH) was used as supplied by Merck or stirred over sodium chips for 5 h at 120 °C and distilled 
under ambient pressure; water (H2O) was degassed before its use applying repeated 
Freeze-Pump-Thaw degassing procedure; 1,2-dichloroethane (DCE), i-BuOH, N,N-dimethylformamide 
(DMF), acetonitrile (MeCN) and dimethylacetamide (DMA) were dried over CaH2 for 8 h, degassed 
and distilled under reduced pressure; dichloromethane and tetrahydrofuran (THF) were purified using 
a solvent purification system (SPS) from MBRAUN; N-methyl-2-pyrrolidone (NMP) was stirred over 
CaH2 for 4 h at 150 °C and subsequently distilled under reduced pressure; methanol (MeOH) was 
distilled from magnesium methanolate; toluene was pre-dried over KH followed by distillation from 
sodium benzophenone ketyl; 1,4-dioxane was dried by distillation from sodium benzophenone ketyl. 
 
Vacuum 
The following pressures were measured on the used vacuum pump and were not corrected: 
membrane pump vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 mbar. 
 
Melting Points (M. p.) 
Melting points were measured using a Stuart® Melting Point Apparatus SMP3 from BARLOWORLD 
SCIENTIFIC. Reported values are uncorrected. 
 
Chromatography 
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-plates 
(MACHEREY-NAGEL) with 254 nm fluorescent indicator from MERCK. Plates were visualized under 
UV-light or developed by treatment with a KMnO4 solution followed by careful applying a heat gun. 
Chromatographic purification of products was accomplished by flash column chromatography on 
MERCK silica gel, grade 60 (0.040–0.063 mm and 0.063–0.200 mm). 
 
Gas Chromatograpgy (GC) 
The conversion of the reactions was monitored applying coupled gas chromatography/mass 
spectrometry using G1760C GCDplus with mass detector HP 5971, 5890 Series II with mass detector 
HP 5972 from HEWLETT-PACKARD and 7890A GC-System with mass detector 5975C 
(Triplex-Axis-Detector) from AGILENT TECHNOLOGIES equipped with HP-5MS columns (30 m × 0.25 
mm × 0.25 m) were used. 
 
High Performance Liquid Chromatography (HPLC) 
Preparative and analytical separations were performed on an HPLC-System from KNAUE (Smartline 
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Pump 100, Dynamic Mixing Chamber, Injection- and Control-Valve, Smartline UV Detector 2500). 
Separation normal phase column (250 × 10 mm) from MACHEREY-NAGEL (MN) was used. Organic 
solvents of HPLC grade were employed. All samples were filtered through Polytetrafluorethylen Filter 
from ROTH (Ø 25 mm, 0.2 μm) or VWR (Ø 13 mm, 0.2 μm) prior to separation. 
 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) spectroscopy was performed at 300, 400 or 600 MHz (1H NMR), 
75 or 125 MHz (13C NMR, APT) and 283 MHz (19F NMR) on BRUKER AM 250, VARIAN Unity-300 and 
Inova 500 instruments. Chemical shifts are reported as δ-values in ppm relative to the residual proton 
peak of the deuterated solvent or its carbon atom, respectively, or the standard trimethylsilyl (TMS) 
peak. For characterization of the observed resonance multiplicities the following abbreviations were 
applied: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), dt 
(doublet of triplet), or analogue representations. The coupling constants J are reported in Hertz (Hz). 
 
Infrared Spectroscopy (IR) 
Infrared spectra were recorded on a BRUKER Alpha-P ATR-spectrometer. Liquid probes were 
measured as film and solid samples neat. Analysis of the spectral data has been done by using the 
OPUS 6. Absorption (ṽ) is given in wave numbers (cm–1). Spectra were recorded in the range of 4000 
to 400 cm–1. 
 
Mass Spectrometry (MS) 
MS (EI) and HR-MS (EI) were measured on a Time-of-Flight mass spectrometer AccuTOF from JOEL. 
ESI-mass spectra were recorded on an Ion-Trap mass spectrometer LCQ from FINNIGAN or on a 
Time-of-Flight mass spectrometer microTOF from BRUKER. ESI-HR-MS spectra were recorded on a 
BRUKER APEX IV or a BRUKER DALTONIC [7T, Fourier Transform Ion Cyclotron Resonance (FTICR)] 
mass spectrometer. The ratios of mass to charge (m/z) are indicated, intensities relative to the base 
peak (I = 100) are written in parentheses. 
 
Reagents 
Chemicals obtained from commercial sources with purity above 95% were used without further 
purification. The following compounds are known and were synthesized according to previously 
described methods.  
2-Phenylpyridines 38,247 tertiary alkyl bromides 50,95 mono-protected amino acids 116,248 
2-phenylpyrimidine 197b−c,247 ketimines 188,249 N-(pyrimidine-2-yl)anilines 161,211 
N-(4-fluorophenyl)pyridin-2-amine 216b,250 secondary alkyl bromides 44n−o,251 44a,91 aryl carbamate 
192,252 oxime 194b−j,253 [Ru2Cl3(p-cymene)2][PF6].211 
The following compounds were obtained by the generous courtesy of the persons named below: 
Karsten Rauch: [RuCl2(p-cymene)]2. 
Dr. Christoph Kornhaaβ: Oximes 194a, 194k−o, Alkynes 155d−f. 
Dr. Nora Hofmann: Secondary alkyl bromide 44d. 
M. Sc. Svenja Warratz: [RuCl(O-Val-Piv)(p-cymene)] (195). 
M. Sc. Keshav Raghuvanshi: 1-Phenylprazoles 131a−e. 
M. Sc. Sebastian Lackner: N-2-Pyrimidyl anilines 161d. 
M. Sc. Zhixiong Ruan: N-2-Pyrimidyl aniline 161h. 
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M. Sc. Weiping Liu: Aryl carbamate [D5]-221b. 
M. Sc. Eloisa Eriko Ishikawa: Tertiary alkyl halide 50g, 4-fluoro-N-phenylaniline (216c) 
Dr. Nora Hofmann & Dr. Marvin Schinkel: 2-phenylpyridines 38g−38h, 38o−38p, 38q−38r, [D5]-38a, 
[D3]-38a, 2-phenylpyrimidine 197a 
 
7.2 General Procedures 
General Procedure A:  
Ruthenium(II)-catalyzed direct meta-alkylation 
Substrate 38b (0.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %), Piv-Val-OH (30.0 mg, 30 mol %) 
and K2CO3 (138 mg, 1.00 mmol) were placed in a pre-dried 25 mL pressure tube. The mixture was 
degassed and purged with N2 for 3 times. Tertiary alkyl bromide 50a (1.50 mmol) and 1,4-dioxane 
(2.0 mL) were then added, and the mixture was stirred at 100 °C for 20 h. At ambient temperature, 
EtOAc (15 mL) was added, and the reaction mixture was filtered through a pad of silica gel. The 
solvents were removed in vacuo and purification of the residue by column chromatography 
(n-hexane/EtOAc) yielded compound 187ba.  
In several specific cases indicated below, Piv-Val-OH was replaced by 
N-(1-adamantane-2-carbonyl)-L-isoleucine (1-Ad-Ile-OH, 44.0 mg, 30 mol %). 
 
General Procedure B:  
Ruthenium(II)-catalyzed direct meta-Alkylation using [RuCl(O-Val-Piv)(p-cymene)] 
Substrate 38b (0.50 mmol), [RuCl(O-Val-Piv)(p-cymene)] (11.8 mg, 5.0 mol %) and K2CO3 (138.0 mg, 
1.00 mmol) were placed in a pre-dried 25 mL pressure tube. The mixture was degassed and purged 
with N2 for 3 times. Tertiary alkyl bromide 50a (1.50 mmol) and 1,4-dioxane (2.0 mL) were then 
added and the mixture was stirred at 100 °C for 20 h. At ambient temperature, EtOAc (15 mL) was 
added and the reaction mixture was filtered through a pad of silica gel. The solvents were removed in 
vacuo and purification of the residue by column chromatography (n-hexane/EtOAc) yielded 
compound 187ba. 
 
General Procedure C:  
Ruthenium(II)-catalyzed direct meta-alkylation of ketimine 188 
Ketimine 188 (0.50 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 2.5 μmol, 5.0 mol %), 1-AdCO2H (27.8 mg, 
30 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a pre-dried 25 mL pressure tube. The 
mixture was degassed and purged with N2 for 3 times. Tertiary alkyl bromide 50 (1.50 mmol) and 
PhMe (2.0 mL) were then added and the mixture was stirred at 120 °C for 20 h. At ambient 
temperature, 2 N HCl (3.0 mL) was added, and the resulting mixture was stirred for additional 3 hours, 
then extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. Purification of the residue by column chromatography (n-hexane/EtOAc or 
n-pentane/Et2O) yielded compound 189. 
 
General Procedure D:  
Ruthenium(II)-catalyzed oxidative alkenylation of aryl carbamate 192 
In a 25 ml schlenk tube, a suspension of carbamate 192 (0.50 mmol), ethyl acrylate (15a) (100.1 mg, 
1.00 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %), AgSbF6 (17.2 mg, 10 mol %) and Cu(OAc)2·H2O 
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(200 mg, 1.00 mmol) in DME (3.0 mL) was stirred at 110 °C for 24 h under an atmosphere of N2. At 
ambient temperature, EtOAc (15 mL) was added, and the mixture was filtered through a pad of silica 
gel. The solvents were removed in vacuo. Purification of the residue by column chromatography 
(n-hexane/EtOAc) yielded compound 193. 
 
General Procedure E:  
Ruthenium(II)-catalyzed oxidative aerobic alkenylation of aryl carbamate 192 with 
cocatalytic amounts of Cu(OAc)2·H2O 
In a 25 ml schlenk tube, a suspension of carbamate 192 (0.50 mmol), ethyl acrylate (15a) (100.1 mg, 
1.00 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2·H2O 
(29.7 mg, 30 mmol %) in DME (3.0 mL) was pre-stirred at ambient temperature for 10 min under N2. 
Thereafter, the reaction mixture was purged with air for 10 min. Then, the reaction tube was sealed 
and the mixture was stirred at 110 °C for 24 h under an atmosphere of ambient air. At ambient 
temperature, EtOAc (15 mL) was added, and the mixture was filtered through a pad of silica gel. The 
solvents were removed in vacuo. Purification of the residue by column chromatography 
(n-hexane/EtOAc) yielded compound 193. 
 
General Procedure F:  
Synthesis of isoquinoline 176 via ruthenium(II)-catalyzed C−H/N−O functionalizations 
Oxime 194 (0.50 mmol), alkyne 155 (1.00 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) and KPF6 
(27.6 mg, 30 mol %) were placed in a pre-dried 25 mL Schlenk tube. The mixture was degassed and 
purged with N2 for 3 times. Dry MeOH (2.0 mL) was added (and the liquid alkyne 155 was also added 
at this stage), and the reaction mixture was stirred at 60 °C for 24 h. At ambient temperature, EtOAc 
(15 mL), was added and the solvents were removed in vacuo. The product 176 was purified by 
column chromatography on silica gel (n-hexane/EtOAc). 
 
General Procedure G:  
Synthesis of Isoquinoline 176 via well-defined cationic ruthenium(II) complex catalyzed 
C−H/N−O functionalizations 
Oxime 194 (0.50 mmol), solid alkyne 155 (1.00 mmol), [Ru2Cl3(p-cymene)2][PF6] (18.0 mg, 5.0 mol %) 
were placed to a pre-dried 25 mL Schlenk tube. The mixture was degassed and purged with N2 for 3 
times. Dry MeOH (2.0 mL) was added (and the liquid alkyne 155 was also added at this stage), and 
the reaction mixture was stirred at 60 °C for 24 h. At ambient temperature, EtOAc (15 mL) was added, 
and the solvents were removed in vacuo. The product 176 was purified by column chromatography 
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7.3 Analytical Data 
7.3.1 Analytical Data for the Products of the Ruthenium(II)-Catalyzed Direct 
meta-Alkylation 
 
Synthesis of 2-[3-(tert-Butyl)-4-methoxyphenyl]pyridine (187ba) 
The general procedure A was followed using substrate 38b (93 mg, 0.50 mmol) and 
t-BuBr (50a) (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 187ba (91 mg, 76%) as a colorless 
oil. 
The general procedure B was followed using substrate 38b (93 mg, 0.50 mmol) and 
t-BuBr (50a) (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 187ba (96 mg, 80%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.66 (d, J = 4.9 Hz, 1H), 7.97 (d, J = 2.3 Hz, 1H), 7.81 (dd, J = 8.5, 2.3 Hz, 
1H), 7.73–7.64 (m, 2H), 7.15 (ddd, J = 6.8, 4.9, 1.9 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 3.90 (s, 3H), 1.46 (s, 
9H).  
13C NMR (75 MHz, CDCl3): δ = 159.4 (Cq), 157.8 (Cq), 149.5 (CH), 138.4 (Cq), 136.5 (CH), 131.4 (Cq), 
125.7 (CH), 125.4 (CH), 121.1 (CH), 120.0 (CH), 111.6 (CH), 55.1 (CH3), 35.0 (Cq), 29.7 (CH3). 
IR (neat): ṽ = 3077, 2954, 1586, 1463, 1270, 1091, 819, 741 cm−1. 
MS (EI) m/z (relative intensity) 241 (42) [M]+, 226 (100), 210 (15), 167 (15).  
HR-MS (EI): m/z calcd for C16H19NO+ [M]+ 241.1461, found 241.1475. 
 
Synthesis of 2-[4-Methoxy-3-(1-methylcyclohexyl)phenyl]pyridine (187bb) 
The general procedure A was followed using substrate 38b (93 mg, 0.50 mmol) 
and bromide 50b (266 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187bb (110 mg, 78%) as a 
colorless oil. 
The general procedure B was followed using substrate 38b (93 mg, 0.50 mmol) 
and bromide 50b (266 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187bb (106 mg, 76%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.67 (d, J = 4.9 Hz, 1H), 8.00 (d, J = 2.4 Hz, 1H), 7.81 (dd, J = 8.5, 2.4 Hz, 
1H), 7.74–7.64 (m, 2H), 7.15 (ddd, J = 6.8, 4.8, 2.0 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 3.87 (s, 3H), 
2.23–2.12 (m, 2H), 1.86–1.75 (m, 2H), 1.67–1.48 (m, 6H), 1.36 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.6 (Cq), 157.9 (Cq), 149.5 (CH), 137.9 (Cq), 136.5 (CH), 131.4 (Cq), 
126.4 (CH), 125.4 (CH), 121.1 (CH), 119.9 (CH), 111.9 (CH), 55.1 (CH3), 38.3 (Cq), 36.9 (CH2), 26.6 
(CH2), 25.1 (CH3), 22.8 (CH2).  
IR (neat): ṽ = 3077, 2922, 1724, 1588, 1429, 1239, 1120, 1025, 856, 593 cm−1.  
MS (EI) m/z (relative intensity) 281 (100) [M]+, 266 (75), 198 (50), 167 (28).  
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Synthesis of 2-[4-Methoxy-3-(2-methylpentan-2-yl)phenyl]pyridine (187bc) 
The general procedure A was followed using substrate 38b (93 mg, 0.50 mmol) and 
bromide 50c (248 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187bc (80 mg, 59%) as a colorless 
oil. 
The general procedure B was followed, using 38b (93 mg, 0.50 mmol) and 50c (248 
mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 20:1) yielded 187bc (68 mg, 50%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.66 (d, J = 4.9 Hz, 1H), 7.91 (d, J = 2.4 Hz, 1H), 7.82 
(dd, J = 8.5, 2.4 Hz, 1H), 7.73–7.64 (m, 2H), 7.15 (ddd, J = 6.8, 4.6, 1.8 Hz, 1H), 6.95 (d, J = 8.5 Hz, 1H), 
3.87 (s, 3H), 1.87–1.80 (m, 2H), 1.43 (s, 6H), 1.12–0.98 (m, 2H), 0.83 (t, J = 7.3 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.4 (Cq), 157.8 (Cq), 149.4 (CH), 137.0 (Cq), 136.5 (CH), 131.3 (Cq), 
126.5 (CH), 125.6 (CH), 121.1 (CH), 119.9 (CH), 111.5 (CH), 55.1 (CH3), 43.4 (CH2), 38.4 (Cq), 28.4 
(CH3), 18.5 (CH2), 14.9 (CH3).  
IR (neat): ṽ = 3052, 2954, 1587, 1562, 1462, 1429, 1159, 1096, 1027, 779 cm−1.  
MS (EI) m/z (relative intensity) 269 (20) [M]+, 226 (100), 198 (17), 167 (16).  
HR-MS (EI): m/z calcd for C18H23NO+ [M]+ 269.1774, found 269.1784. 
 
Synthesis of 2-[4-Methoxy-3-(tert-pentyl)phenyl]pyridine (187bd) 
The general procedure A was followed using substrate 38b (93 mg, 0.50 mmol) and 
bromide 50d (226 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187bd (86 mg, 67%) as a colorless 
oil. 
The general procedure B was followed using substrate 38b (93 mg, 0.50 mmol) and 
bromide 50d (226 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187bd (77 mg, 60%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.67 (d, J = 4.9 Hz, 1H), 7.91 (d, J = 2.3 Hz, 1H), 7.83 (dd, J = 8.5, 2.3 Hz, 
1H), 7.73–7.64 (m, 2H), 7.15 (ddd, J = 6.2, 4.8, 2.3 Hz, 1H), 6.95 (d, J = 8.5 Hz, 1H), 3.87 (s, 3H), 1.90 (q, 
J = 7.5 Hz, 2H), 1.42 (s, 6H), 0.67 (t, J = 7.5 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.4 (Cq), 157.8 (Cq), 149.5 (CH), 136.7 (Cq), 136.5 (CH), 131.3 (Cq), 
126.7 (CH), 125.6 (CH), 121.1 (CH), 119.9 (CH), 111.4 (CH), 55.1 (CH3), 38.7 (Cq), 33.1 (CH2), 27.9 
(CH3), 9.6 (CH3).  
IR (neat): ṽ = 3050, 2960, 1586, 1438, 1396, 1240, 1180, 1093, 778 cm−1.  
MS (EI) m/z (relative intensity) 255 (27) [M]+, 226 (98), 198 (18), 167 (20).  
HR-MS (EI): m/z calcd for C17H21NO+ [M]+ 255.1618, found 255.1627. 
 
Synthesis of 2-[3-(3-Ethylpentan-3-yl)-4-methoxyphenyl]pyridine (187be) 
The general procedure A was followed using substrate 38b (93 mg, 0.50 mmol) and 
bromide 50e (269 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187be (73 mg, 52%) as a white solid. 
The general procedure B was followed using substrate 38b (93 mg, 0.50 mmol) and 
bromide 50e (269 mg, 1.50 mmol). After 20 h, purification by column 
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M. p.: 80–82 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.66 (d, J = 4.9 Hz, 1H), 7.88 (d, J = 2.3 Hz, 1H), 7.83 (dd, J = 8.4, 2.3 Hz, 
1H), 7.73–7.64 (m, 2H), 7.13 (ddd, J = 6.8, 4.6, 2.3 Hz, 1H), 6.92 (d, J = 8.4 Hz, 1H), 3.84 (s, 3H), 1.86 (q, 
J = 7.3 Hz, 6H), 0.64 (t, J = 7.3 Hz, 9H).  
13C NMR (75 MHz, CDCl3): δ = 159.6 (Cq), 157.9 (Cq), 149.5 (CH), 136.5 (CH), 134.8 (Cq), 131.1 (Cq), 
128.3 (CH), 125.5 (CH), 121.1 (CH), 119.9 (CH), 111.5 (CH), 55.2 (CH3), 44.6 (Cq), 26.1 (CH2), 8.5 (CH3).  
IR (ATR): ṽ = 2961, 2938, 2873, 1562, 1460, 1439, 1270, 1238, 1088, 816 cm−1.  
MS (EI) m/z (relative intensity) 283 (23) [M]+, 284 (76), 212 (60), 198 (100), 167 (27).  
HR-MS (EI): m/z calcd for C19H25NO+ [M]+ 283.1931, found 283.1933. 
 
Synthesis of 2-[4-Methoxy-3-(4-methyltetrahydro-2H-pyran-4-yl)phenyl]pyridine (187bf) 
The general procedure A was followed using substrate 38b (93 mg, 0.50 mmol) 
and bromide 50f (269 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 187bf (110 mg, 78%) as a 
colorless oil. 
The general procedure B was followed using substrate 38b (93 mg, 0.50 mmol) 
and bromide 50f (269 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 187bf (106 mg, 75%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.65 (d, J = 4.9 Hz, 1H), 7.92 (d, J = 2.3 Hz, 1H), 7.81 (dd, J = 8.5, 2.3 Hz, 
1H), 7.74–7.63 (m, 2H), 7.17 (ddd, J = 6.7, 4.8, 1.3 Hz, 1H), 6.99 (d, J = 8.5 Hz, 1H), 3.88 (s, 3H), 
3.86–3.41 (m, 4H), 2.37–2.26 (m, 2H), 2.00–1.91 (m, 2H), 1.44 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.4 (Cq), 157.6 (Cq), 149.5 (CH), 136.7 (Cq), 136.6 (CH), 131.6 (Cq), 
125.9 (CH), 125.8 (CH), 121.3 (CH), 119.9 (CH), 111.9 (CH), 69.5 (CH2), 55.1 (CH3), 36.9 (CH2), 35.9 
(Cq), 24.1(CH3).  
IR (neat): ṽ = 3047, 2949, 1585, 1269, 1234, 1023, 779 cm−1.  
MS (EI) m/z (relative intensity) 283 (100) [M]+, 268 (27), 210 (60), 167 (37).  
HR-MS (EI): m/z calcd for C18H20NO2+ [M−H]+ 282.1489, found 282.1503. 
 
Synthesis of 2-[3-(2,6-Dimethylhept-5-en-2-yl)-4-methoxyphenyl]pyridine (187bg) 
The general procedure A was followed, using substrate 38b (93 mg, 0.50 mmol) 
and bromide 50g (308 mg, 1.50 mmol) with [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), After 20 h, purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 187bg (95 mg, 61%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 7.88 (d, J = 
2.3 Hz, 1H), 7.80 (dd, J = 8.5, 2.3 Hz, 1H), 7.71–7.61 (m, 2H), 7.13 (ddd, J = 7.0, 
4.8, 1.5 Hz, 1H), 6.93 (d, J = 8.5 Hz, 1H), 5.05 (tt, J = 7.1, 1.4 Hz, 1H), 3.85 (s, 
3H), 1.90–1.79 (m, 2H), 1.71–1.62 (m, 2H), 1.61 (d, J = 1.3 Hz, 3H), 1.46–1.44 
(m, 3H), 1.42 (s, 6H).  
13C NMR (75 MHz, CDCl3): δ = 159.3 (Cq), 157.7 (Cq), 149.4 (CH), 136.5 (Cq), 136.4 (CH), 131.3 (Cq), 
130.5 (Cq), 126.5 (CH), 125.6 (CH), 125.2 (CH), 121.0 (CH), 119.8 (CH), 111.3 (CH), 55.1 (CH3), 40.9 
(CH2), 38.4 (CH2), 28.5 (CH3), 25.7 (CH3), 24.2 (Cq), 17.4 (CH3).   
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MS (EI) m/z (relative intensity) 309 (12) [M]+, 278 (18), 226 (100), 167 (20).  
HR-MS (EI): m/z calcd for C21H27NO+ [M]+ 309.2087, found 309.2092. 
 
Synthesis of 2-[3-(5-Chloro-2-methylpentan-2-yl)-4-methoxyphenyl]pyridine (187bh) 
The general procedure A was followed using substrate 38b (93 mg, 0.50 mmol) and 
bromide 50h (299 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 80:1) yielded 187bh (90 mg, 59%) as a colorless 
oil. 
The general procedure B was followed using substrate 38b (93 mg, 0.50 mmol) and 
bromide 50h (299 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 80:1) yielded 187bh (90 mg, 59%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.65 (d, J = 4.9 Hz, 1H), 7.89 (d, J = 2.3 Hz, 1H), 7.81 
(dd, J = 8.4, 2.3 Hz, 1H), 7.74–7.63 (m, 2H), 7.16 (ddd, J = 6.9, 4.9, 1.9 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 
3.88 (s, 3H), 3.43 (t, J = 6.7 Hz, 2H), 2.05–1.96 (m, 2H), 1.54–1.46 (m, 2H), 1.44 (s, 6H).  
13C NMR (75 MHz, CDCl3): δ = 159.3 (Cq), 157.7 (Cq), 149.5 (CH), 136.6 (CH), 136.0 (Cq), 131.5 (Cq), 
126.6 (CH), 126.0 (CH), 121.2 (CH), 112.0 (CH), 111.4 (CH), 55.2 (CH3), 46.1 (CH2), 38.1 (Cq), 38.0 
(CH2), 28.9 (CH2), 28.4 (CH3).  
IR (neat): ṽ = 3954, 2955, 2865, 1603, 1586, 1498, 1238, 1087, 1025, 779 cm−1.  
MS (EI) m/z (relative intensity) 305/303 (5/16) [M+], 226 (100), 198 (14), 167 (14).  
HR-MS (EI): m/z calcd for C18H2235ClNO+ [M+] 303.1384, found 303.1390. 
 
Synthesis of 2-[4-Methoxy-3-(2-methyl-4-phenylbutan-2-yl)phenyl]pyridine (187bi) 
The general procedure A was followed using substrate 38b (93 mg, 0.50 mmol) and 
bromide 50i (341 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187bi (110 mg, 66%) as a colorless 
oil. 
The general procedure B was followed using substrate 38b (93 mg, 0.50 mmol) and 
bromide 50i (341 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187bi (98 mg, 59%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.67 (d, J = 4.9 Hz, 1H), 7.96 (d, J = 2.3 Hz, 1H), 7.83 (dd, J = 8.5, 2.3 Hz, 
1H), 7.74–7.65 (m, 2H), 7.25–7.19 (m, 2H), 7.18–7.13 (m, 2H), 7.10–7.06 (m, 2H), 6.97 (d, J = 8.7 Hz, 
1H), 3.88 (s, 3H), 2.34–2.26 (m, 2H), 2.23–2.15 (m, 2H), 1.48 (s, 6H).  
13C NMR (75 MHz, CDCl3): δ = 159.3 (Cq), 157.7 (Cq), 149.4 (CH), 143.6 (Cq), 136.4 (CH), 136.2 (Cq), 
131.4 (Cq), 128.2 (CH), 128.1 (CH), 126.6 (CH), 125.8 (CH), 125.2 (CH), 121.1 (CH), 119.9 (CH), 111.4 
(CH), 55.2 (CH3), 43.0 (CH2), 38.6 (Cq), 32.1 (CH2), 28.6 (CH3).  
IR (neat): ṽ = 3024, 2960, 1586, 1462, 1429, 1270, 1237, 1069, 1026, 779 cm−1. 
MS (EI) m/z (relative intensity) 331 (40) [M]+, 226 (100), 198 (15), 167 (17), 91 (20).  
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Synthesis of 2-[4-Methoxy-3-(2-methyl-1-phenylpropan-2-yl)phenyl]pyridine (187bj) 
The general procedure A was followed, using substrate 38b (93mg, 0.50 mmol) and 
bromide 50j (320 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 80:1) yielded 187bj (93 mg, 59%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.61 (d, J = 4.9 Hz, 1H), 7.86 (dd, J = 8.5, 2.3 Hz, 1H), 
7.69–7.62 (m, 2H), 7.56 (d, J = 8.1 Hz, 1H), 7.16–7.06 (m, 4H), 7.03 (d, J = 8.5 Hz, 1H), 
6.93–6.87 (m, 2H), 3.99 (s, 3H), 3.19 (s, 2H), 1.43 (s, 6H). 
13C NMR (75 MHz, CDCl3): δ = 159.3 (Cq), 157.7 (Cq), 149.4 (CH), 139.9 (Cq), 136.5 (CH), 136.4 (Cq), 
131.5 (Cq), 130.3 (CH), 127.1 (CH), 126.6 (CH), 126.0 (CH), 125.5 (CH), 121.2 (CH), 120.0 (CH), 111.5 
(CH), 55.2 (CH3), 46.0 (CH2), 39.3 (Cq), 28.0 (CH3).  
IR (neat): ṽ = 3002, 2959, 1586, 1462, 1270, 1236, 1086, 1025, 779 cm−1.  
MS (EI) m/z (relative intensity) 317 (5) [M]+, 226 (98), 198 (13), 167 (18), 91 (17).  
HR-MS (EI): m/z calcd for C22H23NO+ [M]+ 317.1774, found 317.1793. 
 
Synthesis of 2-[3-(tert-Butyl)phenyl]pyridine (187aa) 
The general procedure A was followed using substrate 37a (78 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 80:1) yielded 187aa (69 mg, 65%) as a colorless 
oil. 
The general procedure B was followed using substrate 38a (78 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 80:1) yielded 187aa (62 mg, 59%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.71 (d, J = 4.9 Hz, 1H), 8.06 (t, J = 1.6 Hz, 1H), 7.80–7.71 (m, 3H), 
7.50–7.39 (m, 2H), 7.25–7.19 (m, 1H), 1.41 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 158.0 (Cq), 151.6 (Cq), 149.6 (CH), 139.2 (Cq), 136.6 (CH), 128.4 (CH), 
126.0 (CH), 124.1 (CH), 123.9 (CH), 121.9 (CH), 120.7 (CH), 34.8 (Cq), 29.7 (CH3).  
IR (neat): ṽ = 3064, 2961, 1584, 1564, 1460, 1431, 1251, 770 cm−1. 
MS (EI) m/z (relative intensity) 211 (34) [M]+, 196 (100), 167 (18), 155 (12). 
HR-MS (EI): m/z calcd for C15H16N+ [M−H]+ 210.1277, found 210.1287. 
 
Synthesis of 2-[3-(tert-Butyl)-4-fluorophenyl]pyridine (187ca) 
The general procedure A was followed using substrate 38c (87 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 80:1) yielded 187ca (92 mg, 80%) as a colorless 
oil. 
The general procedure B was followed using substrate 38c (87 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 80:1) yielded 187ca (93 mg, 81%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.66 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.98 (dd, J = 8.1, 2.6 Hz, 1H), 
7.79–7.64 (m, 3H), 7.19 (ddd, J = 7.4, 4.7, 1.3 Hz, 1H), 7.09 (ddd, J = 12.3, 8.5, 1.1 Hz, 1H), 1.43 (d, J = 
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13C NMR (75 MHz, CDCl3): δ = 162.7 (d, 1JC-F = 251 Hz, Cq), 157.1 (Cq), 149.6 (CH), 137.3 (d, 2JC-F = 12 
Hz, Cq), 136.7 (CH), 135.1 (d, 4JC-F = 3 Hz, Cq), 126.2 (d, 3JC-F = 2 Hz, CH), 126.1 (d, 3JC-F = 5 Hz, CH), 
121.8 (CH), 120.4 (CH), 116.5 (d, 2JC-F = 24 Hz, CH), 34.4 (d, 3JC-F = 3 Hz, Cq), 29.9 (d, 4JC-F = 3 Hz, CH3).  
19F NMR (282 MHz, CDCl3): δ = -109.4 (s).  
IR (neat): ṽ = 3050, 2958, 1590, 1460, 1432, 1364, 1214, 1088, 778 cm−1. 
MS (EI) m/z (relative intensity) 229 (40) [M]+, 214 (100), 186 (36), 173 (10). 
HR-MS (EI): m/z calcd for C15H15FN+ [M−H]+ 228.1183, found 228.1191. 
 
Synthesis of 1-[2-(tert-Butyl)-4-(pyridin-2-yl)phenyl]ethan-1-one (187da) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 38d (99 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187da (74 mg, 58%) as a white 
solid. 
The general procedure B was followed using [RuCl(O-Val-Piv)(p-cymene)] (23.6 mg, 
10.0 mol %), substrate 38d (99 mg, 0.50 mmol) and bromide 50a (206 mg, 1.50 
mmol). After 20 h, purification by column chromatography (n-hexane/EtOAc 20:1) yielded 187da (69 
mg, 54%) as a white solid. 
M. p.: 84–86 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.68 (d, J = 4.9 Hz, 1H), 8.12 (d, J = 1.6 Hz, 1H), 7.80–7.67 (m, 3H), 
7.25–7.20 (m, 2H), 2.60 (s, 3H), 1.42 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 207.6 (Cq), 157.0 (Cq), 149.7 (CH), 147.4 (Cq), 142.4 (Cq), 140.0 (Cq), 
136.7 (CH), 126.5 (CH), 126.0 (CH), 123.8 (CH), 122.3 (CH), 120.7 (CH), 36.1 (Cq), 32.5 (CH3), 31.8 
(CH3). 
IR (ATR): ṽ = 3060, 3001, 1693, 1583, 1465, 1352, 1240, 1052, 839 cm−1.  
MS (EI) m/z (relative intensity) 253 (5) [M]+, 238 (77), 220 (17), 167 (7).  
HR-MS (EI): m/z calcd for C17H19NO+ [M]+ 253.1461, found 253.1464. 
 
Synthesis of Methyl 2-(tert-Butyl)-4-(pyridin-2-yl)benzoate (187ea) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), sbustrate 38e (107 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187ea (68 mg, 51%) as a 
colorless oil. 
The general procedure B was followed using [RuCl(O-Val-Piv)(p-cymene)] (23.6 
mg, 10.0 mol %), substrate 38e (107 mg, 0.50 mmol) and bromide 50a (206 mg, 
1.50 mmol). After 20 h, purification by column chromatography (n-hexane/EtOAc 20:1) yielded 187ea 
(67 mg, 50%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.68 (d, J = 4.9 Hz, 1H), 8.14 (d, J = 1.7 Hz, 1H), 7.79–7.67 (m, 3H), 7.39 
(d, J = 8.0 Hz, 1H), 6.50 (ddd, J = 6.8, 4.9, 1.9 Hz, 1H), 3.89 (s, 3H), 1.45 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 172.3 (Cq), 156.9 (Cq), 149.7 (CH), 148.2 (Cq), 140.6 (Cq), 136.7 (CH), 
133.0 (Cq), 129.2 (CH), 125.7 (CH), 123.8 (CH), 122.4 (CH), 120.8 (CH), 52.4 (CH3), 36.0 (Cq), 31.3 
(CH3).   
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MS (EI) m/z (relative intensity) 269 (23) [M]+, 254 (64), 222 (100), 194 (37), 167 (17).  
HR-MS (EI): m/z calcd for C17H19NO2+ [M]+ 269.1410, found 269.1418. 
 
Synthesis of 2-[3-(tert-Butyl)-4-methylphenyl]pyridine (187fa) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 38f (85 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 187fa (51 mg, 45%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.66 (d, J = 4.9 Hz, 1H), 8.06 (d, J = 1.9 Hz, 1H), 
7.74–7.64 (m, 3H), 7.23–7.15 (m, 2H), 2.57 (s, 3H), 1.47 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 158.0 (Cq), 149.5 (CH), 148.3 (Cq), 137.3 (Cq), 136.8 (Cq), 136.6 (CH), 
133.2 (CH), 124.8 (CH), 124.2 (CH), 121.6 (CH), 120.4 (CH), 36.0 (Cq), 30.8 (CH3), 23.1 (CH3).  
IR (neat): ṽ = 2957, 2923, 2870, 1584, 1463, 1242, 1087, 776 cm−1.  
MS (EI) m/z (relative intensity) 225 (33) [M]+, 210 (100), 195 (25), 183 (36).  
HR-MS (EI): m/z calcd for C16H19N+ [M]+ 225.1512, found 225.1512. 
 
Synthesis of 2-[3-(tert-Butyl)-4-(trifluoromethyl)phenyl]pyridine (187ga) 
The general procedure A was followed, using substrate 38g (112 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187ga (37 mg, 26%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.71 (ddd, J = 4.8, 1.1, 1.1 Hz, 1H), 8.32 (s, 1H), 
7.87–7.70 (m, 4H), 7.26 (ddd, J = 7.5, 5.2, 2.1 Hz, 1H), 1.51 (s, 9H).  
13C NMR (75 MHz, CDCl3) δ =156.4 (Cq), 149.9 (CH), 149.7 (q, 3JC-F = 2 Hz, Cq), 142.1 
(Cq), 136.8 (CH), 128.9 (q, 3JC-F = 7 Hz, CH), 128.4 (q, 2JC-F = 30 Hz, Cq), 127.5 (CH), 125.1 (q, 1JC-F = 273 
Hz, Cq), 124.1 (CH), 122.7 (CH), 120.9 (CH), 36.8 (Cq), 32.0 (q, 5JC-F = 3 Hz, CH3).  
19F NMR (282 MHz, CDCl3): δ = -152.8 (s).  
IR (neat): ṽ = 2961, 2875, 1587, 1560, 1436, 1238, 1106, 1034, 780 cm−1.  
MS (EI) m/z (relative intensity) 279 (52) [M]+, 264 (100), 244 (83), 223 (62).  
HR-MS (EI): m/z calcd for C16H16F3N+ [M]+ 279.1229, found 279.1230. 
 
Synthesis of 2-(tert-Butyl)-4-(pyridin-2-yl)benzonitrile (187ha) 
The general procedure A was followed using substrate 38h (90 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187ha (17 mg, 14%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.71 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.14 (d, J = 1.7 Hz, 
1H), 7.85–7.70 (m, 4H), 7.29 (ddd, J = 7.2, 4.8, 1.4 Hz, 1H), 1.57 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 155.9 (Cq), 154.2 (Cq), 150.0 (CH), 143.2 (Cq), 137.0 
(CH), 136.0 (CH), 125.0 (CH), 124.4 (CH), 123.1 (CH), 121.1 (CH), 120.3 (Cq), 110.8 (Cq), 35.9 (Cq), 30.2 
(CH3). 
IR (neat): ṽ = 3052, 2962, 2871, 2218, 1586, 1481, 1433, 1192, 990 cm−1. 
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HR-MS (EI): m/z calcd for C16H16N2+ [M]+ 236.1308, found 236.1316. 
Synthesis of 2-[3-(tert-Butyl)-4-vinylphenyl]pyridine (187ia) 
The general procedure A was followed using substrate 38i (91 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187ia (24 mg, 20%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.68 (ddd, J = 4.8, 1.6, 1.6 Hz, 1H), 8.04 (d, J = 1.9 Hz, 
1H), 7.78–7.67 (m, 3H), 7.50 (d, J = 8.0 Hz, 1H), 7.42 (dd, J = 17.1, 10.8 Hz, 1H), 7.19 
(ddd, J = 5.9, 4.8, 2.7 Hz, 1H), 5.52 (dd, J = 17.1, 1.6 Hz, 1H), 5.28 (dd, J = 10.8, 1.6 Hz, 
1H), 1.48 (s, 9H).  
13C NMR (75 MHz, CDCl3) δ = 157.7 (Cq), 149.6 (CH), 147.6 (Cq), 138.7 (CH), 138.6 (Cq), 138.4 (Cq), 
136.6 (CH), 129.5 (CH), 124.5 (CH), 124.5 (CH), 121.9 (CH), 120.5 (CH), 115.36 (CH2), 35.9 (Cq), 31.3 
(CH3).  
IR (neat): ṽ = 3049, 2964, 1711, 1681, 1464, 1366, 1243, 1071, 781 cm−1.  
MS (EI) m/z (relative intensity) 237 (17) [M]+, 222 (52), 206 (22), 193 (6).  
HR-MS (EI): m/z calcd for C17H19N+ [M]+ 237.1512, found 237.1516. 
 
Synthesis of 2-[3-(tert-Butyl)phenyl]-3-methoxypyridine (187ja) 
The general procedure A was followed using substrate 38j (93 mg, 0.50 mmol) 
and bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 187ja (87 mg, 72%) as a 
colorless oil. 
The general procedure B was followed using substrate 38j (93 mg, 0.50 mmol) 
and bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 187ja (86 mg, 71%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.30 (dd, J = 4.6, 1.4 Hz, 1H), 7.90 (dd, J = 1.8, 1.8 Hz, 1H), 7.68 (ddd, J 
= 7.2, 1.8, 1.8 Hz, 1H), 7.44–7.33 (m, 2H), 7.28–7.17 (m, 2H), 3.83 (s, 3H), 1.36 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 153.4 (Cq), 150.5 (Cq), 148.8 (Cq), 141.2 (CH), 137.2 (Cq), 127.5 (CH), 
126.5 (CH), 126.4 (CH), 125.3 (CH), 122.6 (CH), 118.3 (CH), 55.4 (CH3), 34.7 (Cq), 31.4 (CH3).   
IR (neat): ṽ = 3060, 2960, 1579, 1444, 1408, 1249, 1128, 1016, 801 cm−1.  
MS (EI) m/z (relative intensity) 241 (54) [M]+, 226 (100), 211 (20), 185 (17).  
HR-MS (EI): m/z calcd for C16H19NO+ [M]+ 241.1461, found 241.1458. 
 
Synthesis of 2-[3-(tert-Butyl)phenyl]-3-methylpyridine (187ka) 
The general procedure A was followed using substrate 38k (85 mg, 0.50 mmol) 
and bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187ka (69 mg, 61%) as a 
colorless oil. 
The general procedure B was followed using substrate 38k (85 mg, 0.50 mmol) 
and bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187ka (89 mg, 79%) as a 
colorless oil. 
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J = 7.7, 4.6 Hz, 1H), 2.33 (s, 3H), 1.34 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 159.3 (Cq), 150.8 (Cq), 146.8 (CH), 140.1 (Cq), 138.3(CH), 130.8 (Cq), 
127.7 (CH), 126.0 (CH), 125.9 (CH), 124.8 (CH), 121.9 (CH), 34.7 (Cq), 31.3 (CH3), 20.1 (CH3).   
IR (neat): ṽ = 3049, 2959, 1582, 1565, 1445, 1250, 1122, 787 cm−1.  
MS (EI) m/z (relative intensity) 225 (55) [M]+, 210 (100), 194 (20), 168 (33).  
HR-MS (EI): m/z calcd for C16H19N+ [M]+ 225.1512, found 225.1507. 
 
Synthesis of 2-[3-(tert-Butyl)phenyl]-5-methylpyridine (187la) 
The general procedure A was followed using substrate 38l (85 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 187la (64 mg, 57%) as a colorless 
oil. 
The general procedure B was followed using substrate 38l (85 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 187la (73 mg, 65%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.51 (dd, J = 1.4, 0.8 Hz, 1H), 8.00 (td, J = 1.9, 0.6 Hz, 
1H), 7.72 (dt, J = 7.1, 1.9 Hz, 1H), 7.62–7.58 (m, 1H), 7.55–7.50 (m, 1H), 7.45–7.35 (m, 2H), 2.35 (s, 
3H), 1.38 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 155.4 (Cq), 151.5 (Cq), 150.0 (CH), 139.2 (Cq), 137.2 (CH), 131.3 (Cq), 
128.3 (CH), 125.7 (CH), 123.9 (CH), 123.7 (CH), 120.2 (CH), 34.8 (Cq), 31.4 (CH3), 18.1 (CH3).  
IR (neat): ṽ = 3065, 2961, 2867, 1599, 1471, 1253, 999, 832 cm−1.  
MS (EI) m/z (relative intensity) 225 (37) [M]+, 210 (100), 194 (20), 169 (17).  
HR-MS (EI): m/z calcd for C16H19N+ [M]+ 225.1512, found 225.1517. 
 
Synthesis of 2-[3-(tert-Butyl)phenyl]-5-fluoropyridine (187ma) 
The general procedure A was followed using substrate 38m (74 mg, 0.43 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 187ma (55 mg, 56%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.54 (d, J = 3.0 Hz, 1H), 7.98 (dd, J = 2.0, 2.0 Hz, 1H), 
7.73–7.67 (m, 2H), 7.48–7.36 (m, 3H), 1.38 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 158.7 (d, 1JC-F = 257 Hz, Cq), 154.3 (d, 4JC-F = 4 Hz, Cq), 
151.7 (Cq), 138.2 (Cq), 137.6 (d, 2JC-F = 24 Hz, CH), 128.5 (CH), 126.0 (CH), 124.0 (CH), 
123.8 (CH), 123.4 (d, 2JC-F = 19 Hz, CH), 121.5 (d, 3JC-F = 4 Hz, CH), 34.8 (Cq), 31.4 (CH3).  
19F NMR (282 MHz, CDCl3): δ = −130.2 (s).  
IR (neat): ṽ = 3065, 2962, 1671, 1579, 1468, 1224, 1017, 834 cm−1.  
MS (EI) m/z (relative intensity) 229 (38) [M]+, 214 (100), 199 (23), 185 (21).  
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Synthesis of 2-[3-(tert-Butyl)phenyl]-5-phenylpyridine (187na) 
The general procedure A was followed using substrate 38n (116 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187na (35 mg, 24%) as a white solid. 
M. p.: 133–135 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.94 (dd, J = 2.4, 0.8 Hz, 1H), 8.10–8.08 (m, 1H), 7.94 
(dd, J = 8.7, 2.4 Hz, 1H), 7.83–7.77 (m, 2H), 7.65–7.61 (m, 2H), 7.52–7.37 (m, 5H), 
1.40 (s, 9H).  
13C NMR (126 MHz, CDCl3) δ =156.8 (Cq), 151.7 (Cq), 148.0 (CH), 138.8 (Cq), 137.7 
(Cq), 135.0 (CH), 134.7 (Cq), 129.1 (CH), 128.5 (CH), 128.0 (CH), 127.0 (CH), 126.1 (CH), 124.1 (CH), 
123.9 (CH), 120.5 (CH), 34.9 (Cq), 31.4 (CH3).  
IR (ATR): ṽ = 3409, 3058, 3020, 1590, 1472, 1249, 1077, 993, 773 cm−1.  
MS (EI) m/z (relative intensity) 287 (56) [M]+, 272 (100), 256 (17), 231 (24).  
HR-MS (EI): m/z calcd for C21H21N+ [M]+ 287.1669, found 287.1673. 
 
Synthesis of 2-[3-(tert-Butyl)-4-methoxyphenyl]-4-methylpyridine (187oa) 
The general procedure A was followed using substrate 38o (100 mg, 0.50 mmol) 
and bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187oa (66 mg, 52%) as a 
colorless oil. 
The general procedure B was followed using substrate 38o (100 mg, 0.50 mmol) 
and bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187oa (95 mg, 74%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.50 (d, J = 5.0 Hz, 1H), 7.93 (d, J = 2.3 Hz, 1H), 7.77 (dd, J = 8.5, 2.3 Hz, 
1H), 7.46 (dt, J = 1.5, 0.8 Hz, 1H), 6.99–6.92 (m, 2H), 3.87 (s, 3H), 2.37 (s, 3H), 1.43 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 159.3 (Cq), 157.7 (Cq), 149.2 (CH), 147.4 (Cq), 138.3 (Cq), 131.5 (Cq), 
125.6 (CH), 125.4 (CH), 122.2 (CH), 120.9 (CH), 111.5 (CH), 55.1 (CH3), 35.0 (Cq), 29.7 (CH3), 21.2 
(CH3).   
IR (neat): ṽ = 2953, 2913, 1601, 1556, 1452, 1234, 1093, 1027, 810 cm−1.  
MS (EI) m/z (relative intensity) 255 (41) [M]+, 240 (100), 224 (18), 212 (12).  
HR-MS (EI): m/z calcd for C17H21NO+ [M]+ 255.1618, found 255.1626. 
 
Synthesis of 1-{2-[3-(tert-Butyl)phenyl]pyridin-4-yl}ethan-1-one (187pa) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 
5.0 mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 38p (99 mg, 0.50 
mmol) and bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 20:1) yielded 187pa (61 mg, 48%) 
as a white solid. 
M. p.: 86–88 °C. 
1H NMR (300 MHz, CDCl3): δ = 9.22 (dd, J = 2.3, 0.9 Hz, 1H), 8.26 (dd, J = 8.4, 
2.3 Hz, 1H), 8.10 (dd, J = 1.9, 1.9 Hz, 1H), 7.84–7.79 (m, 2H), 7.50 (ddd, J = 
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13C NMR (75 MHz, CDCl3): δ = 196.5 (Cq), 161.5 (Cq), 151.9 (Cq), 150.1 (CH), 137.9 (Cq), 136.2 (CH), 
130.4 (Cq), 128.6 (CH), 127.2 (CH), 124.6 (CH), 124.4 (CH), 120.3 (CH), 34.9 (Cq), 31.3 (CH3), 26.7 
(CH3).  
IR (ATR): ṽ = 3024, 2959, 1593, 1494, 1453, 1044, 1027, 809 cm−1.  
MS (EI) m/z (relative intensity) 253 (15) [M]+, 238 (45), 210 (6), 197 (6).  
HR-MS (EI): m/z calcd for C17H19NO+ [M]+ 253.1461, found 253.1463. 
 
Synthesis of 2-[2-Methoxy-3-(1-methylcyclohexyl)phenyl]pyridine (187qb) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 38q (93 mg, 0.50 mmol) and 
bromide 50b (266 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187qb (65 mg, 46%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.71 (d, J = 4.7 Hz, 1H), 7.74–7.65 (m, 2H), 7.43 
(dd, J = 7.5, 1.7 Hz, 1H), 7.35 (dd, J = 8.0, 1.7 Hz, 1H), 7.20 (ddd, J = 6.5, 4.9, 2.2 
Hz, 1H), 7.12 (dd, J = 7.8, 7.8 Hz, 1H), 3.28 (s, 3H), 2.20–2.11 (m, 2H), 1.74–1.64 (m, 2H), 1.59–1.40 (m, 
6H), 1.31 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 158.1 (Cq), 157.9 (Cq), 149.7 (CH), 142.0 (Cq), 136.1 (CH), 134.5 (Cq), 
129.6 (CH), 128.5 (CH), 124.7 (CH), 123.5 (CH), 121.6 (CH), 61.2 (CH3), 38.8 (Cq), 37.9 (CH2), 27.5 
(CH3), 26.6 (CH2), 23.0 (CH2).  
IR (neat): ṽ = 3058, 2923, 1586, 1407, 1211, 1005, 775 cm−1.  
MS (EI) m/z (relative intensity) 281 (43) [M]+, 266 (90), 248 (47), 222 (36).  
HR-MS (EI): m/z calcd for C19H23NO+ [M]+ 281.1774, found 281.1785. 
 
Synthesis of 2-[3-(tert-Butyl)-2-methoxyphenyl]pyridine (187qa) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 38q (93 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 187qa (50 mg, 41%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.71 (d, J = 4.9 Hz, 1H), 7.76–7.66 (m, 2H), 7.44 (dd, J 
= 7.4, 1.7 Hz, 1H), 7.34 (dd, J = 7.8, 1.7 Hz, 1H), 7.21 (ddd, J = 6.5, 4.9, 2.2 Hz, 1H), 
7.09 (dd, J = 7.8, 7.8 Hz, 1H), 3.31 (s, 3H), 1.42 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 157.8 (Cq), 157.8 (Cq), 149.7 (CH), 142.9 (Cq), 136.1 (CH), 134.1 (Cq), 
129.8 (CH), 127.3 (CH), 124.6 (CH), 123.4 (CH), 121.7 (CH), 61.3 (CH3), 35.1 (Cq), 30.8 (CH3).  
IR (neat): ṽ = 3051, 2867, 1587, 1562, 1473, 1223, 1006, 760 cm−1.  
MS (EI) m/z (relative intensity) 241 (51) [M]+, 226 (83), 210 (100), 167 (32).  
HR-MS (EI): m/z calcd for C16H19NO+ [M]+ 241.1461, found 241.1465. 
 
Synthesis of 2-[3-Methoxy-5-(1-methylcyclohexyl)phenyl]pyridine (187rb) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 
5.0 mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 38r (93 mg, 0.50 
mmol) and bromide 50b (266 mg, 1.50 mmol). After 20 h, purification by 
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35%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.67 (d, J = 4.9 Hz, 1H), 7.75–7.67 (m, 2H), 7.56 (dd, J = 1.6,1.6 Hz, 1H), 
7.36 (dd, J = 2.5, 1.4 Hz, 1H), 7.20 (ddd, J = 6.2, 4.9, 2.3 Hz, 1H), 6.99 (dd, J = 2.5, 1.4 Hz, 1H), 3.88 (s, 
3H), 2.08–1.99 (m, 2H), 1.64–1.40 (m, 8H), 1.22 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.0 (Cq), 158.0 (Cq), 152.2 (Cq), 149.5 (CH), 140.6 (Cq), 136.6 (CH), 
122.0 (CH), 120.8 (CH), 117.4 (CH), 113.9 (CH), 108.2 (CH), 55.3 (CH3), 38.2 (Cq), 38.0 (CH2), 30.4 
(CH3), 26.3 (CH2), 22.7 (CH2). 
IR (neat): ṽ = 2924, 2854, 1583, 1450, 1330, 1214, 1058, 781 cm−1.  
MS (EI) m/z (relative intensity) 281 (100) [M]+, 266 (53), 252 (26), 226 (73).  
HR-MS (EI): m/z calcd for C19H23NO+ [M]+ 281.1774, found 281.1773. 
 
Synthesis of 2-[4-(tert-Butyl)naphthalen-2-yl]pyridine (187sa) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 38s (103 mg, 0.50 mmol) 
and bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 40:1) yielded 187sa (29 mg, 22%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.74 (ddd, J = 4.8, 1.9, 1.0 Hz, 1H), 8.47 (d, J = 
8.7 Hz, 1H), 8.29 (dd, J = 1.7, 0.9 Hz, 1H), 8.19 (d, J = 1.8 Hz, 1H), 7.97 (dd, J = 7.8, 1.9 Hz, 1H), 7.86 (dt, 
J = 8.0, 1.1 Hz, 1H), 7.77 (ddd, J = 7.9, 7.3, 1.8 Hz, 1H), 7.56–7.39 (m, 2H), 7.24 (ddd, J = 7.2, 4.8, 1.2 
Hz, 1H), 1.69 (s, 9H).  
13C NMR (126 MHz, CDCl3) δ =157.7 (Cq), 149.6 (CH), 146.6 (Cq), 136.6 (CH), 135.6 (Cq), 135.1 (Cq), 
131.7 (Cq), 130.4 (CH), 126.8 (CH), 125.7 (CH), 125.1 (CH), 124.9 (CH), 122.1 (CH), 121.9 (CH), 120.9 
(CH), 36.4 (Cq), 31.9 (CH3).  
IR (neat): ṽ = 3052, 2957, 1586, 1563, 1471, 1364, 1153, 990, 781 cm−1. 
MS (EI) m/z (relative intensity) 261 (58) [M]+, 246 (100), 231 (42), 217 (17).  
HR-MS (EI): m/z calcd for C19H19N+ [M]+ 261.1512, found 261.1514 
 
Synthesis of 2-[5-(tert-butyl)thiophen-3-yl]pyridine (187ta) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), 
Piv-Val-OH (30.0 mg, 30 mol %), substrate 38t (81 mg, 0.50 mmol) and bromide 50a 
(206 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 40:1) yielded 187ta (60 mg, 55%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.58 (d, J = 4.9 Hz, 1H), 7.67–7.55 (m, 3H), 7.40 (d, J = 
1.4 Hz, 1H), 7.11 (ddd, J = 7.3, 4.9, 1.3 Hz, 1H), 1.41 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 158.5 (Cq), 153.9 (Cq), 149.4 (CH), 141.3 (Cq), 136.5 (CH), 
121.5 (CH), 120.5 (CH), 120.5 (CH), 120.1 (CH), 34.6 (Cq), 34.2 (CH3).  
IR (neat): ṽ = 3085, 3060, 1768, 1704, 1586, 1483, 1244, 1064, 747 cm−1.  
MS (EI) m/z (relative intensity) 217 (26) [M]+, 202 (100), 187 (10), 168 (8).  
HR-MS (EI): m/z calcd for C13H15NS+ [M]+ 217.0920, found 217.0930. 
 
Synthesis of 1-[3-(tert-Butyl)-4-fluorophenyl]-1H-pyrazole (196aa) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
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bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded 196aa (79 mg, 72%) as a colorless oil. 
The general procedure B was followed using [RuCl(O-Val-Piv)(p-cymene)] (23.6 mg, 10.0 mol %), 
substrate 131a (81 mg, 0.50 mmol) and bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 10:1) yielded 196aa (80mg, 73%) as a colorless oil. 
 
1H NMR (300 MHz, CDCl3): δ = 7.84 (d, J = 2.4 Hz, 1H), 7.71 (d, J = 1.7 Hz, 1H), 7.65 (dd, J = 7.1, 2.8 Hz, 
1H), 7.42 (ddd, J = 8.8, 3.9, 2.8 Hz, 1H), 7.07 (dd, J = 11.8, 8.8 Hz, 1H), 6.45 (dd, J = 2.2, 2.2 Hz, 1H), 
1.42 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 160.3 (d, 1JC-F = 247 Hz, Cq), 140.9 (CH), 138.4 (d, 2JC-F = 13 Hz, Cq), 
136.2 (d, 4JC-F = 2 Hz, Cq), 127.0 (CH), 119.1 (d, 3JC-F = 6 Hz, CH), 118.4 (d, 3JC-F = 9 Hz, CH), 116.9 (d, 2JC-F 
= 26 Hz, CH), 107.4 (CH), 34.5 (d, 3JC-F = 3 Hz, Cq), 29.7 (d, 4JC-F = 4 Hz, CH3).  
19F NMR (282 MHz, CDCl3): δ = −112.1 (s).  
IR (neat): ṽ = 3111, 2960, 1592, 1490, 1394, 1211, 1044, 949 cm−1.  
MS (EI) m/z (relative intensity) 218 (55) [M]+, 203 (100), 175 (60), 133 (5).  
HR-MS (EI): m/z calcd for C13H15FN2+ [M]+ 218.1214, found 218.1216. 
 
Synthesis of 1-[4-Fluoro-3-(1-methylcyclohexyl)phenyl]-1H-pyrazole (196ab) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 131a (81 mg, 0.50 mmol) and 
bromide 50b (266 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 196ab (87 mg, 67%) as a 
colorless oil. 
The general procedure B was followed using [RuCl(O-Val-Piv)(p-cymene)] (23.6 
mg, 10.0 mol %), substrate 131a (81 mg, 0.50 mmol) and bromide 50b (266 mg, 1.50 mmol). After 20 
h, purification by column chromatography (n-hexane/EtOAc 10:1) yielded 196ab (83 mg, 64%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.82 (d, J = 2.4 Hz, 1H), 7.69 (d, J = 1.8 Hz, 1H), 7.66 (dd, J = 7.1, 2.8 Hz, 
1H), 7.39 (ddd, J = 8.7, 3.9, 2.8 Hz, 1H), 7.04 (dd, J = 12.2, 8.7 Hz, 1H), 6.43 (dd, J = 2.4, 1.8 Hz, 1H), 
2.12–2.01 (m, 2H), 1.72–1.45(m, 8H), 1.31 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 160.4 (d, 1JC-F = 248 Hz, Cq), 140.9 (CH), 137.8 (d, 2JC-F = 13 Hz, Cq), 
136.3 (d, 4JC-F = 3 Hz, Cq), 127.0 (CH), 120.0 (d, 3JC-F = 6 Hz, CH), 118.2 (d, 3JC-F = 10 Hz, CH), 117.2 (d, 
2JC-F = 28 Hz, CH), 107.4 (CH), 38.0 (d, 3JC-F = 3 Hz, Cq), 37.0 (d, 4JC-F = 4 Hz, CH2), 26.4 (d, 4JC-F = 4 Hz, 
CH3), 26.3 (CH2), 22.6 (CH2).  
19F NMR (282 MHz, CDCl3): δ = –111.5 (s).  
IR (neat): ṽ = 3112, 2925, 1593, 1490, 1451, 1211, 1043, 947 cm−1. 
MS (EI) m/z (relative intensity) 258 (100) [M]+, 243 (74), 202 (49), 175 (35).  
HR-MS (EI): m/z calcd for C16H19FN2+ [M]+ 258.1527, found 258.1529. 
 
Synthesis of 1-[3-(tert-Butyl)-4-methoxyphenyl]-1H-pyrazole (196ba) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 131b (93 mg, 0.53 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
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oil. 
The general procedure B was followed using [RuCl(O-Val-Piv)(p-cymene)] (23.6 mg, 10.0 mol %), 
substrate 131b (87 mg, 0.50 mmol) and bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 40:1) yielded 196ba (73 mg, 63%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.80 (dd, J = 2.4, 0.7 Hz, 1H), 7.68 (d, J = 1.7 Hz, 1H), 7.59 (d, J = 2.8 Hz, 
1H), 7.40 (dd, J = 8.7, 2.8 Hz, 1H), 6.90 (d, J = 8.7 Hz, 1H), 6.41 (dd, J = 2.1, 2.1 Hz, 1H), 3.85 (s, 3H), 
1.40 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 157.2 (Cq), 140.4 (CH), 139.4 (Cq), 133.5 (Cq), 127.0 (CH), 119.0 (CH), 
118.2 (CH), 111.8 (CH), 106.9 (CH), 55.3 (CH3), 35.0 (Cq), 29.5 (CH3).  
IR (neat): ṽ = 3111, 2997, 1592, 1516, 1428, 1397, 1045, 1027, 951 cm−1.  
MS (EI) m/z (relative intensity) 230 (63) [M]+, 215 (100), 200 (32), 187 (32).  
HR-MS (EI): m/z calcd for C14H18N2O+ [M]+ 230.1414, found 230.1410.  
 
Synthesis of 1-[4-Methoxy-3-(2-methyl-4-phenylbutan-2-yl)phenyl]-1H-pyrazole (196bi) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 131b (87 mg, 0.50 mmol) and 
bromide 50i (341 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 196bi (93 mg, 58%) as a colorless 
oil. 
The general procedure B was followed using [RuCl(O-Val-Piv)(p-cymene)] (23.6 mg, 
10.0 mol %), substrate 131b (87 mg, 0.50 mmol) and bromide 50i (341 mg, 1.50 
mmol). After 20 h, purification by column chromatography (n-hexane/EtOAc 10:1) 
yielded 196bi (87 mg, 54%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.86 (d, J = 2.4 Hz, 1H), 7.73 (d, J = 1.8 Hz, 1H), 7.63 (d, J = 2.8 Hz, 1H), 
7.46 (dd, J = 8.7, 2.8 Hz, 1H), 7.28–7.21 (m, 2H), 7.17–7.08 (m, 3H), 6.94 (d, J = 8.7 Hz, 1H), 6.47–6.45 
(m, 1H), 3.88 (s, 3H), 2.34–2.26 (m, 2H), 2.23–2.16 (m, 2H), 1.48 (s, 6H).  
13C NMR (75 MHz, CDCl3): δ = 157.2 (Cq), 143.5 (Cq), 140.5 (CH), 137.4 (Cq), 133.7 (Cq), 128.3 (CH), 
128.2 (CH), 127.0 (CH), 125.4 (CH), 120.2 (CH), 118.4 (CH), 111.6 (CH), 107.0 (CH), 55.4 (CH3), 42.7 
(CH2), 38.7 (CH2), 32.0 (Cq), 28.4 (CH3).  
IR (neat): ṽ = 3024, 2959, 1593, 1516, 1494, 1235, 1027, 809 cm−1. 
MS (EI) m/z (relative intensity) 320 (62) [M]+, 215 (100), 187 (22), 157 (8), 91 (32).  
HR-MS (EI): m/z calcd for C21H24N2O+ [M]+ 320.1883, found 320.1882. 
 
1-[3-(tert-Butyl)phenyl]-1H-pyrazole (196ca) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 131c (72 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 80:1) yielded 196ca (44 mg, 44%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 7.90 (d, J = 2.4 Hz, 1H), 7.76–7.70 (m, 2H), 7.46–7.29 
(m, 3H), 6.46–6.43 (m, 1H), 1.36 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ =152.9 (Cq), 140.9 (CH), 140.1 (Cq), 128.9 (CH), 126.9 (CH), 123.6 (CH), 
116.8 (CH), 116.4 (CH), 107.3 (CH), 34.9 (Cq), 31.2 (CH3).  
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MS (EI) m/z (relative intensity) 200 (26) [M]+, 185 (100), 157 (13), 115 (6).  
HR-MS (EI): m/z calcd for C13H16N2+ [M]+ 200.1308, found 200.1319. 
 
Synthesis of 1-[3-(1-Methylcyclohexyl)phenyl]-1H-pyrazole (196cb) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 131c (72 mg, 0.50 mmol) and 
bromide 50b (266 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 80:1) yielded 196cb (35 mg, 29%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 7.90 (dd, J = 2.5, 0.6 Hz, 1H), 7.74–7.71 (m, 2H), 
7.45–7.28 (m, 3H), 6.45–6.43 (m, 1H), 2.08–1.98 (m, 2H), 1.63–1.41 (m, 8H), 1.22 (s, 
3H). 
13C NMR (75 MHz, CDCl3): δ =151.8 (Cq), 140.8 (CH), 140.2 (Cq), 129.0 (CH), 126.8 (CH), 124.1 (CH), 
117.3 (CH), 116.2 (CH), 107.2 (CH), 38.2 (Cq), 37.9 (CH2), 30.4 (CH3), 26.3 (CH2), 22.7 (CH2).  
IR (neat): ṽ = 2925, 2856, 1605, 1518, 1466, 1332, 1192, 1043, 964 cm−1.  
MS (EI) m/z (relative intensity) 240 (100) [M]+, 225 (78), 197 (37), 184 (41).  
HR-MS (EI): m/z calcd for C16H20N2+ [M]+ 240.1621, found 240.1623. 
 
Synthesis of 1-[2-(tert-Butyl)-4-(1H-pyrazol-1-yl)phenyl]ethan-1-one (196da) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 131d (93 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 40:1) yielded 196da (46 mg, 38%) as a white 
solid. 
M. p.: 68–70 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.91 (dd, J = 2.5, 0.7 Hz, 1H), 7.84 (d, J = 2.1 Hz, 
1H), 7.71 (d, J = 1.7 Hz, 1H), 7.47 (dd, J = 8.3, 2.1 Hz, 1H), 7.20 (d, J = 8.3 Hz, 1H), 6.45 (dd, J = 2.5, 1.7 
Hz, 1H), 2.58 (s, 3H), 1.40 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 206.8 (Cq), 149.1 (Cq), 141.3 (CH), 140.4 (Cq), 140.1 (Cq), 127.3 (CH), 
126.8 (CH), 118.3 (CH), 115.7 (CH), 107.8 (CH), 36.2 (Cq), 32.4 (CH3), 31.6 (CH3).  
IR (ATR): ṽ = 3129, 2962, 1691, 1517, 1398, 1105, 1047, 945, 760 cm−1.  
MS (EI) m/z (relative intensity) 242 (5) [M]+, 227 (100), 209 (20), 115 (8).  
HR-MS (EI): m/z calcd for C15H18N2O+ [M]+ 242.1414, found 242.1423. 
 
Synthesis of 1-[2-(1-Methylcyclohexyl)-4-(1H-pyrazol-1-yl)phenyl]ethan-1-one (196db) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 131d (93 mg, 0.50 mmol) and 
bromide 50b (266 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 40:1) yielded 196db (30 mg, 21%) as a white 
solid. 
M. p.: 92–94 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.93 (d, J = 2.4 Hz, 1H), 7.85 (d, J = 2.1 Hz, 1H), 7.74 
(d, J = 1.7 Hz, 1H), 7.49 (dd, J = 8.3, 2.1 Hz, 1H), 7.22 (d, J = 8.3 Hz, 1H), 6.48 (dd, J = 2.5, 1.7 Hz, 1H), 
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13C NMR (75 MHz, CDCl3): δ = 206.9 (Cq), 147.5 (Cq), 141.3 (CH), 140.7 (Cq), 140.6 (Cq), 127.4 (CH), 
126.8 (CH), 119.0 (CH), 115.7 (CH), 107.8 (CH), 39.9 (Cq), 38.4 (CH2), 32.1 (CH3), 29.9 (CH3), 26.2 
(CH2), 22.8 (CH2).  
IR (ATR): 3143, 2953, 1689, 1602, 1517, 1408, 1199, 1041, 747 cm−1.  
MS (EI) m/z (relative intensity) 282 (8) [M]+, 267 (100), 249 (23), 225 (18).  
HR-MS (EI): m/z calcd for C18H22N2O+ [M]+ 282.1727, found 282.1730. 
 
Synthesis of 1-(2-methoxy-3-(1-methylcyclohexyl)phenyl)-1H-pyrazole (196eb) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 131e (90 mg, 0.52 mmol) and 
bromide 50b (266 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 196eb (34 mg, 24%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 7.81 (dd, J = 2.4, 0.7 Hz, 1H), 7.71 (dd, J = 1.8, 0.6 Hz, 
1H), 7.37 (dd, J = 7.8, 1.7 Hz, 1H), 7.32 (dd, J = 8.0, 1.7 Hz, 1H), 7.10 (dd, J = 8.0, 8.0 
Hz, 1H), 6.45–6.43 (m, 1H), 3.15 (s, 3H), 2.17–2.07 (m, 2H), 1.69–1.44 (m, 8H), 1.29 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 153.2 (Cq), 143.1 (Cq), 140.5 (CH), 134.6 (Cq), 131.2 (CH), 127.4 (CH), 
124.8 (CH), 123.4 (CH), 106.9 (CH), 59.8 (CH3), 38.9 (Cq), 37.7 (CH2), 27.3 (CH3), 26.5 (CH2), 22.9 
(CH2).  
IR (neat): ṽ = 2924, 2854, 186, 1518, 1423, 1229, 1041, 948, 790 cm−1.  
MS (EI) m/z (relative intensity) 270 (63) [M]+, 255 (100), 237 (37), 187 (26).  
HR-MS (EI): m/z calcd for C17H22N2O+ [M]+ 270.1727, found 270.1731. 
 
Synthesis of 2-[3-(tert-Butyl)phenyl]pyrimidine (198aa) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 197a (78 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 198aa (53 mg, 50%) as a white 
solid. 
The general procedure B was followed using [RuCl(O-Val-Piv)(p-cymene)] (23.6 mg, 
10.0 mol %), substrate 197a (78.1 mg, 0.50 mmol) and bromide 50a (206 mg, 1.50 
mmol). After 20 h, purification by column chromatography (n-hexane/EtOAc 20:1) yielded 198aa (65 
mg, 61%) as a white solid. 
M. p.:74–76 °C.  
1H NMR (300 MHz, CDCl3): δ = 8.79 (d, J = 4.8 Hz, 2 H), 8.48 (dd, J = 1.8, 1.8 Hz, 1H), 8.24 (dd, J = 7.8, 
1.5 Hz, 1H), 7.52 (ddd, J = 7.8, 2.0, 1.2 Hz, 1H), 7.41 (dd, J = 7.8, 7.8 Hz, 1H), 7.15 (dd, J = 4.8, 4.8 Hz, 
1H), 1.40 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 165.1 (Cq), 157.2 (CH), 151.5 (Cq), 137.3 (Cq), 128.3 (CH), 127.9 (CH), 
125.4 (CH), 125.0 (CH), 118.9 (CH), 34.9 (Cq), 31.4 (CH3).  
IR (ATR): ṽ = 3069, 3037, 1567, 1403, 1259, 1244, 781, 697 cm−1.  
MS (EI) m/z (relative intensity) 212 (7) [M]+, 197 (33), 182 (5), 169 (5).  
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Synthesis of 2-[3-(tert-Butyl)-4-methoxyphenyl]pyrimidine (198ba) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 197b (93 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 198ba (53 mg, 44%) as a colorless 
oil. 
The general procedure B was followed using [RuCl(O-Val-Piv)(p-cymene)] (23.6 mg, 
10.0 mol %), substrate 197b (93 mg, 0.50 mmol) and bromide 50a (206 mg, 1.50 
mmol). After 20 h, purification by column chromatography (n-hexane/EtOAc 20:1) yielded 198ba (57 
mg, 47%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.73 (d, J = 4.8 Hz, 2H), 8.40 (d, J = 2.2 Hz, 1H), 8.27 (dd, J = 8.6, 2.2 Hz, 
1H), 7.07 (dd, J = 4.8, 4.8 Hz, 1H), 6.95 (d, J = 8.6 Hz, 1H), 3.89 (s, 3H), 1.43 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 165.0 (Cq), 160.9 (Cq), 157.1 (CH), 138.2 (Cq), 129.5 (Cq), 127.5 (CH), 
126.7 (CH), 118.1 (CH), 111.4 (CH), 55.1 (CH3), 35.0 (Cq), 29.7 (CH3).  
IR (neat): ṽ = 2966, 2955, 1566, 1549, 1395, 1252, 1027, 797 cm−1.  
MS (EI) m/z (relative intensity) 242 (36) [M]+, 227 (100), 199 (23), 169 (17).  
HR-MS (EI): m/z calcd for C15H18N2O+ [M]+ 242.1414, found 242.1423.  
 
Synthesis of 2-[3-(tert-Butyl)-4-fluorophenyl]pyrimidine (198ca) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 197c (87 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 197ca (60 mg, 52%) as a colorless 
oil. 
The general procedure B was followed using [RuCl(O-Val-Piv)(p-cymene)] (23.6 mg, 
10.0 mol %), substrate 197c (87 mg, 0.50 mmol) and bromide 50a (206 mg, 1.50 
mmol). After 20 h, purification by column chromatography (n-hexane/EtOAc 20:1) yielded 198ca (82 
mg, 71%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.76 (d, J = 4.8 Hz, 2H), 8.43 (dd, J = 8.3, 2.3 Hz, 1H), 8.25 (ddd, J = 8.5, 
4.7, 2.3 Hz, 1H), 7.13 (dd, J = 4.8, 4.8 Hz, 1H), 7.02 (dd, J = 12.1, 8.5 Hz, 1H), 1.44 (d, J = 1.0 Hz, 9H).  
13C NMR (75 MHz, CDCl3): δ = 164.0 (d, 1JC-F = 254 Hz, Cq), 164.3 (Cq), 157.1 (CH), 137.2 (d, 2JC-F = 12 
Hz, Cq), 133.2 (d, 4JC-F = 2 Hz, Cq), 127.8 (d, 3JC-F = 10 Hz, CH), 127.5 (d, 3JC-F = 7 Hz, CH), 118.7 (CH), 
116.5 (d, 2JC-F = 26 Hz, CH), 34.4 (d, 3JC-F = 3 Hz, Cq), 29.9 (d, 4JC-F = 3 Hz, CH3).  
19F NMR (282 MHz, CDCl3): δ = −106.4 (s). 
IR (neat): ṽ = 3036, 2959, 2870, 1567, 1415, 1210, 1084, 799 cm−1.  
MS (EI) m/z (relative intensity) 230 (28) [M]+, 215 (100), 187 (48), 134 (10).  
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Mechanistic Studies  
Intermolecular Competition Experiment between Substrates 38f and 38g 
[RuCl2(p-cymene)]2




























A mixture of substrates 38f (169 mg, 1.00 mmol), 38g (223 mg, 1.00 mmol) and bromide 50a (110 mg, 
0.80 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 3.1 mol %), Piv-Val-OH (30.0 mg, 18.6 mol %) and K2CO3 
(276 mg, 2.00 mmol) in 1,4-dioxane (4.0 mL) was stirred at 100 °C for 20 h under an atmosphere of 
N2. At ambient temperature, EtOAc (15 mL) was added, and the mixture was filtered through a pad of 
silica gel. The solvents were removed in vacuo, and the residue was purified by column 
chromatography (n-hexane/EtOAc 20:1). Careful 1H NMR analysis disclosed a ratio of 187fa/187ga to 
be 2.0 : 1.0. Their spectral data were identical to those reported above. 
0.800.850.900.951.001.051.101.151.201.251.301.351.401.451.501.551.601.651.701.751.801.851.901.952.002.052.10
f1 (ppm)

































187ba : 187fa = 3.8 : 1.0 
(1H NMR)
[RuCl2(p-cymene)]2
Piv-Val-OH (18.6 mol %)
(3.1 mol %)
K2CO3




A mixture of substrates 38b (185 mg, 1.00 mmol), 38f (169 mg, 1.00 mmol) and bromide 50a (110 mg, 
0.80 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 3.1 mol %), Piv-Val-OH (30.0 mg, 18.6 mol %) and K2CO3 
(276 mg, 2.00 mmol) in 1,4-dioxane (4.0 mL) was stirred at 100 °C for 20 h under an atmosphere of 
N2. At ambient temperature, EtOAc (15 mL) was added, and the mixture was filtered through a pad of 
silica gel. The solvents were removed in vacuo, and the residue was purified by column 
chromatography (n-hexane/EtOAc 20:1). Careful 1H NMR analysis disclosed a ratio of 187ba/187fa to 




- t -Bu of 187fa - t -Bu of 187ba
 
Experimental Section 

































187ba : 187ca = 1.0 : 1.9
 isolated yields
[RuCl2(p-cymene)]2
Piv-Val-OH (15 mol %)
(2.5 mol %)
K2CO3




A mixture of substrates 38b (278 mg, 1.50 mmol), 38c (260 mg, 1.50 mmol) and bromide 50a (137 mg, 
1.00 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 2.5 mol %), Piv-Val-OH (30.0 mg, 15 mol %) and K2CO3 
(276 mg, 2.00 mmol) in 1,4-dioxane (4.0 mL) was stirred at 100 °C for 20 h under an atmosphere of 
N2. At ambient temperature, EtOAc (15 mL) was added, and the mixture was filtered through a pad of 
silica gel. The solvents were removed in vacuo, and purification of the residue by column 
chromatography (n-hexane/EtOAc 100:1→80:1→20:1) yielded compound 187ba (34 mg, 14%) and 
187ca (60mg, 26%). The ratio of isolated products 187ba to 187ca was established to be 1.0 : 1.9. 
Their spectral data were identical to those reported above. 
 




















187aa : 187ca = 1.0 : 4.5 
(1H NMR)
[RuCl2(p-cymene)]2
Piv-Val-OH (18.6 mol %)
(3.1 mol %)
K2CO3




A mixture of substrates 38a (155 mg, 1.00 mmol), 38c (173 mg, 1.00 mmol) and bromide 50a (110 mg, 
0.80 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 2.5 mol %), Piv-Val-OH (30.0 mg, 30 mol %) and K2CO3 
(276 mg, 2.00 mmol) in 1,4-dioxane (4.0 mL) was stirred at 100 °C for 20 h under an atmosphere of 
Experimental Section 
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N2. At ambient temperature, EtOAc (15 mL) was added, and the mixture was filtered through a pad of 
silica gel. The solvents were removed in vacuo, and the residue was purified by column 
chromatography (n-hexane/EtOAc 20:1). Careful 1H NMR analysis disclosed a ratio of 187aa/187ca to 






































A mixture of substrate 38b (93 mg, 0.50 mmol) and bromides 50b (177 mg, 1.00 mmol) and 42e (165 
mg, 1.00 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %), Piv-Val-OH (30.0 mg, 30 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL) was stirred at 100 °C for 20 h under an atmosphere of 
Experimental Section 
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N2. At ambient temperature, EtOAc (15 mL) was added, and the mixture was filtered through a pad of 
silica gel. The solvents were removed in vacuo, and purification of the residue by column 
chromatography (n-hexane/EtOAc 20:1) yielded compound 187bb (58 mg, 41%) and 103b (35 mg, 
26%) as colorless oils. The spectral data of 187bb was identical to those reported above. 
Analytical Data for 2-(2-n-Hexyl-4-methoxyphenyl)pyridine (103b) 
1H NMR (300 MHz, CDCl3): δ = 8.61 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.65 (dt, J = 7.7, 
1.9 Hz, 1H), 7.29 (dd, J = 7.9, 1.0 Hz, 1H), 7.24 (d, J = 8.3 Hz, 1H), 7.15 (ddd, J = 7.6, 
4.9, 1.2 Hz, 1H), 6.80–6.72 (m, 2H), 3.78 (s, 3H), 2.64 (dd, J = 8.0, 7.8 Hz, 2H), 
1.45-1.33 (m, 2H), 1.21–1.05 (m, 6H), 0.76 (t, J = 6.7 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 160.1 (Cq), 159.5 (Cq), 149.0 (CH), 142.4 (Cq), 135.9 
(CH), 133.2 (Cq), 131.0 (CH), 124.1 (CH), 121.2 (CH), 115.2 (CH), 110.9 (CH), 55.2 
(CH3), 33.1 (CH2), 31.5 (CH2), 31.1 (CH2), 29.1 (CH2), 22.4 (CH2), 14.0 (CH3).  
IR (neat): ṽ = 2927, 2855, 1607, 1587, 1505, 1465, 1427, 1280, 1236, 1162, 1045, 787, 749 cm−1.  
MS (EI) m/z (relative intensity) 269 (33) [M]+, 226 (9), 212 (100), 197 (18), 154 (10).  
HR-MS (ESI) m/z calcd for C18H24NO+ [M+H]+ 270.1852, found 270.1852. 
The spectral data were in accordance with those reported in the literature.140 
 
























Piv-Val-OH (30 mol %)
K2CO3




A mixture of substrate 38b (93 mg, 0.50 mmol), bromides 50f (134 mg, 0.75 mmol) and 44d (145 mg, 
0.75 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %), Piv-Val-OH (30.0 mg, 30 mol %) and K2CO3 (138 
mg, 1.00 mmol) in 1,4-dioxane (2.0 mL) was stirred at 100 °C for 20 h under an atmosphere of N2. At 
ambient temperature, EtOAc (15 mL) was added, and the mixture was filtered through a pad of silica 
gel. The solvents were removed in vacuo, and purification of the residue by column chromatography 
(n-hexane/EtOAc 40:1→20:1) yielded compound 187bf (48 mg, 34%) and 105c (42 mg, 28%) as 
colorless oils. The spectral data of 187bf was identical to those reported above. 
 
Analytical Data for 2-[4-Methoxy-3-(octan-2-yl)phenyl]pyridine (105c) 
1H NMR (300 MHz, CDCl3): δ = 8.66 (ddd, J = 4.4, 1.4, 1.0 Hz, 1H), 7.84 (d, J = 2.0 
Hz, 1H), 7.80 (dt, J = 8.5, 1.8 Hz, 1H), 7.75–7.63 (m, 2H), 7.19–7.11 (m, 1H), 6.94 
(dd, J = 8.4, 1.2 Hz, 1H), 3.87 (s, 3H), 3.23 (qt, J = 7.1, 6.9 Hz, 1H), 1.79–1.50 (m, 
2H), 1.34–1.16 (m, 11H), 0.86 (t, J = 6.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ = 158.0 (Cq), 157.6 (Cq), 149.4 (CH), 136.5 (Cq), 
136.5 (CH), 131.7 (CH), 125.5 (Cq), 125.2 (CH), 121.1 (CH), 119.9 (CH), 110.5 (CH), 
55.5 (CH3), 37.1 (CH2), 32.1 (CH), 31.8 (CH2), 29.4 (CH2), 27.7 (CH2), 22.6 (CH2), 
20.9 (CH3), 14.1 (CH3). 
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MS (EI) m/z (relative intensity) 297 (27) [M]+, 212 (100), 197 (15), 167 (30). 
HR-MS (EI) m/z calculated for C20H27NO+ [M]+ 297.2087; found 297.2094. 
The spectral data were in accordance with those reported in the literature.143  
 































Piv-Val-OH (30 mol %)
[Dn]-187aa: 53% [Dn]-38a: 19%
57% H
 
The general procedure A was followed using substrate [D5]-38a (80 mg, 0.50 mmol) and bromide 50a 
(206 mg, 1.50 mmol). After 20 h, purification by column chromatography (n-hexane/EtOAc 80:1) 

































































Piv-Val-OH (30 mol %)
38b [Dn]-187ba: 4% [Dn]-38b: 82%
67% D
 
The general procedure A was followed using substrate 38b (93 mg, 0.50 mmol) and bromide 50a (206 
mg, 1.50 mmol) in the presence of D2O (0.05 mL). After 20 h, purification by column chromatography 










































57% D 8% D
Experimental Section 

















[D3]-38a [D3]-38a: 32%[D2]-187aa: 46%
K2CO3
1,4-dioxane, 100 °C, 20 h
[RuCl2(p-cymene)]2 
(2.5 mol %)




The general procedure A was followed using substrate [D3]-38a (75 mg, 0.47 mmol) and bromide 50a 
(206 mg, 1.50 mmol). After 20 h, purification by column chromatography (n-hexane/EtOAc 80:1) 





























[D0]-187aa : [D2]-187aa = 1.44
average of 2 runs
38a [D3]-38a [Dn]-38a: 38%[Dn]-187aa: 12%
K2CO3
1,4-dioxane, 100 °C, 20 h
[RuCl2(p-cymene)]2 
(2.5 mol %)




A mixture of substrates 38a (82 mg, 0.53 mmol), [D3]-38a (84 mg, 0.53 mmol) and bromide 50a (137 
mg, 1.0 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 2.5 mol %), Piv-Val-OH (60.0 mg, 30 mol %) and K2CO3 
(276 mg, 2.00 mmol) in 1,4-dioxane (4.0 mL) was stirred at 100 °C for 20 h under an atmosphere of 
N2. At ambient temperature, EtOAc (15 mL) was added, and the mixture was filtered through a pad of 
silica gel. The solvents were removed in vacuo, and purification of the residue by column 
chromatography (n-hexane/EtOAc 40:1→20:1) yielded compound [Dn]-187aa (27 mg, 12%) and the 
reisolated [Dn]-38a (63 mg, 38%) as colorless oils. The ratio of H/D was determined by 1H NMR basing 

























7.3.2 Analytical Data for the Products of the Ruthenium(II)-Catalyzed Direct 
meta-Selective Alkylation of Ketimines with Tertiary Alkyl Bromides 
 
Synthesis of 1-[4-Fluoro-3-(1-methylcyclohexyl)phenyl]ethan-1-one (189ab) 
The general procedure C was followed using substrate 188a (152 mg, 0.50 mmol) 
and bromide 50b (266 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 189ab (68 mg, 58%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.97 (dd, J = 8.1, 2.3 Hz, 1H), 7.77 (ddd, J = 8.4, 
4.5, 2.3 Hz, 1H), 7.03 (dd, J = 12.4, 8.4 Hz, 1H), 2.57 (s, 3H), 2.11–1.99 (m, 2H), 
1.72–1.52 (m, 5H), 1.48–1.37 (m, 3H), 1.28 (d, J = 1.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ = 197.0 (Cq), 165.2 (d, 1JC-F = 257 Hz, Cq), 136.9 (d, 2JC-F = 12 Hz, Cq), 133.2 
(d, 4JC-F = 3 Hz, Cq), 129.1 (d, 3JC-F = 8 Hz, CH), 128.3 (d, 3JC-F = 11 Hz, CH), 116.8 (d, 2JC-F = 26 Hz, CH), 
38.0 (d, 3JC-F = 3 Hz, Cq), 37.0 (d, 4JC-F = 4 Hz, CH2), 26.5 (CH3), 26.5 (CH3), 26.3 (CH2), 22.6 (CH2).  
19F NMR (282 MHz, CDCl3): δ = –101.6 (s).  
IR (neat): ṽ = 2953, 2870, 1687, 1590, 1340, 1280, 1067, 830 cm−1.  
MS (EI) m/z (relative intensity) 234 (24) [M]+, 219 (60), 178 (35), 163 (62).  
HR-MS (EI): m/z calcd for C15H19FO+ [M]+ 234.1414, found 234.1420. 
 
Synthesis of 1-[3-(tert-Butyl)-4-fluorophenyl]ethan-1-one (189aa) 
The general procedure C was followed using substrate 188a (152 mg, 0.50 mmol) 
and bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 189aa (57 mg, 59%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.94 (dd, J = 8.1, 2.3 Hz, 1H), 7.77 (ddd, J = 8.4, 4.6, 
2.3 Hz, 1H), 7.03 (dd, J = 12.0, 8.4 Hz, 1H), 2.56 (s, 3H), 1.38 (d, J = 1.1 Hz, 9H). 
13C NMR (75 MHz, CDCl3): δ = 197.0 (Cq), 165.1 (d, 1JC-F = 257 Hz, Cq), 137.5 (d, 2JC-F = 12 Hz, Cq), 133.1 
(d, 4JC-F = 3 Hz, Cq), 128.6 (d, 3JC-F = 11 Hz, CH), 127.9 (d, 3JC-F = 7 Hz, CH), 116.4 (d, 2JC-F = 25 Hz, CH), 
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19F NMR (282 MHz, CDCl3): δ = –101.6 (s). 
IR (neat): ṽ = 2961, 2873, 1683, 1606, 1490, 1355, 1235, 1094, 817 cm−1.  
MS (EI) m/z (relative intensity) 194 (18) [M]+, 179 (100), 151 (58), 136 (10).  
HR-MS (EI): m/z calcd for C12H15FO+ [M]+ 194.1101, found 194.1106. 
 
Synthesis of 1-[4-Fluoro-3-(tert-pentyl)phenyl]ethan-1-one (189ad) 
The general procedure C was followed using substrate 188a (152 mg, 0.50 
mmol) and bromide 50d (227 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 100:1) yielded 189ad (59 mg, 57%) 
as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.89 (dd, J = 8.1, 2.3 Hz, 1H), 7.78 (ddd, J = 8.4, 
4.5, 2.3 Hz, 1H), 7.02 (dd, J = 12.1, 8.4 Hz, 1H), 2.56 (s, 3H), 1.77 (qd, J = 7.5, 1.5 Hz, 2H), 1.35 (d, J = 
1.1 Hz, 6H), 0.65 (t, J = 7.5 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ = 197.0 (Cq), 165.0 (d, 1JC-F = 257 Hz, Cq), 136.0 (d, 2JC-F = 12 Hz, Cq), 133.0 
(d, 4JC-F = 3 Hz, Cq), 129.1 (d, 3JC-F = 8 Hz, CH), 128.6 (d, 3JC-F = 11 Hz, CH), 116.4 (d, 2JC-F = 26 Hz, CH), 
38.1 (d, 3JC-F = 3 Hz, Cq), 34.0 (d, 4JC-F = 4 Hz, CH2), 27.6 (d, 4JC-F = 3 Hz, CH3), 26.5 (CH3), 9.3 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = –101.6 (s).  
IR (neat): ṽ = 2965, 2877, 1683, 1604, 1491, 1355, 1252, 1094, 822 cm−1.  
MS (EI) m/z (relative intensity) 208 (7) [M]+, 179 (100), 151 (65), 136 (10).  
HR-MS (EI): m/z calcd for C13H17FO+ [M]+ 208.1258, found 208.1266. 
 
Synthesis of 1-[4-Fluoro-3-(2-methylpentan-2-yl)phenyl]ethan-1-one (189ac) 
The general procedure C was followed using substrate 188a (152 mg, 0.50 
mmol) and bromide 50c (248 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/ether 40:1) yielded 189ac (55 mg, 49%) 
as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.90 (dd, J = 8.1, 2.3 Hz, 1H), 7.79 (ddd, J = 
8.4, 4.5, 2.3 Hz, 1H), 7.03 (dd, J = 12.1, 8.4 Hz, 1H), 2.57 (s, 3H), 1.75–1.67 (m, 2H), 1.37 (d, J = 1.1 Hz, 
6H), 1.08–0.96 (m, 2H), 0.82 (t, J = 6.9 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 197.0 (Cq), 164.9 (d, 1JC-F = 257 Hz, Cq), 136.3 (d, 2JC-F = 12 Hz, Cq), 133.0 
(d, 4JC-F = 3 Hz, Cq), 128.9 (d, 3JC-F = 8 Hz, CH), 128.5 (d, 3JC-F = 11 Hz, CH), 116.3 (d, 2JC-F = 26 Hz, CH), 
44.0 (d, 3JC-F = 4 Hz, Cq), 37.9 (d, 4JC-F = 3 Hz, CH2), 28.0 (d, 4JC-F = 3 Hz, CH3), 26.5 (CH3), 18.3 (CH2), 
14.6 (CH3).  
19F NMR (282 MHz, CDCl3): –101.6 (s).  
IR (neat): ṽ = 2958, 2931, 1683, 1583, 1490, 1355, 1247, 1097, 958 cm−1.  
MS (EI) m/z (relative intensity) 222 (5) [M]+, 179 (100), 151 (56), 115 (6).  
HR-MS (ESI): m/z calcd for C14H20FO+ [M+H]+ 223.1493, found 223.1493. 
 
Synthesis of 1-[3-(5-Chloro-2-methylpentan-2-yl)-4-fluorophenyl]ethan-1-one (189ah) 
The general procedure C was followed using substrate 188a (152 mg, 0.50 
mmol) and bromide 50h (299 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/ether 40:1) yielded 189ah (64 mg, 
50%) as a colorless oil. 
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8.4, 4.5, 2.3 Hz, 1H), 7.06 (dd, J = 12.1, 8.4 Hz, 1H), 3.44 (t, J = 6.6 Hz, 2H), 2.58 (s, 3H), 1.92–1.85 (m, 
2H), 1.56–1.44 (m, 2H), 1.40 (s, 6H).  
13C NMR (75 MHz, CDCl3): δ = 196.7 (Cq), 164.7 (d, 1JC-F = 257 Hz, Cq), 135.3 (d, 2JC-F = 12 Hz, Cq), 133.1 
(d, 4JC-F = 3 Hz, Cq), 128.8 (d, 3JC-F = 11 Hz, CH), 128.8 (d, 3JC-F = 8 Hz, CH), 116.5 (d, 2JC-F = 26 Hz, CH), 
45.3 (CH2), 38.7 (d, 4JC-F = 4 Hz, CH2), 37.4 (d, 3JC-F = 3 Hz, Cq), 28.5 (CH2), 28.0 (d, 4JC-F = 3 Hz, CH3), 
26.4 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –101.7 (s).  
IR (neat): ṽ = 2961, 2874, 1682, 1581, 1477, 1258, 1090, 822 cm−1.  
MS (EI) m/z (relative intensity) 258/256 (1/3) [M]+, 179 (100), 151 (48), 115 (5).  
HR-MS (ESI): m/z calcd for C14H19FClO+ [M+H]+ 257.1103, found 257.1103. 
 
Synthesis of 1-[3-(3-Ethylpentan-3-yl)-4-fluorophenyl]ethan-1-one (189ae) 
The general procedure C was followed using substrate 188a (152 mg, 0.50 mmol) 
and bromide 50e (269 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/ether 40:1) yielded 189ae (40 mg, 34%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 7.89 (dd, J = 8.1, 2.2 Hz, 1H), 7.78 (ddd, J = 8.4, 4.5, 
2.3 Hz, 1H), 7.02 (dd, J = 12.5, 8.4 Hz, 1H), 2.57 (s, 3H), 1.78 (qd, J = 7.4, 0.9 Hz, 6H), 0.64 (t, J = 7.4 Hz, 
9H). 
13C NMR (75 MHz, CDCl3): δ = 196.9 (Cq), 164.7 (d, 1JC-F = 257 Hz, Cq), 134.2 (d, 2JC-F = 11 Hz, Cq), 132.8 
(d, 4JC-F = 3 Hz, Cq), 130.5 (d, 3JC-F = 8 Hz, CH), 128.4 (d, 3JC-F = 11 Hz, CH), 116.3 (d, 2JC-F = 27 Hz, CH), 
44.4 (d, 3JC-F = 4 Hz, Cq), 26.8 (d, 4JC-F = 4 Hz, CH2), 26.6 (CH3), 8.3 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –101.7 (s).  
IR (neat): ṽ = 2965, 2878, 1684, 1581, 1469, 1355, 1250, 1093, 829 cm−1.  
MS (EI) m/z (relative intensity) 237 (32) [M]+, 207 (52), 165 (100), 151 (77).  
HR-MS (ESI): m/z calcd for C15H22FO+ [M+H]+ 237.1649 found 237.1649. 
 
Synthesis of 1-[4-Fluoro-3-(2-methyl-1-phenylpropan-2-yl)phenyl]ethan-1-one (189aj) 
The general procedure C was followed using substrate 188a (152 mg, 0.50 
mmol) and bromide 50j (320 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/ether 40:1) yielded 189aj (48 mg, 36%) as 
a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.81 (ddd, J = 8.4, 4.6, 2.3 Hz, 1H), 7.68 (dd, J = 
8.1, 2.3 Hz, 1H), 7.19–7.05 (m, 4H), 6.92–6.81 (m, 2H), 3.04 (s, 2H), 2.49 (s, 3H), 1.40 (d, J = 1.1 Hz, 
6H).  
13C NMR (75 MHz, CDCl3): δ = 196.7 (Cq), 164.8 (d, 1JC-F = 256 Hz, Cq), 138.3 (Cq), 135.6 (d, 2JC-F = 12 
Hz, Cq), 133.1 (d, 4JC-F = 3 Hz, Cq), 130.0 (CH), 129.0 (d, 3JC-F = 8 Hz, CH), 128.7 (d, 3JC-F = 11 Hz, CH), 
127.5 (CH), 125.9 (CH), 116.3 (d, 2JC-F = 26 Hz, CH), 47.2 (d, 4JC-F = 4 Hz, CH2), 38.8 (d, 3JC-F = 3 Hz, Cq), 
27.6 (d, 4JC-F = 3 Hz, CH3), 26.4 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –101.0 (s).  
IR (neat): ṽ = 2966, 2926, 1683, 1581, 1399, 1243, 1089, 823 cm−1.  
MS (EI) m/z (relative intensity) 270 (84) [M]+, 255 (58), 179 (47), 151 (14).  
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Synthesis of 1-[(3-(tert-Butyl)phenyl]ethan-1-one (189ba) 
The general procedure C was followed using substrate 188b (143 mg, 0.50 mmol) 
and bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 189ba (48 mg, 54%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.99 (dd, J = 2.1, 1.7 Hz, 1H), 7.74 (ddd, J = 7.8, 1.7, 
1.1 Hz, 1H), 7.59 (ddd, J = 7.8, 2.1, 1.1 Hz, 1H), 7.38 (dd, J = 7.8, 7.8 Hz, 1H), 2.59 (s, 3H), 1.33 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 198.5 (Cq), 151.7 (Cq), 137.0 (Cq), 130.2 (CH), 128.3 (CH), 125.8 (CH), 
124.9 (CH), 34.8 (Cq), 31.2 (CH3), 26.7 (CH3).  
IR (neat): ṽ = 2962, 2869, 1682, 1581, 1460, 1353, 1283, 967, 795 cm−1.  
MS (EI) m/z (relative intensity) 176 (21) [M]+, 161 (100), 133 (23), 115 (8).  
HR-MS (EI): m/z calcd for C12H16O+ [M]+ 176.1196, found 176.1203. 
 
Synthesis of 1-[3-(tert-Butyl)phenyl]propan-1-one (189ca) 
The general procedure C was followed using substrate 188c (150 mg, 0.50 mmol) 
and bromide 50a (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/ether 40:1) yielded 189ca (52 mg, 55%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.02 (dd, J = 2.1, 2.0 Hz, 1H), 7.77 (ddd, J = 7.7, 2.0, 
1.2 Hz, 1H), 7.59 (ddd, J = 7.8, 2.1, 1.2 Hz, 1H), 7.38 (dd, J = 7.8, 7.8 Hz, 1H), 3.01 (q, J = 7.2 Hz, 2H), 
1.35 (s, 9H), 1.23 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 201.1 (Cq), 151.5 (Cq), 136.7 (Cq), 129.9 (CH), 128.2 (CH), 125.3 (CH), 
124.6 (CH), 34.8 (Cq), 31.9 (CH2), 31.3 (CH3), 8.37 (CH3).  
IR (neat): ṽ = 2963, 2872, 1685, 1581, 1459, 1364, 1209, 850 cm−1.  
MS (EI) m/z (relative intensity) 190 (6) [M]+, 161 (100), 133 (13), 115 (10).  
HR-MS (EI): m/z calcd for C13H19O+ [M+H]+ 191.1430, found 191.1436. 
 
Synthesis of 1-[3-(tert-Butyl)-4-methylphenyl]ethan-1-one (189da) 
The general procedure C was followed using substrate 188d (150 mg, 0.50 mmol) 
and bromide 50a (206 mg, 1.50 mmol) in 1,4-dioxane (2 mL). After 20 h, 
purification by column chromatography (n-pentane/ether 40:1) yielded 189da (45 
mg, 47%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.99 (d, J = 1.9 Hz, 1H), 7.65 (dd, J = 7.8, 1.9 Hz, 
1H), 7.18 (d, J = 7.8 Hz, 1H), 2.58 (s, 3H), 2.56 (s, 3H), 1.42 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 198.1 (Cq), 148.2 (Cq), 142.3 (Cq), 134.8 (Cq), 132.8 (CH), 125.9 (CH), 
125.8 (CH), 36.0 (Cq), 30.8 (CH3), 26.6 (CH3), 23.5 (CH3).  
IR (neat): ṽ = 2960, 2873, 1679, 1402, 1353, 1265, 1197, 1091, 816 cm−1.  
MS (EI) m/z (relative intensity) 190 (26) [M]+, 175 (100), 147 (21), 115 (13).  
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Synthesis of 1-[4-Methoxy-3-(1-methylcyclohexyl)phenyl]ethan-1-one (189eb) 
The general procedure C was followed using substrate 188e (158 mg, 0.50 mmol) 
and bromide 50b (266 mg, 1.50 mmol) in 1,4-dioxane (2 mL). After 20 h, 
purification by column chromatography (n-pentane/ether 40:1) yielded 189eb 
(58 mg, 47%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.95 (d, J = 2.3 Hz, 1H), 7.80 (dd, J = 8.5, 2.3 Hz, 
1H), 6.88 (d, J = 8.5 Hz, 1H), 3.86 (s, 3H), 2.54 (s, 3H), 2.13–2.03 (m, 2H), 
1.77–1.65 (m, 2H), 1.60–1.30 (m, 6H), 1.27 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 197.3 (Cq), 162.7 (Cq), 137.6 (Cq), 129.8 (Cq), 128.3 (CH), 128.3 (CH), 
111.0 (CH), 55.2 (CH3), 38.3 (Cq), 36.8 (CH2), 26.6 (CH2), 26.3 (CH3), 25.1 (CH3), 22.7 (CH2).  
IR (neat): ṽ = 2923, 2853, 1673, 1593, 1492, 1353, 1244, 1022, 812 cm−1.  
MS (EI) m/z (relative intensity) 246 (76) [M]+, 231 (70), 163 (80), 115 (15).  
HR-MS (EI): m/z calcd for C16H22O2+ [M]+ 246.1614, found 246.1618. 
 
Synthesis of 1-[4-Fluoro-3-(1-methylcyclohexyl)phenyl]propan-1-one (189fb) 
The general procedure C was followed using substrate 188f (159 mg, 0.50 mmol) 
and bromide 50b (266 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/ether 100:1) yielded 189fb (77 mg, 62%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.98 (dd, J = 8.1, 2.3 Hz, 1H), 7.78 (ddd, J = 8.5, 
4.5, 2.3 Hz, 1H), 7.02 (dd, J = 12.3, 8.4 Hz, 1H), 2.96 (q, J = 7.2 Hz, 2H), 2.11–2.02 
(m, 2H), 1.71–1.52 (m, 4H), 1.50–1.34 (m, 4H), 1.28 (d, J = 1.0 Hz, 3H), 1.20 (t, J = 7.2 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ = 199.5 (Cq), 165.0 (d, 1JC-F = 257 Hz, Cq), 136.7 (d, 2JC-F = 11 Hz, Cq), 132.8 
(d, 4JC-F = 3 Hz, Cq), 128.8 (d, 3JC-F = 8 Hz, CH), 127.7 (d, 3JC-F = 11 Hz, CH), 116.7 (d, 2JC-F = 26 Hz, CH), 
37.9 (d, 3JC-F = 3 Hz, Cq), 37.0 (d, 4JC-F = 4 Hz, CH2), 31.6 (CH2), 26.5 (CH3), 26.2 (CH2), 22.5 (CH2), 8.2 
(CH3).  
19F NMR (282 MHz, CDCl3): δ = –101.4 (s). 
IR (neat): ṽ = 2927, 2858, 1685, 1581, 1488, 1451, 1228, 1182, 799 cm−1. 
MS (EI) m/z (relative intensity) 248 (8) [M]+, 219 (100), 163 (22), 133 (12). 
HR-MS (EI): m/z calcd for C16H21FO+ [M]+ 248.1571, found 248.1579. 
 
Synthesis of 1-[3-(2-Methyl-4-phenylbutan-2-yl)phenyl]ethan-1-one (189bi) 
The general procedure C was followed using substrate 188b (143 mg, 0.50 
mmol) and bromide 50i (320 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/ether 40:1) yielded 189bi (47 mg, 35%) 
as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.04–8.01 (m, 1H), 7.83–7.78 (m, 1H), 
7.65–7.60 (m, 1H), 7.48–7.42 (m, 1H), 7.28–7.06 (m, 5H), 2.64 (s, 3H), 2.40–2.32 (m, 2H), 2.01–1.94 
(m, 2H), 1.43(s, 6H).  
13C NMR (75 MHz, CDCl3): δ = 198.2 (Cq), 149.6 (Cq), 142.5 (Cq), 137.0 (Cq), 130.6 (CH), 128.3 (CH), 
128.2 (CH), 128.1 (CH), 125.9 (CH), 125.5 (CH), 125.3 (CH), 46.5 (CH2), 38.1 (Cq), 31.3 (CH2), 28.9 
(CH3), 26.8 (CH3).  
IR (neat): ṽ = 3026, 2930, 1682, 1495, 1355, 1263, 797, 696 cm−1.  
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HR-MS (ESI): m/z calcd for C19H23O+ [M+H]+ 267.1743, found 267.1749. 
7.3.3 Analytical Data for the Products of the Ruthenium(II)-Catalyzed Direct 
meta-Selective Alkylation with Secondary Alkyl Bromides 
 
Synthesis of 1-(3-Cycloheptylphenyl)ethan-1-one (206be) 
The general procedure C was followed using substrate 188b (143 mg, 0.50 
mmol) and bromide 44e (266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 100:1) yielded 206be (63 mg, 58%) 
as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.77 (dd, J = 1.8, 1.8 Hz, 1H), 7.72 (ddd, J = 7.2, 
1.8, 1.8 Hz, 1H), 7.40– 7.30 (m, 2H), 2.76–2.66 (m, 1H), 2.57 (s, 3H), 1.90–1.53 
(m, 12H).  
13C NMR (75 MHz, CDCl3): δ = 198.2 (Cq), 150.3 (Cq), 137.1 (Cq), 131.5 (CH), 128.4 (CH), 126.3 (CH), 
125.7 (CH), 47.0 (CH), 36.7 (CH2), 27.9 (CH2), 27.2 (CH2), 26.7 (CH3).  
IR (neat): ṽ =3352, 2921, 2853, 1681, 1582, 1434, 1356, 1270, 793 cm−1.  
MS (EI) m/z (relative intensity) 216 (60) [M]+, 201 (100), 146 (36), 131 (64).  
HR-MS (EI): m/z calcd for C15H20O+ [M]+ 216.1514, found 216.1510. 
 
Synthesis of 1-(3-Cycloheptyl-4-methoxyphenyl)ethan-1-one (206ee) 
The general procedure C was followed, using substrate 188e (158 mg, 0.50 
mmol) and bromide 44e (266 mg, 1.50 mmol) in 1,4-dioxane (2 mL). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 100:1) yielded 206ee 
(65 mg, 53%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.81 (d, J = 2.3 Hz, 1H), 7.76 (dd, J = 8.5, 2.3 Hz, 
1H), 6.82 (d, J = 8.5 Hz, 1H), 3.86 (s, 3H), 3.12–3.02 (m, 1H), 2.52 (s, 3H), 
1.90–1.53 (m, 12H).  
13C NMR (75 MHz, CDCl3): δ = 197.1 (Cq), 160.2 (Cq), 138.2 (Cq), 130.0 (Cq), 127.9 (CH), 127.1 (CH), 
109.5 (CH), 55.5 (CH3), 38.9 (CH), 35.2 (CH2), 27.8 (CH2), 27.4 (CH2), 26.2 (CH3). 
IR (neat): ṽ = 2919, 2852, 1672, 1596, 1495, 1354, 1241, 1025, 810 cm−1. 
MS (EI) m/z (relative intensity) 246 (95) [M]+, 231 (100), 161 (57), 147 (26). 
HR-MS (EI): m/z calcd for C16H22O2+ [M]+ 246.1614, found 246.1630. 
 
Synthesis of 1-(3-Cycloheptyl-4-methylphenyl)ethan-1-one (206de) 
The general procedure C was followed using substrate 188d (150 mg, 0.50 
mmol) and bromide 44e (266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 100:1) yielded 206de (59 mg, 51%) 
as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.80 (d, J = 1.9 Hz, 1H), 7.62 (dd, J = 7.9, 1.9 Hz, 
1H), 7.17 (d, J = 7.9 Hz, 1H), 2.92–2.82 (m, 1H), 2.55 (s, 3H), 2.35 (s, 3H), 
1.88–1.76 (m, 4H), 1.74–1.49 (m, 8H).  
13C NMR (75 MHz, CDCl3): δ = 198.1 (Cq), 148.3 (Cq), 140.4 (Cq), 135.4 (Cq), 130.2 (CH), 125.5 (CH), 
125.4 (CH), 41.7 (CH), 35.9 (CH2), 27.6 (CH2), 27.5 (CH2), 26.5 (CH3), 19.7 (CH3).  
IR (neat): ṽ = 2920, 2853, 1678, 1602, 1444, 1353, 1242, 813 cm−1.  
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HR-MS (EI): m/z calcd for C16H22O+ [M]+ 230.1665, found 230.1673. 
Synthesis of 1-(2-Cycloheptyl-[1,1'-biphenyl]-4-yl)ethan-1-one (206ge) 
The general procedure C was followed using substrate 188g (181 mg, 0.50 
mmol) and bromide 44e (266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 100:1) yielded 206ge (88 mg, 60%) 
as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.95 (d, J = 1.9 Hz, 1H), 7.75 (dd, J = 8.0, 1.9 Hz, 
1H), 7.46–7.32 (m, 3H), 7.28–7.22 (m, 3H), 2.88–2.75 (m, 1H), 2.62 (s, 3H), 
1.84–1.63 (m, 6H), 1.56–1.47 (m, 4H), 1.37–1.24 (m, 2H).  
13C NMR (75 MHz, CDCl3): δ = 197.9 (Cq), 147.9 (Cq), 145.2 (Cq), 140.9 (Cq), 136.4 (Cq), 130.0 (CH), 
128.8 (CH), 127.9 (CH), 127.1 (CH), 126.3 (CH), 125.1 (CH), 41.6 (CH), 36.8 (CH2), 27.6 (CH2), 27.3 
(CH2), 26.7 (CH3).  
IR (neat): ṽ = 2919, 2852, 1681, 1597, 1458, 1353, 1277, 1008, 827 cm−1.  
MS (EI) m/z (relative intensity) 292 (85) [M]+, 221 (46), 165 (41), 115 (6).  
HR-MS (ESI): m/z calcd for C21H25O+ [M+H]+ 293.1900, found 293.1905. 
 
Synthesis of 1-(3-Cycloheptyl-4-(trifluoromethyl)phenyl)ethan-1-one (206he) 
The general procedure C was followed using substrate 188h (177 mg, 0.50 
mmol) and bromide 44e (266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 100:1) yielded 206he (62 mg, 44%) 
as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.97 (d, J = 1.8 Hz, 1H), 7.75 (ddd, J = 8.2, 1.8, 
0.9 Hz, 1H), 7.65 (d, J = 8.2 Hz, 1H), 3.14–3.02 (m, 1H), 2.60 (s, 3H), 1.86–1.52 
(m, 12H).  
13C NMR (75 MHz, CDCl3): δ = 197.2 (Cq), 149.7 (q, 3JC-F = 2 Hz, Cq), 139.7 (Cq), 130.7 (q, 2JC-F = 30 Hz, 
Cq), 127.7 (CH), 125.9 (q, 3JC-F = 6 Hz, CH), 125.3 (CH), 124.1 (q, 1JC-F = 274 Hz, Cq), 41.7 (q, 4JC-F = 2 Hz, 
CH), 36.9 (CH2), 27.6 (CH2), 27.5 (CH2), 26.8 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –59.5 (s).  
IR (neat): ṽ = 2925, 2856, 1692, 1574, 1415, 1310, 1238, 1154, 1035, 829 cm−1.  
MS (EI) m/z (relative intensity) 284 (35) [M]+, 214 (55), 199 (100), 151 (23).  
HR-MS (ESI): m/z calcd for C16H19F3NaO+ [M+Na]+ 307.1280, found 307.1286. 
 
Synthesis of 1-(3-Cycloheptyl-4-fluorophenyl)ethan-1-one (206ae) 
The general procedure C was followed using substrate 188a (152 mg, 0.50 
mmol) and bromide 44e (266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 80:1) yielded 206ae (75 mg, 64%) as 
a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.85 (dd, J = 7.2, 2.3 Hz, 1H), 7.73 (ddd, J = 8.5, 
4.9, 2.3 Hz, 1H), 7.02 (dd, J = 9.9, 8.5 Hz, 1H), 3.06–2.92 (m, 1H), 2.55 (s, 3H), 
1.92–1.50 (m, 12H). 
13C NMR (75 MHz, CDCl3): δ = 196.9 (Cq), 163.1 (d, 1JC-F = 253 Hz, Cq), 136.8 (d, 2JC-F = 16 Hz, Cq), 133.5 
(d, 4JC-F = 3 Hz, Cq), 128.6 (d, 3JC-F = 7 Hz, CH), 127.6 (d, 3JC-F = 10 Hz, CH), 115.4 (d, 2JC-F = 24 Hz, CH), 
39.5 (d, 3JC-F = 1 Hz, CH), 35.2 (d, 4JC-F = 1 Hz, CH2), 27.7 (CH2), 27.2 (CH2), 26.5 (CH3).  
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IR (neat): ṽ = 2921, 2855, 1682, 1585, 1492, 1416, 1355, 1243, 1170, 1104, 819 cm−1.  
MS (EI) m/z (relative intensity) 234 (41) [M]+, 219 (100), 164 (40), 149 (70).  
HR-MS (EI): m/z calcd for C15H19FO+ [M]+ 234.1414, found 234.1416. 
 
Synthesis of 1-(3-Cycloheptyl-4-fluorophenyl)propan-1-one (206fe) 
The general procedure C was followed using substrate 188f (159 mg, 0.50 mmol) 
and bromide 44e (266 mg, 1.50 mmol) in 1,4-dioxane (2 mL). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 100:1) yielded 206fe 
(77 mg, 62%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.86 (dd, J = 7.3, 2.3 Hz, 1H), 7.74 (ddd, J = 8.5, 
5.0, 2.3 Hz, 1H), 7.01 (dd, J = 9.9, 8.5 Hz, 1H), 3.04–2.90 (m, 3H), 1.92–1.47 (m, 
12H), 1.19 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 199.4 (Cq), 162.8 (d, 1JC-F = 253 Hz, Cq), 136.6 (d, 2JC-F = 16 Hz, Cq), 133.2 
(d, 4JC-F = 3 Hz, Cq), 128.3 (d, 3JC-F = 7 Hz, CH), 127.3 (d, 3JC-F = 8 Hz, CH), 115.3 (d, 2JC-F = 24 Hz, CH), 39.5 
(CH), 35.3 (CH2), 31.7 (CH2), 27.8 (CH2), 27.3 (CH2), 8.4 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –111.3 (s).  
IR (neat): ṽ = 2923, 2855, 1685, 1586, 1492, 1350, 1237, 1150, 797 cm−1. 
MS (EI) m/z (relative intensity) 248 (6) [M]+, 219 (100), 149 (10), 109 (13).  
HR-MS (ESI): m/z calcd for C16H22FO+ [M+H]+ 249.1649, found 249.1654. 
 
Synthesis of 1-(3-Cycloheptylphenyl)propan-1-one (206ce) 
The general procedure C was followed using substrate 188c (150 mg, 0.50 mmol) 
and bromide 44e (266 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 206ce (61 mg, 53%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.79 (dd, J = 1.8, 1.8 Hz, 1H), 7.75 (ddd, J = 7.2, 
1.8, 1.8 Hz, 1H), 7.40– 7.30 (m, 2H), 2.99 (q, J = 7.2 Hz, 2H), 2.76–2.66 (m, 1H), 
1.90–1.53 (m, 12H), 1.22 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 201.0 (Cq), 150.3 (Cq), 137.0 (Cq), 131.3 (CH), 128.4 (CH), 126.2 (CH), 
125.3 (CH), 47.0 (CH), 36.7 (CH2), 31.8 (CH2), 27.9 (CH2), 27.2 (CH2), 8.4 (CH3).  
IR (neat): ṽ = 3391, 2921, 2853, 1683, 1582, 1482, 1348, 1233, 1161, 781 cm−1.  
MS (EI) m/z (relative intensity) 230 (5) [M]+, 201 (100), 179 (13), 131 (8).  
HR-MS (EI): m/z calcd for C16H23O + [M+H]+ 231.1743, found 231.1749. 
 
Synthesis of 1-(4-Cycloheptylnaphthalen-2-yl)ethan-1-one (206ie) 
The general procedure C was followed using substrate 188i (168 mg, 0.50 
mmol) and bromide 44e (266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 100:1) yielded 206ie (67 mg, 50%) 
as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.32–8.26 (m, 1H), 8.13 (d, J = 8.6 Hz, 1H), 
8.00–7.92 (m, 2H), 7.63 (tt, J = 8.3, 1.4 Hz, 1H), 7.58–7.49 (m, 1H), 3.54–3.43 
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13C NMR (75 MHz, CDCl3): δ = 198.2 (Cq), 146.5 (Cq), 134.0 (Cq), 133.4 (Cq), 133.0 (Cq), 130.5 (CH), 
128.5 (CH), 128.1 (CH), 126.0 (CH), 123.4 (CH), 120.3 (CH), 41.2 (CH), 36.3 (CH2), 27.9 (CH2), 27.7 
(CH2), 26.6 (CH3).  
IR (neat): ṽ = 2919, 2852, 1674, 1457, 1397, 1260, 1194, 885 cm−1.  
MS (EI) m/z (relative intensity) 266 (100) [M]+, 209 (16), 183 (28), 153 (40).  
HR-MS (EI): m/z calcd for C19H22O+ [M]+ 266.1665, found 266.1661. 
 
Synthesis of (3-Cycloheptyl-4-fluorophenyl)(phenyl)methanone (206je) 
The general procedure C was followed using substrate 188j (183 mg, 0.50 
mmol) and bromide 44e (266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 100:1) yielded 206je (92 mg, 62%) 
as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.79–7.75 (m, 3H), 7.62–7.56 (m, 2H), 
7.52–7.46 (m, 2H), 7.07 (dd, J = 9.9, 8.4 Hz, 1H), 3.10–2.99 (m, 1H), 1.89–1.55 
(m, 12H). 
13C NMR (75 MHz, CDCl3): δ = 195.8 (Cq), 162.9 (d, 1JC-F = 253 Hz, Cq), 137.8 (Cq), 136.8 (d, 2JC-F = 16 
Hz, Cq), 133.7 (d, 4JC-F = 3 Hz, Cq), 132.4 (CH), 130.5 (d, 3JC-F = 7 Hz, CH), 130.0 (CH), 129.8 (d, 3JC-F = 10 
Hz, CH), 128.3 (CH), 115.2 (d, 2JC-F = 24 Hz, CH), 39.4 (CH), 35.2 (CH2), 27.6 (CH2), 27.2 (CH2). 
19F NMR (282 MHz, CDCl3): δ = –111.8 (s).  
IR (neat): ṽ = 2924, 2855, 1657, 1599, 1490, 1446, 1281, 1092, 713 cm−1.  
MS (EI) m/z (relative intensity) 296 (92) [M]+, 226 (68), 149 (53), 105 (100).  
HR-MS (ESI): m/z calcd for C20H22FO+ [M+H]+ 297.1649, found 297.1654. 
 
Synthesis of 1-[3-(sec-Butyl)-4-fluorophenyl]ethan-1-one (206af) 
The general procedure C was followed using substrate 188a (152 mg, 0.50 mmol) 
and bromide 44f (103 mg, 0.75 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 50:1) yielded 206af (42 mg, 43%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 7.84 (dd, J = 7.2, 2.3 Hz, 1H), 7.75 (ddd, J = 8.5, 5.0, 
2.3 Hz, 1H), 7.03 (dd, J = 9.8, 8.5 Hz, 1H), 2.98 (dt, J = 7.1, 7.1 Hz, 1H), 2.55 (s, 3H), 
1.69–1.58 (m, 2H), 1.24 (d, 3H, J = 7.2 Hz), 0.82 (t, 3H, J = 7.3 Hz).  
13C NMR (75 MHz, CDCl3): δ = 196.7 (Cq), 163.9 (d, 1JC-F = 253 Hz, Cq), 134.5 (d, 2JC-F = 16 Hz, Cq), 133.4 
(d, 4JC-F = 3 Hz, Cq), 128.6 (d, 3JC-F = 7 Hz, CH), 128.0 (d, 3JC-F = 10 Hz, CH), 115.4 (d, 2JC-F = 24 Hz, CH), 
34.3 (d, 3JC-F = 1 Hz, CH), 29.8 (CH2), 26.5 (CH3), 20.4 (CH3), 12.1 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –111.0 (s).  
IR (neat): ṽ = 2964, 2976, 1683, 1606, 1586, 1493, 1357, 1283 ,1176, 1101, 820 cm−1.  
MS (EI) m/z (relative intensity) 194 (34) [M]+, 179 (67), 165 (100), 151 (20).  
HR-MS (EI): m/z calcd for C12H15FO+ [M]+ 194.1101, found 194.1102. 
 
Synthesis of 1-[4-Fluoro-3-(pentan-2-yl)phenyl]ethan-1-one (206ag) 
The general procedure C was followed using siubstrate 188a (152 mg, 0.50 mmol) 
and bromide 44g (113 mg, 0.75 mmol). After 20 h, purification by column 
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1H NMR (300 MHz, CDCl3): δ = 7.84 (dd, J = 7.2, 2.3 Hz, 1H), 7.75 (ddd, J = 8.5, 4.9, 2.3 Hz, 1H), 7.03 
(dd, J = 9.8, 8.5 Hz, 1H), 3.08 (dt, J = 7.1, 7.1 Hz, 1H), 2.56 (s, 3H), 1.61–1.51 (m, 2H), 1.33–1.11 (m, 
5H), 0.91–0.82 (m, 3H).  
13C NMR (75 MHz, CDCl3): δ = 196.7 (Cq), 163.8 (d, 1JC-F = 253 Hz, Cq), 134.8 (d, 2JC-F = 16 Hz, Cq), 133.5 
(d, 4JC-F = 3 Hz, Cq), 128.8 (d, 3JC-F = 7 Hz, CH), 128.2 (d, 3JC-F = 10 Hz, CH), 115.5 (d, 2JC-F = 24 Hz, CH), 
39.2 (d, 4JC-F = 1 Hz, CH2), 32.4 (d, 3JC-F = 1 Hz, CH), 26.6 (CH3), 20.8 (CH3), 20.8 (CH2), 14.0 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –111.1(s).  
IR (neat): ṽ = 2960, 2873, 1683, 1493, 1356, 1284, 1175, 1102, 820 cm−1.  
MS (EI) m/z (relative intensity) 208 (28) [M]+, 193 (50), 165 (100), 151 (15).  
HR-MS (EI): m/z calcd for C13H17FO+ [M]+ 208.1258, found 208.1264. 
 
Synthesis of 1-[4-Fluoro-3-(octan-2-yl)phenyl]ethan-1-one (206ad) 
The general procedure C was followed using substrate 188a (152 mg, 0.50 mmol) 
and bromide 44d (145 mg, 0.75 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 40:1) yielded 206ad (50 mg, 40%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 7.84 (dd, J = 7.2, 2.3 Hz, 1H), 7.76 (ddd, J = 8.5, 4.9, 
2.3 Hz, 1H), 7.04 (dd, J = 9.8, 8.5 Hz, 1H), 3.06 (dt, J = 7.1, 7.1 Hz, 1H), 2.57 (s, 3H), 1.64–1.52 (m, 2H), 
1.32–1.12 (m, 11H), 0.90–0.79 (m, 3H).  
13C NMR (75 MHz, CDCl3): δ = 196.7 (Cq), 164.1 (d, 1JC-F = 253 Hz, Cq), 134.9 (d, 2JC-F = 16 Hz, Cq), 133.5 
(d, 4JC-F = 3 Hz, Cq), 128.6 (d, 3JC-F = 7 Hz, CH), 128.0 (d, 3JC-F = 10 Hz, CH), 115.4 (d, 2JC-F = 24 Hz, CH), 
37.0 (d, 4JC-F = 1 Hz, CH2), 32.7 (d, 3JC-F = 1 Hz, CH), 31.8 (CH2), 29.3 (CH2), 27.6 (CH2), 26.6 (CH3), 22.7 
(CH2), 20.9 (CH3), 14.1 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –111.0(s).  
IR (neat): ṽ = 2959, 2856, 1684, 1586, 1493 ,1458, 1356, 1284, 1106, 819 cm−1.  
MS (EI) m/z (relative intensity) 250 (23) [M]+, 235 (35), 165 (100), 151 (22).  
HR-MS (ESI): m/z calcd for C16H24FO+ [M+H]+ 251.1806, found 251.1811. 
 
Synthesis of 1-(4-Isopropylnaphthalen-2-yl)ethan-1-one (206ih) 
The general procedure C was followed using substrate 188i (168 mg, 0.50 mmol) 
and bromide 44h (185 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 206ih (82 mg, 77%) as a white 
solid. 
M. p.: 60–62 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.31–8.27 (m, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.99 (d, 
J = 1.7 Hz, 1H), 7.98–7.92 (m, 1H), 7.62 (ddd, J = 8.5, 6.8, 1.5 Hz, 1H), 7.52 (ddd, J = 8.0, 6.8, 1.2 Hz, 
1H), 3.73 (hept, J = 6.9 Hz, 1H), 2.71 (s, 3H), 1.42 (d, J = 6.9 Hz, 6H).  
13C NMR (75 MHz, CDCl3): δ = 198.2 (Cq), 145.3 (Cq), 134.0 (Cq), 133.6 (Cq), 132.9 (Cq), 130.4 (CH), 
128.7 (CH), 128.2 (CH), 126.0 (CH), 123.3 (CH), 119.4 (CH), 28.7 (CH), 26.6 (CH3), 23.4 (CH3).  
IR (ATR): ṽ = 3063, 2960, 1671, 1397, 1271, 1229, 1194, 1142, 882 cm−1.  
MS (EI) m/z (relative intensity) 212 (58) [M]+, 197 (100), 152 (25), 115 (8).  
















Synthesis of 1-[4-(sec-Butyl)naphthalen-2-yl]ethan-1-one (206if) 
The general procedure C was followed using substrate 188i (168 mg, 0.50 mmol) 
and bromide 44f (206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 206if (84 mg, 74%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.30 (d, J = 1.4 Hz, 1H), 8.13 (ddd, J = 8.5, 1.3, 0.7 
Hz, 1H), 8.00–7.90 (m, 2H), 7.61 (ddd, J = 8.5, 6.8, 1.5 Hz, 1H), 7.52 (ddd, J = 8.0, 
6.8, 1.2 Hz, 1H), 3.50 (dt, J = 6.9 Hz, 1H), 2.72 (s, 3H), 1.97–1.80 (m, 1H), 1.80–1.63 (m, 1H), 1.39 (d, J 
= 6.9 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 198.2 (Cq), 144.5 (Cq), 134.1 (Cq), 134.0 (Cq), 133.0 (Cq), 130.4 (CH), 
128.6 (CH), 128.1 (CH), 126.0 (CH), 123.3 (CH), 120.1 (CH), 35.5 (CH), 30.5 (CH2), 26.6 (CH3), 21.1 
(CH3), 12.3 (CH3).  
IR (neat): ṽ = 3056, 2961, 1674, 1622, 1425, 1396, 1278, 1174, 885 cm−1.  
MS (EI) m/z (relative intensity) 226 (52) [M]+, 197 (100), 153 (525), 127 (10).  
HR-MS (EI): m/z calcd for C16H18O+ [M]+ 226.1352, found 226.1365. 
 
Synthesis of 1-[4-(Pentan-2-yl)naphthalen-2-yl]ethan-1-one (206ig) 
The general procedure C was followed using substrate 188i (168 mg, 0.50 mmol) 
and bromide 44g (227 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 206ig (93 mg, 77%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.29 (dd, J = 1.7, 0.8 Hz, 1H), 8.17–8.10 (m, 1H), 
7.98–7.92 (m, 2H), 7.61 (ddd, J = 8.5, 6.8, 1.5 Hz, 1H), 7.52 (ddd, J = 8.1, 6.8, 1.2 
Hz, 1H), 3.59 (dt, J = 6.9 Hz, 1H), 2.72 (s, 3H), 1.90–1.77 (m, 1H), 1.77–1.61 (m, 1H), 1.46–1.24 (m, 
5H), 0.90 (t, J = 7.3 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 198.2 (Cq), 144.8 (Cq), 134.0 (Cq), 134.0 (Cq), 133.4 (Cq), 130.0 (CH), 
128.6 (CH), 128.1 (CH), 126.0 (CH), 123.3 (CH), 120.1 (CH), 40.0 (CH2), 33.6 (CH), 26.6 (CH3), 21.6 
(CH3), 20.9 (CH2), 14.3 (CH3).  
IR (neat): ṽ = 2957, 2928, 1675, 1623, 1453, 1375, 1277, 1194, 885 cm−1.  
MS (EI) m/z (relative intensity) 240 (53) [M]+, 197 (100), 153 (26), 127 (11).  
HR-MS (EI): m/z calcd for C17H20O+ [M]+ 240.1509, found 240.1523. 
 
Synthesis of 1-(4-(Octan-2-yl)naphthalen-2-yl)ethan-1-one (206id) 
The general procedure C was followed using substrate 188i (168 mg, 0.50 mmol) 
and bromide 44d (290 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 206id (86 mg, 61%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.31–8.27 (m, 1H), 8.17–8.10 (m, 1H), 7.99–7.92 
(m, 2H), 7.61 (ddd, J = 8.5, 6.8, 1.5 Hz, 1H), 7.52 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 
3.57 (dt, J = 6.9 Hz, 1H), 2.72 (s, 3H), 1.91–1.75 (m, 1H), 1.75–1.63 (m, 1H), 1.39 (d, J = 6.9 Hz, 3H), 
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13C NMR (75 MHz, CDCl3): δ = 198.2 (Cq), 144.8 (Cq), 134.0 (Cq), 134.0 (Cq), 133.0 (Cq), 130.4 (CH), 
128.6 (CH), 128.1 (CH), 126.0 (CH), 123.2 (CH), 120.1 (CH), 37.8 (CH2), 33.9 (CH), 31.8 (CH2), 29.5 
(CH2), 27.8 (CH2), 26.6 (CH3), 22.7 (CH2), 21.6 (CH3), 14.1 (CH3). 
IR (neat): ṽ = 2956, 2954, 1677, 1454, 1352, 1276, 1195, 885 cm−1.  
MS (EI) m/z (relative intensity) 282 (50) [M]+, 191 (100), 153 (22), 127 (5). 
HR-MS (EI): m/z calcd for C20H26O+ [M]+ 282.1978, found 282.1994. 
 
Synthesis of N-[1-(3-Cycloheptylphenyl)ethy]-3,4,5-trimethoxyaniline (207be) 
The general procedure C was followed using [RuCl2(p-cymene)]2 (30.6 mg, 5.0 
mol %), 1-AdCO2H (54.1 mg, 30 mol %), substrate 188b (285.3 mg, 1.0 mmol) 
and bromide 44e (531 mg, 3.0 mmol). After 20 h, a solution of ZnCl2 in THF 
(1.7 M, 1.0 mmol), NaBH3CN (126.0 mg, 2.0 mmol) and MeOH (3 mL) were 
successively added to the reaction mixture at ambient temperature. The 
reaction mixture was stirred at ambient temperature for an additional 16 h 
and then distributed between Et2O (15 mL) and sat. aq. K2CO3 (15 mL). The 
aqueous phase was extracted with Et2O (2 × 20 mL), the combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. Purification by 
column chromatography (n-hexane/EtOAc 10:1) yielded 207be (200.0 mg, 
52%) as a yellow oil. 
1H NMR (300 MHz, CDCl3): δ = 7.24–7.19 (m, 1H), 7.19–7.14 (m, 2H), 7.05 (dt, J = 7.5, 1.5 Hz, 1H), 
5.76 (s, 2H), 4.38 (q, J = 6.7 Hz, 1H), 3.71 (s, 3H), 3.67 (s, 6H), 2.68–2.61 (m, 1H), 1.90–1.84 (m, 2H), 
1.83–1.72 (m, 2H), 1.72–1.52 (m, 8H), 1.50 (d, J = 6.7 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 153.4 (Cq), 150.2 (Cq), 145.1 (Cq), 144.0 (Cq), 129.7 (Cq), 128.5 (CH), 
125.1 (CH), 124.3 (CH), 122.7 (CH), 91.0 (CH), 60.9 (CH), 55.6 (CH3), 54.4 (CH3), 47.0 (CH), 36.9 (CH2), 
36.7 (CH2), 27.9 (CH2), 27.9 (CH2), 27.2 (CH2), 27.2 (CH2), 24.7 (CH3).  
IR (neat): ṽ = 3356, 2996, 2850, 1599, 1507, 1447, 1205, 1126, 1008, 812 cm−1.  
MS (EI) m/z (relative intensity) 383 (92) [M]+, 201 (100), 168 (78), 119 (15).  
HR-MS (EI): m/z calcd for C24H33NO3+ [M]+ 383.2455, found 383.2469. 
 
Synthesis of N-[1-(3-Cycloheptyl-4-fluorophenyl)ethyl]-3,4,5-trimethoxyaniline (207ae) 
The general procedure C was followed using [RuCl2(p-cymene)]2 (30.6 mg, 5.0 
mol %), 1-AdCO2H (54.1 mg, 30 mol %), substrate 188a (303.3 mg, 1.0 mmol) 
and bromide 44e (531 mg, 3.0 mmol). After 20 h, a solution of ZnCl2 in THF 
(1.7 M, 1.0 mmol), NaBH3CN (126.0 mg, 2.0 mmol) and MeOH (3 mL) were 
successively added to the reaction mixture at ambient temperature. The 
reaction mixture was stirred at ambient temperature for an additional 16 h 
and then distributed between Et2O (15 mL) and sat. aq. K2CO3 (15 mL). The 
aqueous phase was extracted with Et2O (2 × 20 mL), the combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. Purification by 
column chromatography (n-hexane/EtOAc 10:1) yielded 207ae (245.0 mg, 
61%) as a yellow solid. 
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1H NMR (300 MHz, CDCl3): δ = 7.19 (dd, J = 7.1, 2.3 Hz, 1H), 7.11 (ddd, J = 8.4, 4.9, 2.3 Hz, 1H), 6.91 
(dd, J = 10.1, 8.4 Hz, 1H), 5.73 (s, 2H), 4.36 (q, J = 6.6 Hz, 1H), 4.01–3.78 (m, 1H), 3.70 (s, 3H), 3.67 (s, 
6H), 3.01–2.90 (m, 1H), 1.89–1.49 (m, 12H), 1.46 (d, J = 6.6 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 158.8 (d, 1JC-F = 243 Hz, Cq), 153.5 (Cq), 144.0 (Cq), 140.8 (d, 4JC-F = 3 Hz, 
Cq), 136.3 (d, 2JC-F = 16 Hz, Cq), 129.8 (Cq), 125.4 (d, 3JC-F = 6 Hz, CH), 123.8 (d, 3JC-F = 9 Hz, CH), 115.4 
(d, 2JC-F = 24 Hz, CH), 91.0 (CH), 61.0 (CH), 55.7 (CH3), 53.9 (CH3), 39.7 (d, 3JC-F = 1 Hz, CH), 35.5 (CH2), 
35.3 (CH2), 27.8 (CH2), 27.8 (CH2), 27.3 (CH2), 27.3 (CH2), 24.9 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = –121.7 (s).  
IR (ATR): ṽ = 3378, 2921, 2851, 1607, 1507, 1411, 1232, 1008, 792 cm−1.  
MS (EI) m/z (relative intensity) 401 (85) [M+], 219 (100), 168 (68), 119 (13).  
HR-MS (EI): m/z calcd for C24H32FNO3+ [M]+ 401.2361, found 401.2371. 
 
Synthesis of 1-(2-Cyclobutyl-4-fluorophenyl)ethan-1-one (206aj) 
The general procedure C was followed using substrate 188a (152 mg, 0.50 mmol) 
and bromide 44j (203 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 206aj (48 mg, 50%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 7.55 (dd, J = 8.5, 5.8 Hz, 1H), 7.08 (ddd, J = 10.6, 2.6, 
0.8 Hz, 1H), 6.88 (dddd, J = 8.5, 7.8, 2.6, 0.6 Hz, 1H), 4.13–3.93 (m, 1H), 2.51 (s, 3H), 2.39–2.23 (m, 
2H), 2.07–1.88 (m, 3H), 1.85–1.69 (m, 1H).  
13C NMR (75 MHz, CDCl3): δ = 200.7 (Cq), 164.2 (d, 1JC-F = 253 Hz, Cq), 149.3 (d, 3JC-F = 8 Hz, Cq), 134.0 
(d, 4JC-F = 3 Hz, Cq), 130.9 (d, 3JC-F = 9 Hz, CH), 114.6 (d, 2JC-F = 22 Hz, CH), 112.2 (d, 2JC-F = 22 Hz, CH), 
38.2 (d, 4JC-F = 1 Hz, CH), 29.8 (CH3), 29.3 (CH2), 18.0 (CH2).  
19F NMR (282 MHz, CDCl3): δ = –108.0 (s).  
IR (neat): ṽ = 2923, 2855, 1675, 1579, 1495, 1442, 1355, 1242, 1130, 1026, 815 cm−1.  
MS (EI) m/z (relative intensity) 192 (8) [M]+, 163 (100), 149 (55), 121 (20).  
HR-MS (EI): m/z calcd for C12H13FO+ [M]+ 192.0945, found 192.0947. 
The spectral data were in accordance with those reported in the literature.118 
 
Synthesis of 1-(3-Cyclopentyl-4-fluorophenyl)ethan-1-one (206ak) 
The general procedure C was followed using substrate 188a (152 mg, 0.50 mmol) 
and bromide 44k (224 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 206ak (55 mg, 53%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.90 (dd, J = 7.3, 2.4 Hz, 1H), 7.73 (ddd, J = 8.5, 4.9, 
2.4 Hz, 1H), 7.04 (dd, J = 9.9, 8.5 Hz, 1H), 3.31–3.17 (m, 1H), 2.57 (s, 3H), 2.14–1.97 (m, 2H), 1.87–1.76 
(m, 2H), 1.73–1.57 (m, 4H).  
13C NMR (75 MHz, CDCl3): δ = 199.6 (Cq), 164.0 (d, 1JC-F = 253 Hz, Cq), 133.4 (d, 2JC-F = 15 Hz, Cq), 133.3 
(d, 4JC-F = 3 Hz, Cq), 128.5 (d, 3JC-F = 7 Hz, CH), 128.0 (d, 3JC-F = 10 Hz, CH), 115.3 (d, 2JC-F = 24 Hz, CH), 
38.8 (d, 3JC-F = 1 Hz, CH), 33.1 (d, 4JC-F = 1 Hz, CH2), 26.5 (CH3), 25.4 (CH2).  
19F NMR (282 MHz, CDCl3): δ = –109.7 (s).  
IR (neat): ṽ = 3348, 2954, 2871, 1682, 1585, 1492, 1356, 1250, 1112, 822 cm−1.  
MS (EI) m/z (relative intensity) 206 (23) [M]+, 191 (100), 163 (16), 149 (20).  













Synthesis of 1-(3-Cyclohexyl-4-fluorophenyl)ethan-1-one (206ac) 
 The general procedure C was followed using substrate 188a (152 mg, 0.50 mmol) 
and bromide 44c (245 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 206ac (30 mg, 27%) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.86 (dd, J = 7.3, 2.3 Hz, 1H), 7.75 (ddd, J = 8.5, 
5.0, 2.3 Hz, 1H), 7.03 (dd, J = 9.9, 8.5 Hz, 1H), 2.90–2.80 (m, 1H), 2.55 (s, 3H), 
1.88–1.69 (m, 5H), 1.54–1.20 (m, 5H).  
13C NMR (75 MHz, CDCl3): δ = 196.7 (Cq), 163.6 (d, 1JC-F = 253 Hz, Cq), 134.9 (d, 2JC-F = 16 Hz, Cq), 133.4 
(d, 4JC-F = 3 Hz, Cq), 128.3 (d, 3JC-F = 7 Hz, CH), 128.0 (d, 3JC-F = 10 Hz, CH), 115.3 (d, 2JC-F = 24 Hz, CH), 
37.2 (d, 3JC-F = 2 Hz, CH), 32.9 (CH2), 26.8 (CH2), 26.6 (CH3), 26.1 (CH2).  
19F NMR (282 MHz, CDCl3): δ = –111.6 (s).  
IR (neat): ṽ = 2926, 2852, 1682, 1586, 1492, 1355, 1254, 1107, 820 cm−1.  
MS (EI) m/z (relative intensity) 220 (23) [M]+, 205 (100), 149 (23), 109 (12).  
HR-MS (EI): m/z calcd for C14H17FO+ [M]+ 220.1258, found 220.1262. 
 
1-(3-Cyclooctyl-4-fluorophenyl)ethan-1-one (206al) 
The general procedure C was followed using substrate 188a(152 mg, 0.50 
mmol) and bromide 44l (287 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 100:1) yielded 206al (75 mg, 60%) 
as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.87 (dd, J = 7.3, 2.4 Hz, 1H), 7.75 (ddd, J = 8.5, 
4.9, 2.4 Hz, 1H), 7.03 (dd, J = 9.9, 8.5 Hz, 1H), 3.18–3.06 (m, 1H), 2.57 (s, 3H), 
1.83–1.76 (m, 6H), 1.70–1.56 (m, 8H).  
13C NMR (75 MHz, CDCl3): δ = 196.7 (Cq), 163.1 (d, 1JC-F = 253 Hz, Cq), 137.2 (d, 2JC-F = 16 Hz, Cq), 133.3 
(d, 4JC-F = 3 Hz, Cq), 128.8 (d, 3JC-F = 7 Hz, CH), 127.8 (d, 3JC-F = 10 Hz, CH), 115.4 (d, 2JC-F = 24 Hz, CH), 
37.3 (CH), 33.4 (CH2), 26.7 (CH2), 26.6 (CH3), 26.4 (CH2), 26.0 (CH2).  
19F NMR (282 MHz, CDCl3): δ = –110.6 (s).  
IR (neat): ṽ = 2919, 2852, 1682, 1585, 1492, 1355, 1283, 1108, 822 cm−1.  
MS (EI) m/z (relative intensity) 248 (47) [M]+, 233 (38), 164 (69), 149 (100).  
HR-MS (EI): m/z calcd for C16H22FO+ [M+H]+ 249.1649, found 249.1654. 
 
Synthesis of 2-(2,6-Dicyclobutyl-4-methoxyphenyl)pyridine (208bj) 
The general procedure A was followed using substrate 38b (93 mg, 0.50 
mmol) and bromide 44j (202 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 20:1) yielded 208bj (75 mg, 51%) 
as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H), 7.66 (ddd, J 
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7.8, 1.1 Hz, 1H), 6.76 (s, 2H), 3.86 (s, 3H), 3.38–3.22 (m, 2H), 2.07–1.86 (m, 4H), 1.81–1.57 (m, 8H).  
13C NMR (75 MHz, CDCl3): δ = 159.4 (Cq), 159.3 (Cq), 149.0 (CH), 144.9 (Cq), 135.5 (CH), 131.1 (Cq), 
125.4 (CH), 121.2 (CH), 109.0 (CH), 55.2 (CH3), 38.7 (CH), 30.0 (CH2), 29.3 (CH2), 18.0 (CH2).  
IR (neat): ṽ = 2962, 2962, 1598, 1453, 1302, 1156, 1072, 860 cm−1.  
MS (EI) m/z (relative intensity) 293 (58) [M]+, 264 (92), 236 (100), 192 (23).  
HR-MS (EI): m/z calcd for C20H22NO+ [M–H]+ 292.1696, found 292.1704. 
 
Synthesis of 2-(3-Cyclopentyl-4-methoxyphenyl)pyridine (208bk) 
The general procedure A was followed using substrate 38b (93 mg, 0.50 mmol) and 
bromide 44k (224 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 20:1) yielded 208bk (82 mg, 65%) as a colorless 
oil. 
1H NMR (300 MHz, CDCl3): δ = 8.64 (d, J = 4.9 Hz, 1H), 7.89 (d, J = 2.3 Hz, 1H), 7.77 
(dd, J = 8.5, 2.3 Hz, 1H), 7.72–7.59 (m, 2H), 7.13 (ddd, J = 6.7, 4.9, 2.1 Hz, 1H), 6.91 
(d, J = 8.5 Hz, 1H), 3.86 (s, 3H), 3.42–3.28 (m, 1H), 2.10–1.99 (m, 2H), 1.87–1.75 (m, 
2H), 1.74–1.60 (m, 4H).  
13C NMR (75 MHz, CDCl3): δ = 158.3 (Cq), 157.5 (Cq), 149.3 (CH), 136.4 (CH), 134.7 (Cq), 131.6 (Cq), 
125.4 (CH), 125.2 (CH), 121.1 (CH), 119.8 (CH), 110.3 (CH), 55.5 (CH3), 39.4 (CH), 33.0 (CH2), 25.5 
(CH2).  
IR (neat): ṽ = 2950, 2867, 1587, 1462, 1242, 1122, 777, 594 cm−1.  
MS (EI) m/z (relative intensity) 253 (100) [M]+, 212 (83), 196 (22), 167 (33).  
HR-MS (EI): m/z calcd for C17H19NO+ [M]+ 253.1461, found 253.1465. 
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The general procedure C was followed using [RuCl2(p-cymene)]2 (30.6 mg, 5.0 mol %), 1-AdCO2H 
(54.1 mg, 30 mol %), ketimine 188a (304 mg, 1.0 mmol) and bromides 44j (270 mg, 2.0 mmol), 44k 
(298 mg, 2.0 mmol). After 20 h, 2 N HCl (3.0 mL) was added, and the resulting mixture was stirred at 
ambient temperature for additional 3 hours, then extracted with EtOAc (3 × 20 mL). The combined 
organic layer was dried over Na2SO4 and concentrated in vacuo. Purification by column 
chromatography (n-hexane/EtOAc 100:1) yielded 206aj (63 mg, 33%) and 209 (70 mg, 27%) as 
colorless oils. The spectral data of 206aj were identical to those reported above. 
 
Analytical Data for 1-(2-Cyclobutyl-5-cyclopentyl-4-fluorophenyl)ethan-1-one (209) 
1H NMR (300 MHz, CDCl3): δ = 7.44 (d, J = 7.8 Hz, 1H), 7.03 (d, J = 12.0 Hz, 
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2.09–1.94 (m, 5H), 1.86–1.75 (m, 3H), 1.73–1.58 (m, 4H).  
13C NMR (75 MHz, CDCl3): δ = 201.2 (Cq), 162.7 (d, 1JC-F = 251 Hz, Cq), 146.0 (d, 3JC-F = 8 Hz, Cq), 134.0 
(d, 4JC-F = 3 Hz, Cq), 129.9 (d, 2JC-F = 15 Hz, Cq), 128.8 (d, 3JC-F = 7 Hz, CH), 114.4 (d, 2JC-F = 24 Hz, CH), 
38.7 (CH), 37.8 (d, 3JC-F = 1 Hz, CH), 33.1 (d, 4JC-F = 1 Hz, CH2), 29.9 (CH3), 29.5 (CH2), 29.4 (CH2), 18.1 
(CH2). 
19F NMR (282 MHz, CDCl3): δ = –112.5 (s).  
IR (neat): ṽ = 2940, 2853, 1584, 1460, 1232, 1120, 747, 594 cm−1.  
MS (EI) m/z (relative intensity) 260 (26) [M]+, 231 (100), 217 (37), 149 (18).  
HR-MS (ESI): m/z calcd for C17H22FO+ [M+H]+ 261.1649, found 261.1655. 
 
Synthesis of 1-{4-(exo-Bicyclo[2.2.1]heptan-2-yl)naphthalen-2-yl}ethan-1-one (206im) and 
1-{3-(exo-Bicyclo[2.2.1]heptan-2-yl)naphthalen-2-yl}ethan-1-one (206im’) 
The general procedure C was followed using substrate 188i (168 mg, 0.50 mmol) and 44m (263 mg, 
1.50 mmol). After 20 h, purification by column chromatography (n-pentane/Et20 80:1) yielded 206im 
(61 mg, 46%) and 206im’ (25 mg ,19%) as colorless oils. 
Analytical Data: 
206im: 1H NMR (300 MHz, CDCl3): δ = 8.27 (s, 1H), 8.10 (d, J = 8.6 Hz, 1H), 
7.96–7.92 (m, 2H), 7.64–7.58 (m, 1H), 7.55-7.49 (m, 1H), 3.38–3.31 (m, 1H), 
2.71 (s, 3H), 2.62–2.59 (m, 1H), 2.42–2.37 (m, 1H), 2.02–1.92 (m, 1H), 
1.74–1.61 (m, 4H), 1.57–1.47 (m, 1H), 1.44–1.38 (m, 1H), 1.33–1.27 (m, 1H). 
13C NMR (75 MHz, CDCl3): δ = 198.2 (Cq), 143.7 (Cq), 134.3 (Cq), 133.8 (Cq), 
133.1 (Cq), 130.3 (CH), 128.6 (CH), 128.1 (CH), 126.1 (CH), 124.3 (CH), 119.2 (CH), 43.4 (CH), 41.6 
(CH), 39.4 (CH2), 37.1 (CH), 36.6 (CH2), 30.4 (CH2), 29.3 (CH2), 26.7 (CH3).  
IR (neat): ṽ = 2950, 2938, 1670, 1623, 1353, 1275, 1277, 1094, 880 cm−1.  
MS (EI) m/z (relative intensity) 264 (100) [M]+, 184 (73), 153 (64), 141 (64).  
HR-MS (EI): m/z calcd for C19H20O+ [M]+ 264.1509, found 264.1514. 
 
206im’: 1H NMR (300 MHz, CDCl3): δ = 8.00 (s, 1H), 7.80 (ddd, J = 8.6, 7.3, 1.2 Hz, 
2H), 7.74 (s, 1H), 7.51 (ddd, J = 8.2, 6.9, 1.5 Hz, 1H), 7.44 (ddd, J = 8.2, 6.9, 1.5 Hz, 
1H), 3.42–3.36 (m, 1H), 2.67 (s, 3H), 2.52–2.48 (m, 1H), 2.36–2.32 (m, 1H), 
1.88–1.79 (m, 1H), 1.65–1.54 (m, 4H), 1.48–1.40 (m, 1H),1.35–1.29 (m, 1H), 
1.29–1.25 (m, 1H). 
13C NMR (75 MHz, CDCl3): δ = 203.2 (Cq), 142.9 (Cq), 138.1 (Cq), 134.2 (Cq), 130.4 
(Cq), 138.8 (CH), 128.0 (CH), 127.6 (CH), 127.5 (CH), 125.9 (CH), 124.7 (CH), 43.5 
(CH), 42.3 (CH), 39.9 (CH2), 37.3 (CH), 36.5 (CH2), 30.7 (CH3), 30.4 (CH2), 29.0 (CH2). 
IR (neat): ṽ = 2937, 2928, 1675, 1623, 1450, 1375, 1247, 1193, 775 cm−1. 
MS (EI) m/z (relative intensity) 264 (71) [M]+, 195 (100), 181 (27), 152 (30).  
HR-MS (EI): m/z calcd for C19H20O+ [M]+ 264.1509, found 264.1523. 
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The general procedure C was followed using [RuCl2(p-cymene)]2 (15.3 mg, 6.2 mol %), 1-AdCO2H 
(38.5 mg, 30 mol %), ketimines 188b (143.0 mg, 0.50 mmol) and 188a (152.0 mg, 0.50 mmol), 
bromide 44e (71.0 mg, 0.4 mmol). After 20 h, HCl (3.0 mL, 2 N) was added, and the resulting mixture 
was stirred at ambient temperature for additional 3 h, then extracted with EtOAc (3 × 20 mL). The 
combined organic layer was dried over Na2SO4 and concentrated in vacuo. Careful 1H-NMR analysis 
displayed a ratio of 206be/206ae = 1.0 : 4.0. Their spectral data were identical to those reported 
above. 
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The general procedure C was followed, using [RuCl2(p-cymene)]2 (15.3 mg, 6.2 mol %), 1-AdCO2H 
(27.8 mg, 38.5 mol %), ketimines 188d (150.0 mg, 0.50 mmol) and 188h (177.0 mg, 0.50 mmol), 
bromide 44e (71.0 mg, 0.4 mmol). After 20 h, HCl (3.0 mL, 2 N) was added, and the resulting mixture 
was stirred at ambient temperature for additional 3 h, then extracted with EtOAc (3 × 20 mL). The 
combined organic layer was dried over Na2SO4 and concentrated in vacuo. Careful 1H NMR analysis 
displayed a ratio of 206de/206he = 1.0 : 1.5. Their spectral data were identical to those reported 
above. 
 
7.3.4 Analytical Data for the Products of the Ruthenium-Catalyzed Direct meta-Selective 
Alkylations of N-(Pyrimidyl-2-yl)anilines and N-(Pyridin-2-yl)anilines  
 
Synthesis of N-[3-(tert-Butyl)-4-fluorophenyl]pyrimidin-2-amine (215aa) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol 
%), Piv-Val-OH (30.0 mg, 30 mol %), substrate 161a (95 mg, 0.50 mmol) and bromide 
50a (206 mg, 1.50 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc/Et3N 10:1:0.1) yielded 215aa (81 mg, 66%) as a yellow solid. 
M. p.: 129–131 oC. 
1H NMR (600 MHz, CDCl3): δ = 8.37 (d, J = 4.8 Hz, 2H), 7.53–7.46 (m, 2H), 7.35 (dd, J 
= 7.2, 2.8 Hz, 1H), 6.96 (dd, J = 12.1, 8.7 Hz, 1H), 6.67 (t, J = 4.8 Hz, 1H), 1.37 (d, J = 
1.0 Hz, 9H).  
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Hz, Cq), 134.7 (d, 4JC-F = 3 Hz, Cq), 119.4 (d, 3JC-F = 6 Hz, CH), 119.2 (d, 3JC-F = 9 Hz, CH), 116.3 (d, 2JC-F = 
26 Hz, CH), 112.2 (CH), 34.4 (d, 3JC-F = 3 Hz, Cq), 29.9 (d, 4JC-F = 4 Hz, CH3).  
19F NMR (282 MHz, CDCl3): δ = –116.3 (s).  
IR (ATR): ṽ = 3252, 3080, 2964, 1577, 1487, 1420, 1201, 784 cm–1.  
MS (EI) m/z (relative intensity) 245 (100) [M]+, 230 (100), 188 (24), 160 (10).  




Synthesis of N-[3-(tert-Butyl)-4-fluorophenyl]pyridin-2-amine (217) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 213b (94 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 16 h, purification by column 
chromatography (n-hexane/EtOAc/Et3N 10:1:0.1) yielded 217 (44 mg, 36%) as a 
yellow solid. 
M. p.: 131–133 °C. 
1H NMR (400 MHz, CDCl3): δ = 8.15 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.44 (ddd, J = 8.5, 
7.2, 1.9 Hz, 1H), 7.18–7.12 (m, 2H), 6.98–6.91 (m, 1H), 6.82 (s, 1H), 6.72 (ddd, J = 8.5, 8.5, 0.9 Hz, 1H), 
6.68 (ddd, J = 7.2, 5.0, 0.9 Hz, 1H), 1.36 (d, J = 1.1 Hz, 9H).  
13C NMR (75 MHz, CDCl3): δ = 158.2 (d, 1JC-F = 246 Hz, Cq), 156.8 (Cq), 148.3 (CH), 137.9 (d, 2JC-F = 13 
Hz, Cq), 137.7 (CH), 135.8 (d, 4JC-F = 3 Hz, Cq), 121.0 (d, 3JC-F = 6 Hz, CH), 120.5 (d, 3JC-F = 9 Hz, CH), 
116.7 (d, 2JC-F = 26 Hz, CH), 114.6 (CH), 107.5 (CH), 34.3 (d, 3JC-F = 3 Hz, Cq), 29.8 (d, 4JC-F = 4 Hz, CH3).  
19F NMR (282 MHz, CDCl3): δ = –115.8 (s).  
IR (ATR): ṽ = 3225, 3199, 2980, 1604, 1578, 1492, 1437, 1205, 786 cm–1.  
MS (EI) m/z (relative intensity) 244 (100) [M]+, 229 (72), 188 (32), 100 (15).  
HR-MS (EI): m/z calcd for C15H16FN2+ [M–H]+ 243.1292, found 243.1304. 
 
Synthesis of N-[4-Fluoro-3-(1-methylcyclohexyl)phenyl]pyrimidin-2-amine (215ab) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 161a (95 mg, 0.50 mmol) and 
bromide 50b (266 mg, 1.50 mmol). After 16 h, purification by column 
chromatography (n-hexane/EtOAc/Et3N 10:1:0.1) yielded 215ab (85 mg, 60%) as a 
yellow solid. 
M. p.: 95–97 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.37 (d, J = 4.8 Hz, 2H), 7.51–7.44 (m, 2H), 7.39 (dd, J 
= 7.2, 2.7 Hz, 1H), 6.95 (dd, J = 12.5, 8.7 Hz, 1H), 6.67 (t, J = 4.8 Hz, 1H), 2.11–1.96 
(m, 2H), 1.69–1.36 (m, 8H), 1.28 (d, J = 1.0 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ = 160.3 (Cq), 157.9 (CH), 157.9 (d, 1JC-F = 244 Hz, Cq), 136.5 (d, 2JC-F = 12 
Hz, Cq), 134.7 (d, 4JC-F = 3 Hz, Cq), 120.4 (d, 3JC-F = 6 Hz, CH), 118.9 (d, 3JC-F = 9 Hz, CH), 116.6 (d, 2JC-F = 
26 Hz, CH), 112.2 (CH), 38.0 (d, 3JC-F = 4 Hz, Cq), 37.2 (d, 4JC-F = 4 Hz, CH2), 26.9 (CH3), 26.4 (CH2), 22.7 
(CH2).  
19F NMR (282 MHz, CDCl3): δ = –115.6 (s).  
IR (ATR): ṽ = 3256, 3060, 2926, 1578, 1494, 1388, 1185, 820 cm–1.  
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HR-MS (EI): m/z calcd for C17H20FN3+ [M]+ 285.1636, found 285.1645. 
 
Synthesis of N-[4-Fluoro-3-(tert-pentyl)phenyl]pyrimidin-2-amine (215ad) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 161a (95 mg, 0.50 mmol) and 
bromide 50d (227 mg, 1.50 mmol). After 16 h, purification by column 
chromatography (n-hexane/EtOAc/Et3N 10:1:0.1) yielded 215ad (75 mg, 58%) as 
a yellow solid. 
M. p.: 94–96 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.39 (d, J = 4.8 Hz, 2H), 7.70 (s, 1H), 7.62–7.48 (m, 
1H), 7.30 (dd, J = 7.2, 2.6 Hz, 1H), 6.96 (dd, J = 12.1, 8.7 Hz, 1H), 6.69 (t, J = 4.8 Hz, 1H), 1.77 (q, J = 7.5 
Hz, 2H), 1.34 (s, 6H), 0.71 (t, J = 7.5 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 160.3 (Cq), 157.9 (CH), 157.6 (d, 1JC-F = 244 Hz, Cq), 135.7 (d, 2JC-F = 13 
Hz, Cq), 134.7 (d, 4JC-F = 3 Hz, Cq), 120.4 (d, 3JC-F = 6 Hz, CH), 119.0 (d, 3JC-F = 9 Hz, CH), 116.2 (d, 2JC-F = 
26 Hz, CH), 112.2 (CH), 38.1 (d, 3JC-F = 4 Hz, Cq), 34.2 (d, 4JC-F = 4 Hz, CH2), 27.7 (d, 4JC-F = 3 Hz, CH3), 9.5 
(CH3).  
19F NMR (282 MHz, CDCl3): δ = –116.4 (s).  
IR (ATR): ṽ = 3249, 3039, 2929, 1581, 1444, 1384, 1203, 995, 798 cm–1.  
MS (EI) m/z (relative intensity) 259 (44) [M]+, 244 (12), 230 (100), 188 (13).  
HR-MS (EI): m/z calcd for C15H18FN3+ [M]+ 259.1479, found 259.1491. 
 
Synthesis of N-[4-Fluoro-3-(2-methylpentan-2-yl)phenyl]pyrimidin-2-amine (215ac) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 161a (95 mg, 0.50 mmol) 
and bromide 50c (248 mg, 1.50 mmol). After 16 h, purification by column 
chromatography (n-hexane/EtOAc/Et3N 10:1:0.1) yielded 215ac (73 mg, 53%) 
as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 8.37 (d, J = 4.8 Hz, 2H), 7.65 (s, 1H), 7.52 (ddd, J 
= 8.7, 4.0, 2.8 Hz, 1H), 7.29 (dd, J = 7.2, 2.8 Hz, 1H), 6.94 (dd, J = 12.1, 8.7 Hz, 
1H), 6.67 (t, J = 4.8 Hz, 1H), 1.74–1.62 (m, 2H), 1.33 (d, J = 1.1 Hz, 6H), 1.15–1.00 (m, 2H), 0.82 (t, J = 
7.3 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 160.4 (Cq), 158.0 (CH), 157.8 (d, 1JC-F = 244 Hz, Cq), 136.1 (d, 2JC-F = 13 
Hz, Cq), 134.8 (d, 4JC-F = 3 Hz, Cq), 120.3 (d, 3JC-F = 6 Hz, CH), 119.1 (d, 3JC-F = 9 Hz, CH), 116.3 (d, 2JC-F = 
26 Hz, CH), 112.2 (CH), 44.2 (d, 4JC-F = 4 Hz, CH2), 37.8 (d, 3JC-F = 3 Hz, Cq), 28.2 (d, 4JC-F = 3 Hz, CH3), 
18.3 (CH2), 14.7 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –116.3 (s).  
IR (neat): ṽ = 3270, 3104, 2956, 1580, 1489, 1446, 1205, 992, 783 cm–1.  
MS (EI) m/z (relative intensity) 273 (42) [M]+, 230 (100), 188 (12), 160 (5).  
HR-MS (EI): m/z calcd for C16H20FN3+ [M]+ 273.1636, found 273.1635. 
 
Synthesis of N-[3-(5-Chloro-2-methylpentan-2-yl)-4-fluorophenyl]pyrimidin-2-amine (215ah) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 
5.0 mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 161a (95 mg, 0.50 
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column chromatography (n-hexane/EtOAc/Et3N 10:1:0.1) yielded 215ah (99 mg, 64%) as a yellow oil. 
1H NMR (600 MHz, CDCl3): δ = 8.38 (d, J = 4.8 Hz, 2H), 7.55–7.43 (m, 2H), 7.33 (dd, J = 7.2, 2.8 Hz, 
1H), 6.95 (dd, J = 12.1, 8.7 Hz, 1H), 6.68 (t, J = 4.8 Hz, 1H), 3.44 (t, J = 6.8 Hz, 2H), 1.90–1.79 (m, 2H), 
1.62–1.50 (m, 2H), 1.36 (d, J = 1.0 Hz, 6H).  
13C NMR (75 MHz, CDCl3): δ = 160.2 (Cq), 157.9 (CH), 157.4 (d, 1JC-F = 245 Hz, Cq), 135.0 (d, 2JC-F = 13 
Hz, Cq), 134.9 (d, 4JC-F = 3 Hz, Cq), 120.0 (d, 3JC-F = 6 Hz, CH), 119.2 (d, 3JC-F = 9 Hz, CH), 116.4 (d, 2JC-F = 
26 Hz, CH), 112.3 (CH), 45.6 (CH2), 39.1 (d, 3JC-F = 4 Hz, Cq), 37.5 (d, 4JC-F = 3 Hz, CH2), 28.8 (CH2), 28.2 
(d, 4JC-F = 3 Hz, CH3).  
19F-NMR (282 MHz, CDCl3): δ = –116.6 (s).  
IR (neat): ṽ = 3267, 3106, 2960, 1580, 1489, 1416, 1297, 1204, 992, 639 cm–1.  
MS (EI) m/z (relative intensity) 309/307 (13/38) [M]+, 230 (100), 188 (14), 160 (6).  
HR-MS (EI): m/z calcd for C16H1935ClFN3+ [M]+ 307.1246, found 307.1265. 
 
Synthesis of N-[3-(2,6-Dimethylhept-5-en-2-yl)-4-fluorophenyl]pyrimidin-2-amine (215ag) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 
mg, 5.0 mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 161a (94.6 mg, 
0.50 mmol) and bromide 50g (308 mg, 1.50 mmol). After 16 h, 
purification by column chromatography (n-hexane/EtOAc/Et3N 10:1:0.1) 
yielded 215ag (90 mg, 57%) as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 8.37 (d, J = 4.8 Hz, 2H), 7.65–7.51 (m, 2H), 
7.29 (dd, J = 7.2, 2.8 Hz, 1H), 6.95 (dd, J = 12.1, 8.7 Hz, 1H), 6.67 (t, J = 
4.8 Hz, 1H), 5.06–5.01 (m, 1H), 1.75–1.71 (m, 4H), 1.64–1.59 (m, 3H), 1.48 (d, J = 1.2 Hz, 3H), 1.35 (d, J 
= 1.0 Hz, 6H). 
13C NMR (75 MHz, CDCl3): δ = 160.2 (Cq), 157.9 (CH), 157.6 (d, 1JC-F = 244 Hz, Cq), 135.7 (d, 2JC-F = 13 
Hz, Cq), 134.7 (d, 4JC-F = 3 Hz, Cq), 131.1 (Cq), 124.6 (CH), 120.2 (d, 3JC-F = 6 Hz, CH), 119.0 (d, 3JC-F = 9 
Hz, CH), 116.3 (d, 2JC-F = 26 Hz, CH), 112.3 (CH), 41.8 (d, 4JC-F = 4 Hz, CH2), 37.8 (d, 3JC-F = 3 Hz, Cq), 28.2 
(d, 4JC-F = 3 Hz, CH3), 25.7 (CH3), 24.0 (CH2), 17.4 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –116.3 (s).  
IR (neat): ṽ = 3273, 2964, 2863, 1580, 1489, 1447, 1417, 1205, 992, 783 cm–1.  
MS (EI) m/z (relative intensity) 313 (30) [M]+, 293 (18), 231 (100), 188 (16).  
HR-MS (EI): m/z calcd for C19H24FN3+ [M]+ 313.1949, found 313.1967. 
 
Synthesis of N-[4-Fluoro-3-(2-methyl-4-phenylbutan-2-yl)phenyl]pyrimidin-2-amine (215ai) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 161a (95 mg, 0.50 mmol) 
and bromide 50i (341 mg, 1.50 mmol). After 16 h, purification by column 
chromatography (n-hexane/EtOAc/Et3N 10:1:0.1) yielded 215ai (93 mg, 55%) 
as a yellow oil. 
1H NMR (300 MHz, CDCl3): δ = 8.38 (d, J = 4.8 Hz, 2H), 7.55 (ddd, J = 8.7, 4.0, 
2.7 Hz, 1H), 7.39 (dd, J = 7.2, 2.8 Hz, 2H), 7.27–7.17 (m, 2H), 7.17–7.06 (m, 3H), 
6.99 (dd, J = 12.1, 8.7 Hz, 1H), 6.68 (t, J = 4.8 Hz, 1H), 2.43–2.32 (m, 2H), 2.13–2.00 (m, 2H), 1.42 (d, J 
= 1.0 Hz, 6H).  
13C NMR (75 MHz, CDCl3): δ = 160.2 (Cq), 157.9 (CH), 157.2 (d, 1JC-F = 243, Cq), 142.8 (Cq), 135.4 (d, 
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CH), 119.1 (d, 3JC-F = 9 Hz, CH), 116.4 (d, 2JC-F = 24 Hz, CH), 112.3 (CH), 43.9 (d, 3JC-F = 5 Hz, Cq), 38.0 (d, 
4JC-F = 3 Hz, CH2), 31.8 (CH2), 28.3 (d, 4JC-F = 3 Hz, CH3).  
19F NMR (282 MHz, CDCl3): δ = –116.5 (s).  
IR (neat): ṽ = 3266, 3083, 2866, 1579, 1532, 1489, 1416, 1204, 796 cm–1.  
MS (EI) m/z (relative intensity) 335 (56) [M]+, 231 (100), 188 (16), 91 (42).  





Synthesis of N-[3-(tert-Butyl)-4-chlorophenyl]pyrimidin-2-amine (215ba) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 161b (103 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 16 h, purification by column 
chromatography (n-hexane/EtOAc/Et3N 10:1:0.1) yielded 215ba (76 mg, 58%) as a 
yellow solid. 
M. p.: 110–112 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.40 (d, J = 4.7 Hz, 2H), 7.66 (s, 1H), 7.55 (dd, J = 8.5, 
2.7 Hz, 1H), 7.52 (d, J = 2.7 Hz, 1H), 7.28 (d, J = 8.5 Hz, 1H), 6.70 (t, J = 4.7 Hz, 1H), 1.47 (s, 9H). 
13C NMR (126 MHz, CDCl3): δ = 160.0 (Cq), 157.9 (CH), 146.8 (Cq), 137.8 (Cq), 132.0 (CH), 127.0 (Cq), 
119.1 (CH), 118.3 (CH), 112.5 (CH), 36.16 (Cq), 29.6 (CH3).  
IR (ATR): ṽ = 3235, 3164, 2962, 1603, 1566, 1526, 1441, 1273, 1034, 796 cm–1.  
MS (EI) m/z (relative intensity) 263/261 (33/100) [M]+, 248/246 (23/73), 207/205 (9/28), 117 (5/15).  
HR-MS (EI): m/z calcd for C14H1635ClN3 [M]+ 261.10327, found 261.1023. 
 
Synthesis of N-[4-Bromo-3-(tert-butyl)phenyl]pyrimidin-2-amine (215ca) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 161c (125 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 16 h, purification by column 
chromatography (n-hexane/EtOAc/Et3N 10:1:0.1) yielded 215ca (70 mg, 46%) as a 
yellow solid. 
M. p.: 103–105 °C.  
1H NMR (300 MHz, CDCl3): δ = 8.42 (d, J = 4.8 Hz, 2H), 7.75 (s, 1H), 7.58 (dd, J = 2.5 
Hz, 1H), 7.56–7.45 (m, 2H), 6.73 (t, J = 4.8 Hz, 1H), 1.52 (s, 9H). 
13C NMR (126 MHz, CDCl3): δ = 160.0 (Cq), 158.0 (CH), 148.2 (Cq), 138.5 (Cq), 135.9 (CH), 119.4 (CH), 
118.6 (CH), 115.2 (Cq), 112.6 (CH), 36.6 (Cq), 29.6 (CH3).  
IR (ATR): ṽ = 3243, 3079, 2903, 1574, 1521, 1407, 1232, 1012, 794 cm–1.  
MS (EI) m/z (relative intensity) 307/305 (100/100) [M]+, 292/290 (44/44), 210 (68), 170 (30).  
HR-MS (EI): m/z calcd for C14H1679BrN3+ [M]+ 305.0522, found 305.0519. 
 
Synthesis of N-[3-(tert-Butyl)-4-methoxyphenyl]pyrimidin-2-amine (215da) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 161d (101 mg, 0.50 mmol) and 
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chromatography (n-hexane/EtOAc/Et3N 10:1:0.1) yielded 215da (70 mg, 54%) as a yellow solid. 
M. p.: 134–136 °C.  
1H NMR (300 MHz, CDCl3): δ = 8.36 (d, J = 4.7 Hz, 2H), 7.51 (dd, J = 8.6, 1.9 Hz, 1H), 7.35–7.25 (m, 
2H), 6.88 (d, J = 8.6 Hz, 1H), 6.64 (t, J = 4.7 Hz, 1H), 3.83 (s, 3H), 1.38 (s, 9H). 
13C NMR (126 MHz, CDCl3): δ = 160.7 (Cq), 157.9 (CH), 154.8 (Cq), 138.7 (Cq), 131.5 (Cq), 120.2 (CH), 
119.6 (CH), 112.0 (CH), 111.7 (CH), 55.4 (CH3), 34.9 (Cq), 29.7 (CH3).  
IR (ATR): ṽ = 3255, 3175, 2955, 1604, 1583, 1497, 1275, 1030, 807 cm–1.  
MS (EI) m/z (relative intensity) 257 (100) [M]+, 242 (95), 227 (25), 214 (15).  
HR-MS (EI): m/z calcd for C15H19N3O+ 257.1523, found 257.1529. 
Synthesis of N-[3-(tert-Butyl)phenyl]pyrimidin-2-amine (215ea) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 161e (86 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 16 h, purification by column 
chromatography (n-hexane/EtOAc/Et3N 10:1:0.1) yielded 215ea (60 mg, 53%) as a 
yellow solid. 
M. p.: 72–74 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.42 (d, J = 4.8 Hz, 2H), 7.61–7.50 (m, 3H), 7.29 (dd, J 
= 7.9, 7.9 Hz, 1H), 7.10 (d, J = 7.8 Hz, 1H), 6.69 (t, J = 4.8 Hz, 1H), 1.34 (s, 9H). 
13C NMR (126 MHz, CDCl3): δ = 160.3 (Cq), 157.8 (CH), 151.9 (Cq), 138.9 (Cq), 128.4 (CH), 119.9 (CH), 
117.0 (CH), 117.0 (CH), 112.2 (CH), 34.7 (Cq), 31.4 (CH3).  
IR (ATR): ṽ = 3254, 3100, 2960, 1608, 1575, 1429, 1358, 1253, 780 cm–1.  
MS (EI) m/z (relative intensity) 227 (80) [M]+, 212 (100), 170 (25), 142 (7).  
HR-MS (EI): m/z calcd for C14H17N3+ [M]+ 227.1417, found 227.1417. 
 
Synthesis of N-[3-(tert-Butyl)-2-fluorophenyl]pyrimidin-2-amine (215fa) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol 
%), Ad-Ile-OH (44.0 mg, 30 mol %), substrate 161f (95 mg, 0.50 mmol) and bromide 
50a (206 mg, 1.50 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc/Et3N 10:1:0.1) yielded 215fa (75 mg, 61%) as a white solid. 
M. p.: 102–104 °C. 
1H NMR (400 MHz, CDCl3): δ = 8.41 (d, J = 4.8 Hz, 2H), 8.26 (ddd, J = 7.8, 7.8, 1.7 Hz, 
1H), 7.49 (s, 1H), 7.05 (ddd, J = 8.0, 8.0, 1.1 Hz, 1H), 6.94 (ddd, J = 7.8, 7.8, 1.7 Hz, 
1H), 6.72 (t, J = 4.8 Hz, 1H), 1.38 (d, J = 1.1 Hz, 9H).  
13C NMR (75 MHz, CDCl3): δ = 159.9 (Cq), 157.8 (CH), 151.8 (d, 1JC-F = 245 Hz, Cq), 136.5 (d, 2JC-F = 11 
Hz, Cq), 128.2 (d, 2JC-F = 12 Hz, Cq), 123.2 (d, 3JC-F = 4 Hz, CH), 120.1 (d, 3JC-F = 6 Hz, CH), 118.8 (CH), 
112.7 (CH), 34.4 (d, 3JC-F = 2 Hz, Cq), 30.0 (d, 4JC-F = 4 Hz, CH3).  
19F NMR (282 MHz, CDCl3): δ = –129.1 (s).  
IR (ATR): ṽ = 3264, 3090, 2965, 1574, 1535, 1410, 1200, 997, 783 cm–1.  
MS (EI) m/z (relative intensity) 245 (100) [M]+, 230 (95), 210 (55), 188 (77).  
HR-MS (EI): m/z calcd for C14H16FN3+ [M]+ 245.1323, found 245.1322. 
 
Synthesis of N-[3-(tert-Butyl)-2-methoxyphenyl]pyrimidin-2-amine (215ga) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol 
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bromide 50a (206 mg, 1.50 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc/Et3N 10:1:0.1) yielded 215ga (52 mg, 40%) as a white solid. 
M. p.: 144–146 °C.  
1H NMR (300 MHz, CDCl3): δ = 8.42 (d, J = 4.8 Hz, 2H), 8.07 (dd, J = 6.1, 3.5 Hz, 1H), 7.45 (s, 1H), 
7.12–7.01 (m, 2H), 6.70 (t, J = 4.8 Hz, 1H), 3.80 (s, 3H), 1.41 (s, 9H). 
13C NMR (126 MHz, CDCl3): δ = 160.4 (Cq), 158.1 (CH), 150.0 (Cq), 142.7 (Cq), 133.0 (Cq), 123.5 (CH), 
121.5 (CH), 120.2 (CH), 112.4 (CH), 60.8 (CH3), 35.0 (Cq), 30.9 (CH3).  
IR (ATR): ṽ = 3240, 3077, 2958, 1599, 1528, 1420, 1270, 995, 797 cm–1.  
MS (EI) m/z (relative intensity) 257 (18) [M]+, 242 (12), 226 (100), 210 (20).  
HR-MS (EI): m/z calcd for C15H19N3O+ [M]+ 257.1523, found 257.1527. 
 
Synthesis of N-[3-(tert-Butyl)-2,4-difluorophenyl]pyrimidin-2-amine (215ha) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol 
%), Ad-Ile-OH (44.0 mg, 30 mol %), substrate 161h (104 mg, 0.50 mmol) and 
bromide 50a (206 mg, 1.50 mmol). After 16 h, purification by column 
chromatography (n-hexane/EtOAc/Et3N 10:1:0.1) yielded 215ha (72 mg, 55%) as a 
white solid. 
M. p.: 102–104 °C. 
1H NMR (400 MHz, CDCl3): δ = 8.39 (d, J = 4.8 Hz, 2H), 8.13 (ddd, J = 9.1, 9.1, 5.4, 
1H), 7.28 (s, 1H), 6.80 (ddd, J = 12.5, 9.1, 2.1 Hz, 1H), 6.71 (t, J = 4.8 Hz, 1H), 1.46 (dd, J = 2.3, 2.3 Hz, 
9H).  
13C NMR (75 MHz, CDCl3): δ = 160.0 (Cq), 157.8 (CH), 156.5 (dd, 1JC-F = 245, 3JC-F = 10 Hz, Cq), 152.0 
(dd, 1JC-F = 245, 3JC-F = 10 Hz, Cq), 124.7 (dd, 2JC-F = 13, 4JC-F = 2 Hz, Cq), 124.1 (dd, 2JC-F = 16, 2JC-F = 14 
Hz, Cq), 119.0 (dd, 3JC-F = 11, 3JC-F = 2 Hz, CH), 112.8 (CH), 111.5 (dd, 2JC-F = 27, 4JC-F = 3 Hz, CH), 36.0 
(dd, 3JC-F =3, 3JC-F = 3 Hz, Cq), 31.1 (dd, 4JC-F =6, 4JC-F = 6 Hz, CH3).  
19F NMR (282 MHz, CDCl3): δ = –113.6 (s), –123.7 (s).  
IR (ATR): ṽ = 3256, 3196, 3000, 1582, 1471, 1408, 1241, 1001, 785 cm–1.  
MS (EI) m/z (relative intensity) 263 (87) [M]+, 248 (100), 228 (37), 206 (32).  
HR-MS (EI): m/z calcd for C14H15F2N3+ [M]+ 263.1229, found 263.1226. 
 
Synthesis of N-(3-Cycloheptyl-4-fluorophenyl)pyrimidin-2-amine (220ae) 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), Piv-Val-OH (30.0 mg, 30 mol %), substrate 161a (95 mg, 0.50 mmol) and 
bromide 44e (266 mg, 1.50 mmol). After 16 h, purification by column 
chromatography (n-hexane/EtOAc/Et3N 10:1:0.1) yielded 220ae (40 mg, 28%) as a 
yellow solid. 
M. p.: 121–123 °C. 
1H NMR (400 MHz, CDCl3): δ = 8.39 (d, J = 4.8 Hz, 2H), 7.79 (bs, 1H), 7.45 (ddd, J = 
8.8, 4.4, 2.8 Hz, 1H), 7.33 (dd, J = 6.5, 2.8 Hz, 1H), 6.96 (dd, J = 9.8, 8.8 Hz, 1H), 6.68 (t, J = 4.8 Hz, 1H), 
2.99 (tt, J = 10.3, 3.4 Hz, 1H), 1.96–1.89 (m, 2H), 1.85–1.76 (m, 2H), 1.73–1.53 (m, 8H). 
13C NMR (125 MHz, CDCl3): δ = 160.3 (Cq), 157.9 (CH), 155.9 (Cq, 1JC-F = 240 Hz), 136.5 (Cq, 2JC-F = 16 
Hz), 135.1 (Cq, 4JC-F = 3 Hz), 119.8 (CH, 3JC-F = 5 Hz), 118.7 (CH, 3JC-F = 8 Hz), 115.3 (CH, 2JC-F = 24 Hz), 
112.1 (CH), 39.6 (CH), 35.3 (CH2), 27.9 (CH2), 27.3 (CH2). 
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IR (ATR): ṽ = 2920, 2853, 1583, 1537, 1487, 1450, 1244, 1198, 796, 554 cm–1. 
MS (EI) m/z (relative intensity) 285 (100) [M]+, 216 (47), 188 (18).  








The general procedure A was followed using [RuCl2(p-cymene)]2 (7.7 mg, 5.0 
mol %), 1-AdCO2H (13.5 mg, 30 mol %), substrate 161f (47 mg, 0.25 mmol) 
and bromide 44o (186 mg, 0.75 mmol). After 16 h, purification by column 
chromatography (n-hexane/EtOAc/Et3N 5:1:0.1) yielded 212fo (18 mg, 20%) 
as a yellow solid. 
M. p.: 165–167 °C. 
1H NMR (400 MHz, CDCl3): δ = 8.42 (d, J = 4.8 Hz, 2H), 8.29 (ddd, J = 8.1, 8.1, 
1.5 Hz, 1H), 7.32 (s, 1H), 7.08 (ddd, J = 8.0, 8.0, 1.0 Hz, 1H), 6.85–6.80 (m, 1H), 6.75 (t, J = 4.8 Hz, 1H), 
4.61–4.52 (m, 2H), 3.20–3.07 (m, 1H), 2.94–2.82 (m, 2H), 1.91–1.82 (m, 2H), 1.71–1.62 (m, 2H), 1.30 
(s, 9H). 
13C NMR (75 MHz, CDCl3): δ = 176.2 (Cq), 159.9 (CH), 158.0 (Cq), 150.2 (d, 1JC-F = 242 Hz, Cq), 131.5 (d, 
2JC-F = 13 Hz, Cq), 127.8 (d, 2JC-F = 11 Hz, Cq), 124.0 (d, 3JC-F = 4 Hz, CH), 120.2 (d, 3JC-F = 4 Hz, CH), 118.7 
(CH), 113.1 (CH), 45.8 (CH2), 38.7 (CH2), 35.8 (d, 3JC-F = 3 Hz, CH), 32.1 (Cq), 28.5 (CH3). 
19F NMR (282 MHz, CDCl3): δ = –138.0 (s).  
IR (ATR): ṽ = 3247, 2977, 2911, 1600, 1574, 1428, 1296, 1188, 971, 795 cm–1.  
MS (EI) m/z (relative intensity) 356 (29) [M]+, 299 (100), 216 (77), 188 (34).  
HR-MS (ESI): m/z calcd for C20H26FN4O+ [M+H]+ 357.2085, found 357.2091. 
 
Removal of Directing Group 
meta-Alkylated product 215aa (61.3 mg, 0.25 mmol) was dissolved in concentrated HCl (1 mL) in a 
microwave vial. The vial was heated up to 150 oC for 1 h in microwave. The reaction mixture was 
allowed to cool to ambient temperature and poured into to EtOAc (15 mL), then saturated NaHCO3 
solution was added until the pH was adjusted to 7. Aqueous layer was extracted with EtOAc (3 × 10 
mL), the combined organic layers were dried over Na2SO4 and concentrated in vacuo affording 191 
(35 mg, 84%) as a yellow oil. 
 
Analytical Data for 3-(tert-Butyl)-4-fluoroaniline (191) 
1H NMR (400 MHz, CDCl3): δ = 6.77 (ddd, J = 12.2, 8.5, 0.3 Hz, 1H), 6.59 (dd, J = 7.0, 
2.9 Hz, 1H), 6.45 (ddd, J = 8.5, 3.7, 2.9 Hz, 1H), 3.47 (bs, 2H), 1.32 (d, J = 1.0 Hz, 9H). 
13C NMR (75 MHz, CDCl3): δ = 155.6 (d, 1JC-F = 244 Hz, Cq), 141.8 (d, 4JC-F = 2 Hz, Cq), 
137.6 (d, 2JC-F = 13 Hz, Cq), 116.5 (d, 2JC-F = 26 Hz, CH), 114.0 (d, 3JC-F = 6 Hz, CH), 113.4 
(d, 3JC-F = 6 Hz, CH), 34.1 (d, 3JC-F = 3 Hz, Cq), 29.8 (d, 4JC-F = 4 Hz, CH3).  
19F NMR (282 MHz, CDCl3): δ = –122.9 (s).  
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MS (EI) m/z (relative intensity) 167 (55) [M]+, 152 (100), 124 (70), 109 (20).  
HR-MS (EI): m/z calcd for C10H14FN+ [M]+ 167.1105, found 167.1111. 
 
Experiment with Substrate 161a in the Presence of D2O 
The general procedure A was followed using [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), Piv-Val-OH 
(30.0 mg, 30 mol %), substrate 161a (95 mg, 0.50 mmol) and bromide 50a (206 mg, 1.50 mmol) and 
D2O (0.05 mL). After 20 h, purification by column chromatography (n-hexane/EtOAc/Et3N 5:1:0.1) 














44% D 15% D[RuCl2(p-cymene)]2 
(5 mol %)
Piv-Val-OH (30 mol %)
t-BuBr















































- 139 - 
 
 
7.3.5 Analytical Data for the Products of Ruthenium(II)-Catalyzed Oxidative Alkenylation of 
Aryl Carbamates 
 
Synthesis of Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy)]}-4-methylphenyl}acrylate (193aa) 
The general procedure D was followed using substrate 192a (90 mg, 0.50 
mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193aa 
(117 mg, 84%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.76 (d, J = 16.1 Hz, 1H), 7.46 (d, J = 8.0 Hz, 
1H), 6.97 (d, J = 8.0 Hz, 1H), 6.94 (s, 1H), 6.34 (d, J = 16.1 Hz, 1H), 4.20 (q, J = 7.1 Hz, 2H), 3.11 (s, 3H), 
2.97 (s, 3H), 2.30 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.8 (Cq), 154.2 (Cq), 149.9 (Cq), 141.7 (Cq), 138.1 (CH), 126.9 (CH), 
126.5 (CH), 124.3 (Cq), 123.7 (CH), 118.5 (CH), 60.2 (CH2), 36.6 (CH3), 36.3 (CH3), 21.2 (CH3), 14.1 
(CH3).  
IR (neat): ṽ = 2934, 1708, 1632, 1381, 1149, 884, 619 cm–1.  
MS (EI) m/z (relative intensity) 277 (5) [M]+, 189 (25), 132 (5), 72 (100).  
HR-MS (EI): m/z calcd for C15H19NO4+ [M]+ 277.1309, found 277.1316. 
 
Synthesis of Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy]phenyl}acrylate (193ba) 
The general procedure D was followed using substrate 192b (83 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193ba (89 mg, 
68%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 7.81 (d, J = 16.1 Hz, 1H), 7.58 (dd, J = 7.8, 1.7 Hz, 
1H), 7.35 (dd, J = 7.8, 7.8 Hz, 1H), 7.21–7.12 (m, 2H), 6.41 (d, J = 16.1 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 
3.14 (s, 3H), 2.99 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.8 (Cq), 154.2 (Cq), 150.0 (Cq), 138.2 (CH), 130.9 (CH), 127.2 (CH), 
127.2 (Cq), 125.6 (CH), 123.3 (CH), 119.7 (CH), 60.4 (CH2), 36.8 (CH3), 36.4 (CH3), 14.2 (CH3).  
IR (neat): ṽ = 2938, 1708, 1635, 1149, 1094, 754 cm–1. 
MS (EI) m/z (relative intensity) 263 (5) [M]+, 175 (25), 118 (6), 72 (100). 
HR-MS (EI): m/z calcd for C14H17NO4+ [M]+ 263.1152, found 263.1159.  
The spectral data were in accordance with those reported in the literature.254  
 
Synthesis of Ethyl (E)-3-{2-[(N,N-Diethylcarbamoyl)oxy]phenyl}acrylate (222ba)  
The general procedure D was followed using substrate 221b (97 mg, 0.50 mmol) 
and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 222ba (98 mg, 67%) as a 
colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 7.82 (d, J = 16.1 Hz, 1H), 7.60 (dd, J = 7.8, 1.7 Hz, 
1H), 7.35 (ddd, J = 7.8, 7.8, 1.7 Hz, 1H), 7.21–7.13 (m, 2H), 6.40 (d, J = 16.1 Hz, 1H), 4.22 (q, J = 7.1 Hz, 
2H), 3.49 (q, J = 7.1 Hz, 2H), 3.37 (q, J = 7.1 Hz, 2H), 1.33–1.25 (m, 6H), 1.19 (t, J = 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 167.7 (Cq), 153.5 (Cq), 150.1 (Cq), 138.2 (CH), 130.9 (CH), 127.3 (Cq), 
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(CH3), 13.2 (CH3).  
IR (neat): ṽ = 2978, 1708, 1636, 1148, 1038, 881 cm–1.  
MS (EI) m/z (relative intensity) 291 (5) [M]+, 175 (10), 118 (10), 100 (100), 72 (55), 44 (15).  





Synthesis of (E)-2-(3-Ethoxy-3-oxoprop-1-en-1-yl)phenyl Pyrrolidine-1-carboxylate (222ca) 
The general procedure D was followed using substrate 221c (96 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 222ca (79 mg, 
55%) as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 7.85 (d, J = 16.1 Hz, 1H), 7.58 (dd, J = 7.8, 1.7 Hz, 
1H), 7.34 (ddd, J = 7.8, 7.8, 1.7 Hz, 1H), 7.21–7.13 (m, 2H), 6.40 (d, J = 16.1 Hz, 
1H), 4.22 (q, J = 7.1 Hz, 2H), 3.61 (t, J = 6.7 Hz, 2H), 3,46 (t, J = 6.7 Hz, 2H), 2.01–1.83 (m, 4H), 1.29 (t, J 
= 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.8 (Cq), 152.3 (Cq), 149.9 (Cq), 138.4 (CH), 130.9 (CH), 127.1 (Cq), 
127.1 (CH), 125.4 (CH), 123.3 (CH), 119.5 (CH), 60.4 (CH2), 46.5 (CH2), 46.4 (CH2), 25.7 (CH2), 24.8 
(CH2), 14.2 (CH3).  
IR (neat): ṽ = 2978, 1708, 1635, 1392, 1170, 757 cm–1.  
MS (EI) m/z (relative intensity) 289 (5) [M]+, 175 (13), 118 (14), 98 (100), 55 (50), 43 (44).  
HR-MS (ESI): m/z calcd for C16H19NNaO4+ [M+H]+ 312.1206, found 312.1207. 
 
Synthesis of Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy]-3-methylphenyl}acrylate (193ca) 
The general procedure D was followed using substrate 192c (90 mg, 0.50 mmol) 
and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193ca (97 mg, 70%) as a 
colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 7.75 (d, J = 16.1 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 
7.21 (d, J = 7.6 Hz, 1H) , 7.10 (dd, J = 7.6, 8.0 Hz, 1H), 6.38 (d, J = 16.1 Hz, 1H), 
4.22 (q, J = 7.1 Hz, 2H), 3.17 (s, 3H), 3.00 (s, 3H), 2.18 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.8 (Cq), 153.7 (Cq), 148.8 (Cq), 138.6 (CH), 132.7 (CH), 131.9 (Cq), 
127.9 (Cq), 125.7 (CH), 124.8 (CH), 119.7 (CH), 60.3 (CH2), 36.8 (CH3), 36.4 (CH3), 16.1 (CH3), 14.2 
(CH3).  
IR (neat): ṽ = 2934, 1708, 1635, 1463, 1149, 1035, 847 cm–1.  
MS (EI) m/z (relative intensity) 277 (5) [M]+, 189 (25), 160 (6), 131 (6), 72 (100).  
HR-MS (EI): m/z calcd for C15H19NO4+ [M]+ 277.1309, found 277.1316.  
  
Synthesis of Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy]-[1,1'-biphenyl]-3-yl}acrylate (193da) 
The general procedure D was followed using 192d (121 mg, 0.50 mmol) and 
ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193da (130 mg, 77%) as 
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1H NMR (300 MHz, CDCl3): δ = 7.83 (d, J = 16.1 Hz, 1H), 7.61 (dd, J = 7.8, 1.9 Hz, 1H), 7.41–7.25 (m, 
7H), 6.47 (d, J = 16.1 Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 2.90 (s, 3H), 2.77 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.6 (Cq), 153.6 (Cq), 147.3 (Cq), 138.5 (CH), 137.3 (Cq), 136.4 (Cq), 
132.3 (CH), 128.8 (CH), 128.7 (Cq), 127.9 (CH), 127.4 (CH), 126.3 (CH), 125.9 (CH), 120.0 (CH), 60.3 
(CH2), 36.5 (CH3), 36.2 (CH3), 14.2 (CH3).  
IR (neat): ṽ = 2934, 1709, 1635, 1429, 1382, 1148, 841 cm–1. 
MS (EI) m/z (relative intensity) 339 (5) [M]+, 251 (25), 194 (10), 165 (10), 72 (100).  
HR-MS (EI): m/z calcd for C20H21NO4+ [M]+ 339.1465, found 339.1468.  
 
Synthesis of Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy]-3-isopropylphenyl}acrylate (193ea) 
The general procedure A was followed using substrate 192e (104 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193ea (119 mg, 
78%) as a colorless oil. 
 1H NMR (300 MHz, CDCl3): δ = 7.73 (d, J = 16.0 Hz, 1H), 7.44 (dd, J = 7.7, 1.6 
Hz, 1H), 7.31 (dd, J = 7.8, 1.6 Hz, 1H), 7.18 (dd, J = 7.8, 7.7 Hz, 1H), 6.38 (d, J = 
16.0 Hz, 1H), 4.22 (q, J = 7.2 Hz, 2H), 3.09 (s, 3H), 3.07–2.95 (m, 1H), 3.01 (s, 3H), 1.30 (t, J = 7.2 Hz, 
3H). 1.20 (d, J = 6.9 Hz, 6H).  
13C NMR (75 MHz, CDCl3): δ = 167.2 (Cq), 154.7 (Cq), 148.0 (Cq), 142.4 (Cq), 139.4 (CH), 128.7 (CH), 
128.6 (Cq), 126.5 (CH), 125.1 (CH), 120.1 (CH), 60.8 (CH2), 37.3 (CH3), 36.9 (CH3), 27.8 (CH3), 23.4 
(CH), 14.7 (CH3).  
IR (neat): ṽ = 2979, 1708, 1636, 1392, 1170, 1056, 911, 757 cm–1. 
MS (EI) m/z (relative intensity) 305 (5) [M]+ 217 (15), 72 (100).  
HR-MS (ESI): m/z calcd for C17H23NNaO4+ [M+Na]+ 328.1519, found 328.1521. 
 
Synthesis of Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy]-3-methoxyphenyl}acrylate (193fa) 
The general procedure D was followed using substrate 192f (98 mg, 0.50 mmol) 
and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193fa (96 mg, 65%) as a 
white solid.  
M. p.: 99–101 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.78 (d, J = 16.1 Hz, 1H), 7.16 (dd, J = 8.0, 2.0 Hz, 
1H), 7.11 (dd, J = 7.6, 8.0 Hz, 1H), 6.91 (dd, J = 7.6, 2.0 Hz, 1H), 6.40 (d, J = 16.1 Hz, 1H), 4.20 (q, J = 7.1 
Hz, 2H), 3.77 (s, 3H), 3.12 (s, 3H), 2.97 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.6 (Cq), 153.9 (Cq), 152.1 (Cq), 139.5 (Cq), 138.2 (CH), 128.7 (Cq), 
125.9 (CH), 120.0 (CH), 118.5 (CH), 113.4 (CH), 60.3 (CH2), 56.0 (CH3), 36.7 (CH3), 36.5 (CH3), 14.1 
(CH3).  
IR (ATR): ṽ = 2984, 1715, 1634, 1580, 1181, 1059, 781 cm–1.  
MS (EI) m/z (relative intensity) 293 (5) [M]+, 205 (12), 176 (5), 148 (5), 105 (5), 72 (100).   
HR-MS (EI): m/z calcd for C15H19NO5+ [M]+ 293.1258, found 293.1253. 
 
Synthesis of Ethyl (E)-3-[2-(N,N-Dimethylcarbamoyloxy)-3-fluorophenyl]acrylate (193ga)  
The general procedure D was followed using substrate 192g (92 mg, 0.50 mmol) 
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chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193ga (102 mg, 73%) as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 7.74 (d, J = 16.2 Hz, 1H), 7.37–7.32 (m, 1H), 7.17–7.10 (m, 2H), 6.42 (d, 
J = 16.2 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.14 (s, 3H), 3.00 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.4 (Cq), 155.1 (d, 1JC-F = 250 Hz, Cq), 153.1 (Cq), 138.8 (d, 2JC-F = 13 Hz, 
Cq), 137.1 (d, 4JC-F = 3 Hz, CH), 130.0 (Cq), 126.2 (d, 3JC-F = 8 Hz, CH), 122.4 (d, 4JC-F = 3 Hz, CH), 121.0 
(CH), 117.6 (d, 2JC-F = 19 Hz, CH), 60.5 (CH2), 36.9 (CH3), 36.5 (CH3), 14.2 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –(128.1–128.2) (m).  
IR (neat): ṽ = 2938, 1709, 1639, 1584, 1259, 1145, 845 cm–1.  
MS (EI) m/z (relative intensity) 281 (5) [M]+, 193 (18), 164 (5), 136 (5), 107 (5), 72 (100).   
HR-MS (EI): m/z calcd for C14H16FNO4+ [M]+ 281.1058, found 281.1060. 
 
Synthesis of Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy]-3-[trifluoromethyl]phenyl}acrylate 
(193ha)  
The general procedure D was followed using substrate 192h (117 mg, 0.50 
mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193ha (107 mg, 65%) as 
a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 7.77 (d, J = 8.0 Hz, 1H), 7.67 (d, J = 16.0 Hz, 1H), 
7.62 (d, J = 8.0 Hz, 1H), 7.29 (dd, J = 8.0, 8.0 Hz, 1H), 6.43 (d, J = 16.0 Hz, 1H), 
4.22 (q, J = 7.2 Hz, 2H), 3.13 (s, 3H), 2.98 (s, 3H), 1.28 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.2 (Cq), 153.3 (Cq), 147.6 (q, 4JC-F = 2 Hz, Cq), 136.8 (CH), 130.7 (CH), 
130.7 (Cq), 128.0 (q, 3JC-F = 5 Hz, CH), 125.9 (CH), 124.5 (q, 2JC-F = 31 Hz, Cq), 122.8 (q, 1JC-F = 272 Hz, 
Cq), 121.4 (CH), 60.3 (CH2), 36.5 (CH3), 36.2 (CH3), 14.2 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –62.1 (s).  
IR (neat): ṽ = 2940, 1713, 1640, 1443, 1329, 1127, 1034, 979, 848 cm–1.  
MS (EI) m/z (relative intensity) 331 (5) [M]+, 243 (20), 186 (5), 72 (100).  
HR-MS (ESI): m/z calcd for C15H16F3NNaO4+ [M]+ 354.0924, found 354.0924. 
 
Synthesis of Ethyl (E)-3-{3-Chloro-2-[(N,N-Dimethylcarbamoyl)oxy]phenyl}acrylate (193ia)  
 The general procedure D was followed using substrate 192i (100 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193ia (76 mg, 
51%) as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 7.72 (d, J = 16.1 Hz, 1H), 7.48 (dd, J = 8.0, 1.5 Hz, 
1H), 7.40 (dd, J = 8.0, 1.5 Hz, 1H), 7.13 (dd, J = 8.0, 8.0 Hz, 1H), 6.41 (d, J = 16.1 
Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.17 (s, 3H), 3.00 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.4 (Cq), 153.0 (Cq), 146.4 (Cq), 137.6 (CH), 131.3 (CH), 130.2 (Cq), 
128.7 (Cq), 126.4 (CH), 125.6 (CH), 121.1 (CH), 60.5 (CH2), 36.9 (CH3), 36.5 (CH3), 14.2 (CH3).  
IR (neat): ṽ = 2938, 1709, 1637, 1567, 1438, 1148, 842 cm–1.  
MS (EI) m/z (relative intensity) 299/297 (2/5) [M]+, 211/209 (4/12), 154/152 (3/8), 89 (8), 72 (100).  
HR-MS (EI): m/z calcd for C14H1635ClNO4+ [M]+ 297.0762, found 297.0761.  
 
Synthesis of Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy]-5-methylphenyl}acrylate (193ja) 

















- 143 - 
 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 10/1→5/1) yielded 193ja (77 mg, 56%) as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 7.77 (d, J = 16.1 Hz, 1H), 7.38 (d, J = 1.9 Hz, 1H), 7.15 (dd, J = 8.3, 1.9 
Hz, 1H), 7.01 (d, J = 8.3 Hz, 1H), 6.39 (d, J = 16.1 Hz, 1H), 4.22 (q, J = 7.2 Hz, 2H), 3.13 (s, 3H), 2.99 (s, 
3H), 2.30 (s, 3H), 1.29 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.8 (Cq), 154.4 (Cq), 147.9 (Cq), 138.4 (CH), 135.1 (Cq), 131.7 (CH), 
127.5 (CH), 126.8 (Cq), 123.0 (CH), 119.4 (CH), 60.3 (CH2), 36.7 (CH3), 36.4 (CH3), 20.8 (CH3), 14.2 
(CH3).  
IR (neat): ṽ = 2984, 1707, 1607, 1497, 1158, 1035, 1035, 978, 855 cm–1.  
MS (EI) m/z (relative intensity) 277 (3) [M]+, 189 (25), 132 (6), 72 (100).   
HR-MS (EI): m/z calcd for C15H19NO4+ [M]+ 277.1309, found 277.1316. 
 
Synthesis of Ethyl (E)-3-{4-[(N,N-Dimethylcarbamoyl)oxy]-[1,1'-biphenyl]-3-yl}acrylate (193ka) 
The general procedure D was followed using substrate 192k (121 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193ka 
(100 mg, 59%) as a white solid. 
M. p.: 112–114 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.88 (d, J = 16.1 Hz, 1H), 7.79 (d, J = 2.2 Hz, 1H), 7.59–7.52 (m, 3H), 
7.46–7.39 (m, 2H), 7.37–7.31 (m, 1H), 7.24 (d, J = 8.6 Hz, 1H), 6.51 (d, J = 16.1 Hz, 1H), 4.25 (q, J = 7.1 
Hz, 2H), 3.17 (s, 3H), 3.03 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.7 (Cq), 154.2 (Cq), 149.4 (Cq), 139.8 (Cq), 138.8 (Cq), 138.2 (CH), 
129.7 (CH), 128.7 (CH), 127.5 (CH), 127.4 (Cq), 127.0 (CH), 125.8 (CH), 123.6 (CH), 120.0 (CH), 60.4 
(CH2), 36.8 (CH3), 36.4 (CH3), 14.2 (CH3).  
IR (ATR): ṽ = 2927, 1720, 1700, 1477, 1386, 1154, 996, 756, 693 cm–1.  
MS (EI) m/z (relative intensity) 339 (8) [M+], 251 (15), 194 (8), 165 (8), 72 (100).   
HR-MS (EI): m/z calcd for C20H21NO4+ [M+] 339.1465, found 339.1476.  
 
Synthesis of Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy]-5-methoxyphenyl}acrylate (193la) 
The general procedure D was followed using substrate 192l (98 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification 
by column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193la 
(95 mg, 65%) as a white solid.  
M. p.: 52–54 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.75 (d, J = 16.1 Hz, 1H), 7.06 (d, J = 2.9 Hz, 1H), 7.05 (d, J = 8.9 Hz, 1H), 
6.90 (dd, J = 8.9, 2.9 Hz, 1H), 6.38 (d, J = 16.1 Hz, 1H), 4.22 (q, J = 7.2 Hz, 2H), 3.79 (s, 3H), 3.14 (s, 3H), 
2.99 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.7 (Cq), 156.9 (Cq), 154.7 (Cq), 143.9 (Cq), 138.3 (CH), 127.9 (Cq), 
124.3 (CH), 119.9 (CH), 117.1 (CH), 111.1 (CH), 60.5 (CH2), 55.6 (CH3), 36.8 (CH3), 36.4 (CH3), 14.3 
(CH3).  
IR (ATR): ṽ = 2984, 1707, 1607, 1497, 1385, 1158, 1035, 855 cm–1.  
MS (EI) m/z (relative intensity) 293 (10) [M+], 205 (20), 176 (8), 72 (100).   
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Synthesis of Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy]-5-fluorophenyl}acrylate (193ma) 
The general procedure D was followed using substrate 192m (90 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193ma (84 
mg, 61 %) as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ  = 7.72 (dd, J = 16.1, 1.5 Hz, 1H), 7.25 (dd, J = 
9.1, 2.9 Hz, 1H), 7.12–6.99 (m, 2H), 6.37 (d, J = 16.1 Hz, 1H), 4.22 (q, J = 7.2 Hz, 2H), 3.13 (s, 3H), 2.99 
(s, 3H), 1.29 (t, J  = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.4 (Cq), 159.7 (d, 1JC-F = 248 Hz, Cq), 154.1 (Cq), 145.9 (d, 4JC-F = 3 Hz, 
Cq), 137.1 (d, 4JC-F = 2 Hz, CH), 128.8 (d, 3JC-F = 9 Hz, Cq), 124.8 (d, 3JC-F = 9 Hz, CH), 120.9 (CH), 117.6 (d, 
2JC-F = 25 Hz, CH), 113.0 (d, 2JC-F = 25 Hz, CH), 60.6 (CH2), 36.8 (CH3), 36.4 (CH3), 14.2 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –(116.6–116.7) (m).  
IR (neat): ṽ = 2938, 1709, 1637, 1483, 1385, 1145, 1033, 865, 751 cm–1.  
MS (EI) m/z (relative intensity) 281 (5) [M]+, 193 (8), 164 (5), 136 (5), 107 (5), 72 (100).   
HR-MS (EI): m/z calcd for C14H16FNO4+ [M]+ 281.1058, found 281.1073. 
 
Synthesis of Ethyl (E)-3-{5-Bromo-2-[(N,N-dimethylcarbamoyl)oxy]phenyl}acrylate (193na) 
The general procedure D was followed using substrate 192n (122 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193na (103 
mg, 60%) as a white solid.  
M. p.: 107–109 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.69 (d, J = 16.1 Hz, 1H), 7.69 (d, J = 2.4 Hz, 1H), 7.42 (dd, J = 8.7, 2.4 
Hz, 1H), 7.03 (d, J = 8.7 Hz, 1H), 6.38 (d, J = 16.1 Hz, 1H), 4.21 (q, J = 7.2 Hz, 2H), 3.11 (s, 3H), 2.97 (s, 
3H), 1.28 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.3 (Cq), 153.7 (Cq), 148.9 (Cq), 136.7 (CH), 133.5 (CH), 129.8 (CH), 
129.2 (Cq), 125.0 (CH), 120.9 (CH), 118.6 (Cq), 60.6 (CH2), 36.8 (CH3), 36.4 (CH3), 14.2 (CH3).  
IR (ATR): ṽ = 2932, 1699, 1474, 1384, 1215, 1107, 973, 855 cm–1.  
MS (EI) m/z (relative intensity) 343/341 (5/5) [M]+, 255/253 (15/15), 198/196 (5/5), 89 (6), 72 (100).   
HR-MS (EI): m/z calcd for C14H1679BrNO4+ [M]+ 341.0257, found 341.0265.   
 
Synthesis of Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy]-3,4-dimethylphenyl}acrylate (193oa)  
The general procedure D was followed using substrate 192o (97 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193oa 
(114 mg, 78%) as a white solid.  
The general procedure E was followed using substrate 192o (97 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193oa (64 mg, 44%) as a white solid.  
M. p.: 63–65 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.72 (d, J = 16.1 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.00 (d, J = 7.8 Hz, 1H), 
6.35 (d, J = 16.1 Hz, 1H), 4.21 (q, J = 7.2 Hz, 2H), 3.18 (s, 3H), 3.00 (s, 3H), 2.26 (s, 3H), 2.06 (s, 3H), 
1.29 (t, J = 7.2 Hz, 3H).  
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127.3 (CH), 125.4 (Cq), 123.9 (CH), 118.5 (CH), 60.2 (CH2), 36.8 (CH3), 36.4 (CH3), 20.2 (CH3), 14.2 
(CH3), 12.4 (CH3).  
IR (ATR): ṽ = 2926, 1704, 1631, 1453, 1313, 1156, 978, 862 cm–1.  
MS (EI) m/z (relative intensity) 291 (5) [M]+, 203 (15), 174 (5), 72 (100).   
HR-MS (EI): m/z calcd for C16H21NO4+ [M]+ 291.1465, found 291.1472. 
 
Synthesis of Ethyl (E)-3-{1-[(N,N-Dimethylcarbamoyl)oxy]naphthalen-2-yl}acrylate (193pa) 
The general procedure D was followed using [RuCl2(p-cymene)]2 (15.3 
mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %), substrate 192p (108 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification 
by column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193pa 
(119 mg, 76%) as a white solid.  
The general procedure E was followed using substrate 192p (108 mg, 0.50 mmol) and ethyl acrylate 
(15a) (100 mg, 1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 10/1→5/1) 
yielded 193pa (82 mg, 54%) as a white solid. 
M. p.: 86–88 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.98 (d, J = 16.1 Hz, 1H), 7.89–7.80 (m, 2H), 7.74–7.66 (m, 2H), 
7.56–7.48 (m, 2H), 6.54 (d, J = 16.1 Hz, 1H), 4.28 (q, J = 7.2 Hz, 2H), 3.35 (s, 3H), 3.09 (s, 3H), 1.35 (t, J 
= 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.9 (Cq), 154.3 (Cq), 146.7 (Cq), 138.1 (CH), 135.3 (Cq), 128.0 (CH), 
127.4 (CH), 127.1 (CH), 126.1 (CH), 124.0 (Cq), 124.0 (Cq), 122.8 (CH), 122.2 (CH), 119.9 (CH), 60.5 
(CH2), 37.0 (CH3), 36.7 (CH3), 14.3 (CH3).  
IR (ATR): ṽ = 2962, 1712, 1631, 1441, 1393, 1294, 1032, 872, 751 cm–1.  
MS (EI) m/z (relative intensity) 313 (5) [M]+, 225 (12), 196 (8), 168 (10), 139 (10), 72 (100).   
HR-MS (EI): m/z calcd for C18H19NO4+ [M]+ 313.1309, found 313.1317.  
 
Synthesis of Ethyl (E)-3-{1-[(N,N-Dimethylcarbamoyl)oxy]-4-methoxynaphthalen-2-yl} acrylate 
(193qa)  
The general procedure D was followed using [RuCl2(p-cymene)]2 (15.3 
mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %), substrate 192q (123 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification 
by column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193qa 
(116 mg, 68%) as a yellow solid.   
M. p.: 131–133 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.23–8.18 (m, 1H), 7.95 (d, J = 16.0 Hz, 1H), 7.80–7.75 (m, 1H), 
7.55–7.45 (m, 2H), 6.89 (s, 1H), 6.49 (d, J = 16.0 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 3.98 (s, 3H), 3.31 (s, 
3H), 3.06 (s, 3H), 1.34 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.8 (Cq), 154.6 (Cq), 153.2 (Cq), 140.7 (Cq), 138.4 (CH), 128.5 (Cq), 
127.5 (CH), 127.5 (Cq), 126.8 (CH), 123.5 (Cq), 122.4 (CH), 122.0 (CH), 119.3 (CH), 99.5 (CH), 60.5 
(CH2), 55.5 (CH3), 37.0 (CH3), 36.7 (CH3), 14.3 (CH3).  
IR (ATR): ṽ = 2937, 1717, 1702, 1633, 1511, 1446, 1288, 1088, 820 cm–1.  
MS (EI) m/z (relative intensity) 343 (10) [M]+, 255 (5), 226 (8), 198 (5), 183 (10), 72 (100).  


















Synthesis of Ethyl (E)-3-{4-Chloro-1-[(N,N-Dimethylcarbamoyl)oxy]naphthalen-2-yl}acrylate (193ra)  
The general procedure D was followed using [RuCl2(p-cymene)]2 (15.3 
mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %), substrate 192r (123 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification 
by column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193ra 
(128 mg, 75%) as a yellow solid.  
M. p.: 127–129 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.21 (d, J = 8.6 Hz, 1H), 7.87 (d, J = 16.0 Hz, 1H), 7.88–7.84 (m, 1H), 
7.77 (s, 1H), 7.65–7.54 (m, 2H), 6.50 (d, J = 16.0 Hz, 1H), 4.26 (q, J = 7.2 Hz, 2H), 3.33 (s, 3H), 3.06 (s, 
3H), 1.33 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ= 166.6 (Cq), 154.1 (Cq), 145.6 (Cq), 136.9 (CH), 132.2 (Cq), 129.9 (Cq), 
129.0 (Cq), 128.4 (CH), 127.8 (CH), 125.0 (CH), 124.4 (Cq), 122.9 (CH), 122.7 (CH), 120.7 (CH), 60.6 
(CH2), 37.0 (CH3), 36.7 (CH3), 14.3 (CH3).  
IR (ATR): ṽ = 2976, 1728, 1704, 1593, 1453, 1393, 1255, 1088, 754 cm–1.  
MS (EI) m/z (relative intensity) 349/347 (5) [M]+, 261/259 (2/5), 232/230 (2/5), 139 (10), 72 (100).  
HR-MS (EI): m/z calcd for C18H1835ClNO4+ [M]+ 347.0919, found 347.0920. 
 
Synthesis of Ethyl (E)-3-{3-[(N,N-Dimethylcarbamoyl)oxy]naphthalen-2-yl}acrylate (193sa) 
The general procedure D was followed using [RuCl2(p-cymene)]2 (15.3 
mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %), substrate 192s (108 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification 
by column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193sa 
(137 mg, 87%) as a white solid. 
The general procedure E was followed using substrate 192s (108 mg, 0.50 mmol) and ethyl acrylate 
(15a) (100 mg, 1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 10/1→5/1) 
yielded 193sa (78 mg, 50%) as a white solid. 
M. p.: 82–84 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.07 (s, 1H), 7.92 (d, J = 16.1 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.73 (d, 
J = 7.5 Hz, 1H), 7.60 (s, 1H), 7.49–7.38 (m, 2H), 6.57 (d, J = 16.1 Hz, 1H), 4.26 (q, J = 7.2 Hz, 2H), 3.19 (s, 
3H), 3.03 (s, 3H), 1.32 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.7 (Cq), 154.4 (Cq), 147.2 (Cq), 138.9 (CH), 134.4 (Cq), 130.9 (Cq), 
128.1 (CH), 128.0 (CH), 127.4 (CH), 127.3 (CH), 127.0 (Cq), 126.0 (CH), 120.2 (CH), 120.2 (CH), 60.4 
(CH2), 36.8 (CH3), 36.5 (CH3), 14.2 (CH3).  
IR (ATR): ṽ = 2987, 1711, 1638, 1440, 1270, 1157, 979, 860, 734 cm–1.  
MS (EI) m/z (relative intensity) 313 (10) [M]+, 225 (20), 196 (8), 168 (10), 139 (10), 72 (100).   
HR-MS (EI): m/z calcd for C18H19NO4+ [M]+ 313.1309, found 313.1318.  
 
Synthesis of Ethyl (E)-3-{6-Bromo-3-[(N,N-dimethylcarbamoyl)oxy]naphthalen-2-yl}acrylate (193ta)  
The general procedure D was followed using [RuCl2(p-cymene)]2 
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(147 mg, 0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193ta (143 mg, 73%) as a white solid.   
M. p.: 120–122 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.92 (s, 1H), 7.92 (s, 1H), 7.86 (d, J = 16.0 Hz, 1H), 7.59–7.53 (m, 2H), 
7.49 (d, J = 8.7 Hz, 1H), 6.52 (d, J = 16.0 Hz, 1H), 4.25 (q, J = 7.2 Hz, 2H), 3.18 (s, 3H), 3.03 (s, 3H), 1.32 
(t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.5 (Cq), 154.1 (Cq), 147.5 (Cq), 138.3 (CH), 132.7 (Cq), 131.9 (Cq), 
130.6 (CH), 130.0 (CH), 128.9 (CH), 128.0 (Cq), 126.8 (CH), 121.0 (CH), 120.2 (CH), 119.8 (Cq), 60.5 
(CH2), 36.9 (CH3), 36.5 (CH3), 14.2 (CH3).  
IR (ATR): ṽ = 2927, 1730, 1633, 1481, 1362, 1161, 1052, 884 cm–1.  
MS (EI) m/z (relative intensity) 393/391 (5/5) [M]+, 303 (10), 276/274 (5/5), 248/246 (8/8), 72 (100).  
HR-MS (EI): m/z calcd for C18H1879BrNO4+ [M]+ 391.0414, found 391.0411.  
 
Synthesis of Ethyl (E)-3-{3-[(N,N-Dimethylcarbamoyl)oxy]-[1,1'-biphenyl]-4-yl}acrylate (193ua) 
The general procedure D was followed using substrate 192u (121 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193ua 
(165 mg, 97%) as a white solid. 
The general procedure E was followed using substrate 192u (121 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 10/1→5/1) yielded 193ua (116 mg, 68%) as a white solid. 
M. p.: 110–112 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.85 (d, J = 16.0 Hz, 1H), 7.66 (d, J = 8.2 Hz, 1H), 7.60–7.56 (m, 2H), 
7.47–7.37 (m, 4H), 7.36–7.30 (m, 1H), 6.46 (d, J = 16.0 Hz, 1H), 4.25 (q, J = 7.2 Hz, 2H), 3.18 (s, 3H), 
3.03 (s, 3H), 1.32 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.8 (Cq), 154.2 (Cq), 150.4 (Cq), 144.0 (Cq), 139.3 (Cq), 137.9 (CH), 
128.8 (CH), 128.0 (CH), 127.6 (CH), 127.0 (CH), 126.0 (Cq), 124.3 (CH), 121.8 (CH), 119.4 (CH), 60.4 
(CH2), 36.8 (CH3), 36.5 (CH3), 14.2 (CH3).  
IR (ATR): ṽ = 2982, 1631, 1610, 1483, 1383, 1157, 893, 762 cm–1.  
MS (EI) m/z (relative intensity) 339 (5) [M]+, 251 (20), 194 (8), 165 (10),72 (100).  
HR-MS (EI): m/z calcd for C20H21NO4+ [M]+ 339.1465, found 339.1470. 
 
Synthesis of Ethyl (E)-3-{4-Bromo-2-[(N,N-dimethylcarbamoyl)oxy]phenyl}acrylate (193va) 
The general procedure D was followed using substrate 192v (122 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193va (101 
mg, 59%) as a white solid.  
M. p.: 68–70 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.71 (d, J = 16.1 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.35–7.28 (m, 2H), 
6.38 (d, J = 16.1 Hz, 1H), 4.20 (q, J = 7.2 Hz, 2H), 3.11 (s, 3H), 2.98 (s, 3H), 1.28 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.5 (Cq), 153.6 (Cq), 150.2 (Cq), 137.1 (CH), 128.9 (CH), 128.1 (CH), 
126.7 (CH), 126.3 (Cq), 123.9 (Cq), 120.1 (CH), 60.5 (CH2), 36.8 (CH3), 36.4 (CH3), 14.2 (CH3).   
IR (ATR): ṽ = 2939, 1713, 1636, 1590, 1370, 1146, 1032, 889, 815 cm–1.   
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HR-MS (EI): m/z calcd for C14H1679BrNO4+ [M]+ 341.0257, found 341.0278. 
 
 
Synthesis of Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy]-4-iodophenyl}acrylate (193wa) 
The general procedure D was followed using substrate 192w (146 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193wa (104 
mg, 53%) as a yellow solid.  
M. p.: 84–86 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.70 (d, J = 16.1 Hz, 1H), 7.53–7.49 (m, 2H), 7.28 (d, J = 8.9 Hz, 1H), 
6.40 (d, J = 16.1 Hz, 1H), 4.21 (q, J = 7.2 Hz, 2H), 3.11 (s, 3H), 2.99 (s, 3H), 1.29 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.5 (Cq), 153.7 (Cq), 149.9 (Cq), 137.3 (CH), 134.8 (CH), 132.5 (CH), 
128.2 (CH), 127.0 (Cq), 120.2 (CH), 95.5 (Cq), 60.5 (CH2), 36.8 (CH3), 36.5 (CH3), 14.2 (CH3).  
IR (ATR): ṽ = 2938, 1707, 1636, 1477, 1370, 1147, 1032, 868 cm–1.  
MS (EI) m/z (relative intensity) 389 (5) [M]+, 301 (20), 243 (5), 72 (100).   
HR-MS (EI): m/z calcd for C14H16INO4+ [M]+ 389.0119, found 389.0117. 
 
Synthesis of Ethyl (E)-3-{7-[(N,N-Dimethylcarbamoyl)oxy]-4-methyl-2-oxo-2H-chromen-8-yl}acrylate 
(193xa) 
The general procedure D was followed using [RuCl2(p-cymene)]2 
(15.3 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %), substrate 192x 
(117 mg, 0.47 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 
10/1→5/1) yielded 193xa (96 mg, 59%) as a yellow solid. 
M. p.: 201–203 °C.  
1H NMR (300 MHz, CDCl3): δ = 7.88 (d, J = 16.5 Hz, 1H), 7.58 (d, J = 
8.9 Hz, 1H), 7.16 (d, J = 8.9 Hz, 1H), 6.95 (d, J = 16.5 Hz, 1H), 6.27 (d, J = 1.2 Hz, 1H), 4.25 (q, J = 7.2 Hz, 
2H), 3.17 (s, 3H), 3.02 (s, 3H), 2.42 (d, J = 1.2 Hz, 3H), 1.32 (t, J = 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 167.3 (Cq), 159.7 (Cq), 153.4 (Cq), 152.7 (Cq), 152.6 (Cq), 152.2 (Cq), 
132.2 (CH), 125.5 (CH), 125.5 (CH), 119.3 (CH), 117.6 (Cq), 116.6 (Cq), 114.3 (CH), 60.7 (CH2), 37.0 
(CH3), 36.6 (CH3), 19.0 (CH3), 14.3 (CH3).  
IR (ATR): ṽ = 2980, 1726, 1703, 1629, 1382, 1296, 1152, 1032, 869 cm–1.  
MS (EI) m/z (relative intensity) 345 (5) [M]+, 257 (10), 228 (5), 172 (5), 72 (100), 43 (7).   
HR-MS (EI): m/z calcd for C18H19NO6+ [M]+ 345.1207, found 345.1208. 
 
Synthesis of Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy]-4,5-dimethylphenyl}acrylate (193ya)  
The general procedure D was followed using substrate 192y (97 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193ya 
(126 mg, 87%) as a white solid.  
M. p.: 86–88 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.75 (d, J = 16.1 Hz, 1H), 7.35 (s, 1H), 6.91 (s, 1H), 6.36 (d, J = 16.1 Hz, 
1H), 4.22 (q, J = 7.2 Hz, 2H), 3.14 (s, 3H), 3.00 (s, 3H), 2.23 (s, 3H), 2.22 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H).  
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128.0 (CH), 124.4 (Cq), 124.2 (CH), 118.4 (CH), 60.3 (CH2), 36.8 (CH3), 36.5 (CH3), 19.9 (CH3), 19.2 
(CH3), 14.3 (CH3).  
IR (ATR): ṽ = 2937, 1702, 1630, 1498, 1452, 1154, 1029, 991, 875 cm–1. 
MS (EI) m/z (relative intensity) 291 (5) [M]+, 203 (30), 174 (5), 146 (6), 72 (100).   
HR-MS (EI): m/z calcd for C16H21NO4+ [M]+ 291.1471, found 291.1482.  
The spectral data were in accordance with those reported in the literature.254 
 
Synthesis of Ethyl (E)-3-{5-[(N,N-Dimethylcarbamoyl)oxy]benzo[d][1,3]dioxol-4-yl}acrylate (193za)  
The general procedure D was followed using substrate 192z (105 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 193za 
(100 mg, 65%) as a white solid. 
The general procedure E was followed using substrate 192z (105 mg, 
0.50 mmol) and ethyl acrylate (15a) (100 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 10/1→5/1) yielded 193za (65 mg, 42%) as a white solid. 
M. p.: 115–117 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.59 (d, J = 16.1 Hz, 1H), 6.75 (d, J = 8.4 Hz, 1H), 6.73 (d, J = 16.1 Hz, 
1H), 6.57 (d, J = 8.4 Hz, 1H), 6.05 (s, 2H), 4.22 (q, J = 7.2 Hz, 2H), 3.13 (s, 3H), 2.98 (s, 3H), 1.29 (t, J = 
7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 167.3 (Cq), 154.7 (Cq), 147.0 (Cq), 145.2 (Cq), 144.2 (Cq), 133.4 (CH), 
122.7 (CH), 115.3 (CH), 112.3 (Cq), 108.9 (CH), 102.2 (CH2), 60.4 (CH2), 36.9 (CH3), 36.5 (CH3), 14.3 
(CH3).   
IR (ATR): ṽ = 2909, 1714, 1633, 1457, 1304, 1201, 1162, 977, 862 cm–1.  
MS (EI) m/z (relative intensity) 307 (5) [M]+, 219 (5), 190 (8), 72 (100), 43 (7).  
HR-MS (EI): m/z calcd for C15H17NO6+ [M]+ 307.1050, found 307.1059. 
 
Deprotection of Carbamate 193aa 
To a solution of the carbamate 193aa (170 mg, 0.61 mmol) in EtOH (5 mL) was added NaOH (245 mg, 
6.13 mmol). The reaction mixture was stirred at 80 °C for 15 h. At ambient temperature, EtOH was 
evaporated under reduced pressure, the residue was diluted with H2O (20 mL), and the excess of 
NaOH was neutralized at 0 °C using a solution of HCl (5 mL, 2 N). The aqueous solution was extracted 
with Et2O (3 × 20 mL), and the combined organic layers were washed with brine, dried over Na2SO4, 
and evaporated under reduced pressure. The crude product was washed with CH2Cl2 to afford 223 
(80 mg, 74%) as a yellow solid. 
 
Analytical Data for (E)-3-(2-Hydroxy-4-methylphenyl)acrylic acid (223)  
M. p.: 191–193 °C. 
1H NMR (300 MHz, d6-DMSO): δ = 12.04 (sbr, 1H), 10.00 (s, 1H), 7.78 (d, J 
= 16.1 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 6.71 (s, 1H), 6.65 (d, J = 8.0 Hz, 1H), 
6.43 (d, J = 16.1 Hz, 1H), 2.23 (s, 3H).  
13C NMR (75 MHz, DMSO): δ = 168.0 (Cq), 156.4 (Cq), 141.4 (Cq), 139.5 (CH), 128.5 (CH), 120.3 (CH), 
118.2 (Cq), 117.0 (CH), 116.4 (CH), 21.0 (CH3).  
IR (ATR): ṽ = 2925, 1660, 1601, 1421, 1298, 1259, 1205, 986, 854 cm–1.  
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HR-MS (EI): m/z calcd for C10H10O3+ [M]+ 178.0624, found 178.0634. 
 
 























DME, 110 °C, 24 h






A mixture of substrates 192l (195 mg, 1.00 mmol), 192a’ (233 mg, 1.00 mmol), ethyl acrylate (15a) 
(50 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %), AgSbF6 (17.2 mg, 10 mol %) and 
Cu(OAc)2·H2O (200 mg, 1.00 mmol) in DME (3.0 mL) was stirred at 110 °C for 24 h under an 
atmosphere of N2. At ambient temperature, EtOAc (15 mL) was added, and the mixture was filtered 
through a pad of silica gel. The solvents were removed in vacuo. Purification of the residue by column 
chromatography (n-hexane/EtOAc: 10/1) yielded 193la (119 mg, 81%) as a white solid and 193a’a (28 
mg, 17%) as a white solid. The spectral data of 193la were identical to those reported above. 
 
Analytical Data for Ethyl (E)-3-{2-[(N,N-Dimethylcarbamoyl)oxy]-5-(trifluoromethyl)phenyl}acrylate 
(193a’a) 
M. p.: 107–109 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.83 (d, J = 1.9 Hz, 1H), 7.80 (d, J = 16.3 
Hz, 1H), 7.59 (dd, J = 8.6 Hz, 1.9 Hz, 1H), 7.30 (d, J = 8.6 Hz, 1H), 6.48 (d, J 
= 16.3 Hz, 1H), 4.24 (q, J = 7.2 Hz, 2H), 3.15 (s, 3H), 3.01 (s, 3H), 1.30 (t, J 
= 7.2 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 166.3 (Cq), 153.5 (Cq), 152.3 (Cq), 136.8 (CH), 127.9 (q, 2JC-F = 33 Hz, Cq), 
127.9 (Cq), 127.5 (q, 3JC-F = 4 Hz, CH), 124.5 (q, 3JC-F = 4 Hz, CH), 124.0 (CH), 123.6 (q, 1JC-F = 272 Hz, Cq), 
121.6 (CH), 60.8 (CH2), 36.9 (CH3), 36.5 (CH3), 14.2 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = –62.5 (s).  
IR (ATR): ṽ = 2943, 1702, 1486, 1334, 1110, 1008, 858, 858 cm–1.  
MS (EI) m/z (relative intensity) 331 (5) [M]+, 243 (18), 186 (8), 72 (100).  











































DME, 110 °C, 24 h






A mixture of substrates 192f (195 mg, 1.00 mmol), 192h (233 mg, 1.00 mmol), ethyl acrylate (15a) (50 
mg, 0.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %), AgSbF6 (17.2 mg, 10 mol %) and 
Cu(OAc)2·H2O (200 mg, 1.00 mmol) in DME (3.0 mL) was stirred at 110 °C for 24 h under an 
atmosphere of N2. At ambient temperature, EtOAc (15 mL) was added, and the mixture was filtered 
through a pad of silica gel. The solvents were removed in vacuo. Purification of the residue by column 
chromatography (n-hexane/EtOAc: 10/1) yielded 193fa (81 mg, 55%) as a white solid and 193ha (21 
mg, 13%) as a colorless oil. Their spectral data were identical to those reported above. 
 






DME, 110 °C, 7 h

















[D5]-221b 15a [Dn]-222ba  
The general procedure D was followed using substrate [D5]-221b (99 mg, 0.50 mmol) and ethyl 
acrylate (15a) (100 mg, 1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 
10/1→5/1) yielded [Dn]-222ba (55 mg, 37%) as a colorless oil. 
 
7.3.6 Analytical Data for the Products of Ruthenium(II)-Catalyzed Isoquinoline Synthesis 
 
Synthesis of 9-Methyl-2,3-diphenyl-8,9-dihydro-7H-benzo[de]quinoline (176ba) 
The representative procedure F was followed using substrate 194b (88 mg, 0.50 
mmol) and diphenylacetylene (155a) (178 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 40/1) yielded 176ba (157 mg, 94%) as a yellow 
solid.  
M. p.: 145–147 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.51–7.46 (m, 2H), 7.45–7.28 (m, 7H), 7.25–7.12 (m, 4H), 3.54–3.41 (m, 
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13C NMR (75 MHz, C2D2Cl4, 100 °C): δ = 162.0 (Cq), 148.7 (Cq), 141.3 (Cq), 138.0 (Cq), 138.0 (Cq), 
136.2 (Cq), 131.2 (CH), 130.3 (CH), 129.3 (CH), 128.4 (Cq), 127.9 (CH), 127.0 (CH), 126.7 (CH), 126.4 
(CH), 124.3 (CH), 123.3 (CH), 123.0 (Cq), 37.4 (CH), 30.8 (CH2), 27.8 (CH2), 19.6 (CH3).  
IR (ATR): ṽ = 2929, 1604, 1577, 1442, 1377, 1306, 1178, 1071, 1023, 767, 699 cm–1.  
MS (EI) m/z (relative intensity) 335 (91) [M]+, 334 (100), 320 (50), 241 (8), 43 (13). 
HR-MS (EI): m/z calcd for C25H20N+ [M–H]+ 334.1590, found 334.1608. 
The spectral data were in accordance with those reported in the literature.255 
 
Synthesis of 3,4-Diphenyl-1-n-propylisoquinoline (176ca) 
The representative procedure F was followed using substrate 194c (82 mg, 0.50 
mmol) and diphenylacetylene (155a) (178 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 50/1) yielded 176ca (144 mg, 89%) as a yellow 
solid.  
M. p.: 118–120 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.23–8.14 (m, 1H), 7.64–7.56 (m, 1H), 7.54–7.45 (m, 2H), 7.37–7.22 (m, 
5H), 7.20–7.05 (m, 5H), 3.32 (t, J = 7.7 Hz, 2H), 1.95 (dt, J = 7.7, 7.3 Hz 2H), 1.08 (t, J = 7.3 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 161.3 (Cq), 149.3 (Cq), 141.1 (Cq), 137.8 (Cq), 136.3 (Cq), 131.4 (CH), 
130.3 (CH), 129.6 (CH), 128.9 (Cq), 128.2 (CH), 127.5 (CH), 127.5 (CH), 127.1 (CH), 126.9 (CH), 126.3 
(CH), 125.6 (Cq), 125.2 (CH), 37.7 (CH2), 23.2 (CH2), 14.5 (CH3).  
IR (ATR): ṽ = 3063, 2962, 1612, 1568, 1550, 1444, 1385, 1087, 1031, 757, 697 cm–1.  
MS (EI) m/z (relative intensity) 323 (22) [M]+, 295 (100), 308 (16), 252 (7).  
HR-MS (EI): m/z calcd for C24H20N+ [M–H]+ 322.1590, found 322.1607. 
 
Synthesis of 1-n-Butyl-3,4-diphenylisoquinoline (176da) 
The representative procedure F was followed using substrate 194d (89 mg, 0.50 
mmol) and diphenylacetylene (155a) (178 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 40/1) yielded 176da (151 mg, 89%) as a yellow 
solid.  
The representative procedure G was followed using substrate 194d (89 mg, 0.50 
mmol) and diphenylacetylene (155a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 40/1) yielded 176da (144 mg, 85%) as a yellow solid.  
M. p.: 78–80 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.27–8.21 (m, 1H), 7.69–7.64 (m, 1H), 7.60–7.54 (m, 2H), 7.40–7.31 (m, 
5H), 7.26–7.15 (m, 5H), 3.42 (t, J = 8.0 Hz, 2H), 2.02–1.90 (m, 2H), 1.58 (dt, J = 7.7, 7.3 Hz, 2H), 1.04 (t, 
J = 7.3 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 161.5 (Cq), 149.3 (Cq), 141.1 (Cq), 137.7 (Cq), 136.3 (Cq), 131.4 (CH), 
130.3 (CH), 129.6 (CH), 128.8 (Cq), 128.2 (CH), 127.5 (CH), 127.5 (CH), 127.0 (CH), 126.8 (CH), 126.3 
(CH), 125.4 (Cq), 125.2 (CH), 35.5 (CH2), 32.1 (CH2), 23.1 (CH2), 14.1 (CH3).  
IR (ATR): ṽ = 3061, 2958, 2876, 1611, 1504, 1442, 1382, 1337, 1172, 1073, 763, 697 cm–1.  
MS (EI) m/z (relative intensity) 337 (6) [M]+, 308 (10), 295 (100), 252 (6).  
HR-MS (EI): m/z calcd for C25H22N+ [M–H]+ 336.1747, found 336.1747.  
 
Synthesis of 1-Isopropyl-3,4-diphenylisoquinoline (176ea) 














- 153 - 
 
mmol), diphenylacetylene (155a) (178 mg, 1.00 mmol) and molecular sieves 4 Å (100 mg). 
Purification by column chromatography (n-hexane/EtOAc: 400/1) yielded 176ea (70 mg, 43%) as a 
yellow solid.  
M.p.: 140–142 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.32–8.24 (m, 1H), 7.68–7.62 (m, 1H), 7.58–7.51 (m, 2H), 7.47–7.39 
(m, 2H), 7.39–7.31 (m, 3H), 7.28–7.20 (m, 2H), 7.20–7.13 (m, 3H), 4.02 (dt, J = 6.7, 6.7 Hz, 1H), 1.52 
(d, J = 6.7 Hz, 6H). 
13C NMR (75 MHz, CDCl3): δ = 164.8 (Cq), 148.4 (Cq), 141.2 (Cq), 138.0 (Cq), 136.4 (Cq), 131.3 (CH), 
130.5 (CH), 129.3 (CH), 128.3 (Cq), 128.2 (CH), 127.3 (CH), 127.0 (CH), 126.8 (CH), 126.4 (CH), 126.2 
(CH), 124.69 (Cq), 124.43 (CH), 31.4 (CH), 22.34 (CH3). 
IR (ATR): ṽ = 3073, 2969, 1551, 1446, 1381, 1258, 1104, 1007, 866 cm–1. 
MS (EI) m/z (relative intensity) 322 (100) [M]+, 295 (86), 252 (13), 176 (8). 
HR-MS (EI): m/z calcd for C24H20N+ [M–H]+ 322.1590, found 322.1596.  
 
Synthesis of 1-Cyclopropyl-3,4-diphenylisoquinoline (176fa) 
The representative procedure F was followed using substrate 194f (81 mg, 0.50 
mmol), diphenylacetylene (155a) (178 mg, 1.00 mmol) and molecular sieves 4 Å 
(100 mg). Purification by column chromatography (n-hexane/EtOAc: 200/1) 
yielded 176fa (135 mg, 84%) as a yellow solid.  
M. p.: 148–150 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.50 (dd, J = 7.2, 2.0 Hz, 1H), 7.69–7.62 (m, 1H), 
7.62–7.51 (m, 2H), 7.42–7.27 (m, 5H), 7.27–7.21 (m, 2H), 7.20–7.08 (m, 3H), 2.89–2.74 (m, 1H), 
1.44–1.32 (m, 2H), 1.18–1.05 (m, 2H).  
13C NMR (75 MHz, CDCl3): δ = 160.6 (Cq), 148.7 (Cq), 141.2 (Cq), 138.0 (Cq), 136.1 (Cq), 131.4 (CH), 
130.4 (CH), 129.6 (CH), 128.2 (CH), 128.0 (Cq), 127.3 (CH), 127.0 (CH), 126.8 (CH), 126.3 (CH), 126.3 
(Cq), 126.2 (CH), 124.8 (CH), 13.6 (CH), 9.4 (CH2).  
IR (ATR): ṽ = 3055, 1611, 1568, 1547, 1444, 1410, 1318, 1261, 1075, 1014, 767, 694 cm–1.  
MS (EI) m/z (relative intensity) 321 (68) [M]+, 320 (100), 278 (5), 243 (8), 152 (5), 43 (13).  
HR-MS (EI): m/z calcd for C24H18N+ [M–H]+ 320.1434, found 320.1438.  
The spectral data were in accordance with those reported in the literature.256 
 
Synthesis of 1-Cyclohexyl-3,4-diphenylisoquinoline (176ga)  
The representative procedure F was followed using substrate 194g (102 mg, 0.50 
mmol), diphenylacetylene (155a) (178 mg, 1.00 mmol) and molecular sieves 4 Å 
(100 mg). Purification by column chromatography (n-hexane/EtOAc: 200/1) 
yielded 176ga (147 mg, 81%) as a yellow solid. 
M. p.: 158–160 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.31–8.25 (m, 1H), 7.68–7.62 (m, 1H), 7.58–7.49 
(m, 2H), 7.46–7.40 (m, 2H), 7.38–7.32 (m, 3H), 7.26–7.20 (m, 2H), 7.20–7.14 (m, 
2H), 3.68–3.57 (m, 1H), 2.12–1.75 (m, 7H), 1.64–1.31 (m, 3H).  
13C NMR (75 MHz, CDCl3): δ = 164.4 (Cq), 148.6 (Cq), 141.3 (Cq), 138.1 (Cq), 136.5 (Cq), 131.4 (CH), 
130.6 (CH), 129.3 (CH), 128.25 (CH), 128.23 (Cq), 127.4 (CH), 127.0 (CH), 126.8 (CH), 126.5 (CH), 126.2 
(CH), 124.7 (Cq), 124.5 (CH), 41.8 (CH), 32.5 (CH2), 26.9 (CH2), 26.3 (CH2).  
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MS (EI) m/z (relative intensity) 362 (50) [M]+, 334 (13), 308 (100), 295 (50), 280 (8), 43 (6).  
HR-MS (EI+): m/z calcd for C27H24N+ [M–H]+ 362.1903, found 362.1903.  
The spectral data were in accordance with those reported in the literature.256 
 
Synthesis of 1-Benzyl-3,4-diphenylisoquinoline (176ha) 
The representative procedure F was followed using substrate 194h (106 mg, 0.50 
mmol), diphenylacetylene (155a) (178 mg, 1.00 mmol) and molecular sieves 4 Å 
(100 mg). Purification by column chromatography (n-hexane/EtOAc: 100/1) 
yielded 176ha (100 mg, 54%) as a yellow solid. 
M. p.: 118–120 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.26–8,19 (m, 1H), 7.69–7.62 (m, 1H), 7.56–7.46 
(m, 2H), 7.46–7.39 (m, 4H), 7.39–7.14 (m, 11H), 4.79 (s, 2H).  
13C NMR (75 MHz, CDCl3): δ = 159.1 (Cq), 149.4 (Cq), 140.9 (Cq), 139.7 (Cq), 137.5 (Cq), 136.7 (Cq), 
131.3 (CH), 130.4 (CH), 129.7 (CH), 129.6 (Cq), 129.0 (Cq), 128.7 (CH), 128.4 (CH), 128.2 (CH), 127.6 
(CH), 127.2 (CH), 127.0 (CH), 126.6 (CH), 126.4 (CH), 126.2 (CH), 125.7 (CH), 42.4 (CH2).  
IR (ATR): ṽ = 3024, 1616, 1576, 1554, 1521, 1493, 1490, 1473, 1440, 1376, 1072, 754, 697 cm–1.  
MS (EI) m/z (relative intensity) 370 (100) [M]+, 293 (7), 265 (6), 91 (5), 43 (13).  
HR-MS (EI+): m/z calcd for C28H20N+ [M–H]+ 370.1590, found 370.1584.  
 
Synthesis of 6-Bromo-1-methyl-3,4-diphenylisoquinoline (176ia) 
The representative procedure F was followed using substrate 194i (107 mg, 
0.50 mmol), diphenylacetylene (155a) (178 mg, 1.00 mmol) and molecular 
sieves 4 Å (100 mg). Purification by column chromatography 
(n-hexane/EtOAc: 20/1) yielded 176ia (102 mg, 55%) as a yellow solid.  
M. p.: 193–195 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.06 (d, J = 8.9 Hz, 1H), 7.80 (d, J = 2.0 Hz, 1H), 7.67 (dd, J = 8.9, 2.0 Hz, 
1H), 7.39–7.30 (m, 5H), 7.23–7.14 (m, 5H), 3.06 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 157.6 (Cq), 150.5 (Cq), 140.5 (Cq), 137.3 (Cq), 136.7 (Cq), 131.2 (CH), 
130.0 (CH), 129.9 (CH), 128.3 (CH), 128.3 (CH), 128.2 (Cq), 127.6 (CH), 127.4 (CH), 127.2 (CH), 127.1 
(CH), 125.0 (Cq), 124.5 (Cq), 22.8 (CH3).  
IR (ATR): ṽ = 3064, 1597, 1561, 1481, 1445, 1386, 1329, 1259, 1071, 1029, 751, 697 cm–1.  
MS (EI) m/z (relative intensity) 375/373 (100/100) [M]+, 293 (26), 252 (28), 189 (15), 43 (56).  
HR-MS (ESI): m/z calcd for C22H1779BrN+ [M+H]+ 374.0539, found 374.0538.  
The spectral data were in accordance with those reported in the literature.257 
 
Synthesis of 1-Methyl-3,4-diphenyl-5H-pyrido[4,3-b]indole (176ja) 
The representative procedure F was followed using substrate 194j (87 mg, 0.50 
mmol) diphenylacetylene (155a) (178 mg, 1.00 mmol) and molecular sieves 4 Å 
(100 mg). Purification by column chromatography (n-hexane/EtOAc: 20/1) 
yielded 176ja (62 mg, 37%) as a yellow solid.  
M. p.: 182–184 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.47 (s, 1H), 8.18 (dd, J = 7.8, 1.0 Hz, 1H), 7.50–7.26 (m, 10H), 
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13C NMR (75 MHz, CDCl3): δ = 151.9 (Cq), 151.5 (Cq), 143.8 (Cq), 140.4 (Cq), 139.5 (Cq), 136.1 (Cq), 
130.3 (CH), 130.2 (CH), 129.0 (CH), 127.6 (CH), 127.4 (CH), 127.1 (CH), 126.0 (CH), 122.6 (Cq), 122.3 
(CH), 120.8 (CH), 116.9 (Cq), 116.82 (Cq), 110.81 (CH), 23.8 (CH3). 
IR (ATR): ṽ = 3640, 3050, 1594, 1492, 1405, 1234, 1118, 1020, 793 cm–1. 
MS (EI) m/z (relative intensity) 334 (30) [M]+, 291 (5), 167 (8), 77 (2). 
HR-MS (EI): m/z calcd for C24H19N2+ [M+H]+ 335.1543, found 335.1541. 
 
Synthesis of 1-Methyl-3,4-diphenylisoquinoline (176aa)  
The representative procedure G was followed using substrate 194a (68 mg, 0.50 
mmol) diphenylacetylene (155a) (178 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 176aa (96 mg, 65%) as a yellow 
solid.  
M. p.: 152–155 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.23–8.20 (m, 1H), 7.71–7.67 (m, 1H), 7.63–7.57 (m, 2H), 7.44–7.32 (m, 
5H), 7.29–7.17 (m, 5H), 3.11 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 157.7 (Cq), 149.4 (Cq), 141.0 (Cq), 137.6 (Cq), 136.0 (Cq), 131.4 (CH), 
130.2 (CH), 129.9 (CH), 129.1 (Cq), 128.1 (CH), 127.6 (CH), 127.1 (CH), 126.9 (CH), 126.5 (CH), 126.2 
(CH), 126.1 (Cq), 125.5 (CH), 22.7 (CH3).  
IR (ATR): ṽ = 3025, 1567, 1389, 1334, 1072, 1026, 765, 695, 612, 563, 496 cm–1.  
MS (EI) m/z (relative intensity) 295 (50) [M]+, 294 (100), 278 (5), 252 (17), 177 (15), 43 (14).  
HR-MS (EI): m/z calcd for C22H17N+ [M]+ 295.1356, found 295.1348.  
The spectral data were in accordance with those reported in the literature.255 
 
Synthesis of 1,6-Dimethyl-3,4-diphenylisoquinoline (176ka) 
The representative procedure G was followed using substrate 194k (75 mg, 
0.50 mmol) and diphenylacetylene (155a) (178 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1) yielded 176ka (124 mg, 80%) 
as a white solid.  
M. p.: 160–163 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.09 (d, J = 9.2 Hz, 1H), 7.44–7.39 (m, 2H), 7.39–7.30 (m, 5H), 
7.25–7.14 (m, 5H), 3.05 (s, 3H), 2.43 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 157.3 (Cq), 149.5 (Cq), 141.1 (Cq), 140.1 (Cq), 137.7 (Cq), 136.2 (Cq), 
131.4 (CH), 130.2 (CH), 128.7 (Cq), 128.6 (CH), 128.1 (CH), 127.5 (CH), 127.0 (CH), 126.8 (CH), 125.4 
(CH), 125.0 (CH), 124.5 (Cq), 22.6 (CH3), 22.1 (CH3).  
IR (ATR): ṽ = 3062, 1495, 1444, 1385, 1336, 1071, 1029, 813, 767, 755, 696, 614 cm–1.  
MS (EI) m/z (relative intensity) 309 (40) [M]+, 308 (100), 293 (5), 265 (5), 252 (12), 43 (4).  
HR-MS (ESI): m/z calcd for C23H20N+ [M+H]+ 310.1590, found 310.1592.  
The spectral data were in accordance with those reported in the literature.255 
 
Synthesis of 1-Ethyl-6-fluoro-3,4-diphenylisoquinoline (176la) 
The representative procedure G was followed using substrate 194l (83 mg, 0.50 
mmol) and diphenyl acetylene (155a) (178 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 15/1→12/1) yielded 176la (98 mg, 
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M. p.: 141–142 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.27 (dd, J = 9.2, 5.7 Hz, 1H), 7.45– 7.10 (m, 12H), 3.42 (q, J = 7.5 Hz, 
2H), 1.53 (t, J = 7.5 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 163.0 (d, 1JC–F = 245 Hz, Cq), 162.0 (Cq), 150.7 (Cq), 140.8 (Cq), 138.4 (d, 
3JC–F = 10 Hz, Cq), 137.3 (Cq), 131.2 (CH), 130.3 (CH), 128.7 (d, 4JC–F = 5 Hz, Cq), 128.4 (CH), 128.2 (d, 
3JC–F = 10 Hz, CH), 127.6 (CH), 127.3 (CH), 127.1 (CH), 122.5 (d, 4JC–F = 1 Hz, Cq), 116.6 (d, 2JC–F = 25 Hz, 
CH), 110.0 (d, 2JC–F = 22 Hz, CH), 28.9 (CH2), 13.9 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –107.9 (s).  
IR (ATR): ṽ = 2973, 1619, 1573, 1447, 1386, 1182, 1072, 876, 788, 753, 697 cm–1.  
MS (EI) m/z (relative intensity) 327 (53) [M]+, 326 (100), 311 (12), 298 (10), 98 (10), 57 (10). 
HR-MS (ESI): m/z calcd for C23H19FN+ [M+H]+ 328.1496, found 328.1498. 
 
Synthesis of 6-(Trifluoromethyl)-1-methyl-3,4-diphenylisoquinoline (176ma) 
The representative procedure G was followed using substrate 194m (102 mg, 
0.50 mmol) and diphenylacetylene (155a) (178 mg, 1.00 mmol). Purification 
by column chromatography (n-hexane/EtOAc: 12/1) yielded 176ma (86 mg, 
47%) as an orange solid.  
M. p.: 109–114 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.31 (d, J = 8.8 Hz, 1H), 7.96 (d, J = 1.8 Hz, 1H), 
7.75 (dd, J = 8.8, 1.8 Hz, 1H), 7.40–7.33 (m, 5H), 7.23–7.16 (m, 5H), 3.10 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 157.8 (Cq), 150.9 (Cq), 140.4 (Cq), 136.5 (Cq), 135.4 (Cq), 131.5 (q, 2JC–F 
= 32 Hz, Cq), 131.2 (CH), 130.2 (CH), 129.7 (Cq), 128.5 (CH), 127.7 (CH), 127.6 (CH), 127.3 (CH), 127.0 
(Cq), 126.8 (CH), 123.9 (q, 3JC–F = 5 Hz, CH), 123.8 (d, 1JC–F = 272 Hz, Cq), 122.2 (q, 3JC–F = 3 Hz, CH), 
22.8 (CH3).  
19F NMR (282 MHz, CDCl3): δ = –62.9 (s).  
IR (ATR): ṽ = 2958, 1555, 1336, 1305, 1257, 1176, 1155, 1134, 1082, 909, 769, 696, 618 cm–1.  
MS (EI) m/z (relative intensity) 363 (50) [M]+, 362 (100), 252 (8), 146 (5), 43 (5).  
HR-MS (EI): m/z calcd for C23H16F3N+ [M]+ 363.1229, found 363.1219.  
The spectral data were in accordance with those reported in the literature.257 
 
Synthesis of 5,6-(Methylenedioxy)-1-methyl-3,4-diphenylisoquinoline (176na) 
The representative procedure G was followed using substrate 194n (90 mg, 
0.50 mmol) and diphenylacetylene (155a) (178 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 10/1) yielded 176na (146 mg, 86%) 
as a white solid.  
M. p.: 251–254 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.82 (d, J = 8.8 Hz, 1H), 7.37–7.06 (m, 11H), 5.83 (s, 2H), 2.99 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 157.7 (Cq), 150.2 (Cq), 147.6 (Cq), 141.7 (Cq), 140.8 (Cq), 138.4 (Cq), 
131.1 (CH), 130.2 (CH), 127.5 (CH), 127.0 (CH), 126.8 (CH), 126.7 (CH), 124.8 (Cq), 123.2 (Cq), 122.5 
(Cq), 120.9 (CH), 110.8 (CH), 101.4 (CH2), 23.4 (CH3).  
IR (ATR): ṽ = 2899, 1626, 1549, 1512, 1432, 1383, 1353, 1279, 1209, 1119, 1049, 794 cm–1.  
MS (EI) m/z (relative intensity) 339 (100) [M]+, 338 (98), 310 (18), 292 (14), 176 (5).  




















Synthesis of 1,7-Dimethyl-3,4-diphenylisoquinoline (176oa) 
The representative procedure G was followed using substrate 194o (75 mg, 0.50 
mmol) and diphenylacetylene (155a) (178 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 12/1) yielded 176oa (119 mg, 77%) as a pale 
orange solid. 
M. p.: 134–139 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.96 (dq, J = 1.8, 0.9 Hz, 1H), 7.57 (d, J = 8.6 Hz, 1H), 
7.45–7.30 (m, 6H), 7.26–7.14 (m, 5H), 3.06 (s, 3H), 2.57 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 156.9 (Cq), 148.6 (Cq), 141.0 (Cq), 137.7 (Cq), 136.3 (Cq), 134.1 (Cq), 
132.0 (CH), 131.3 (CH), 130.2 (CH), 129.0 (Cq), 128.1 (CH), 127.5 (CH), 127.0 (CH), 126.7 (CH), 126.2 
(Cq), 126.0 (CH), 124.4 (CH), 22.7 (CH3), 21.8 (CH3).  
IR (ATR): ṽ = 3023, 2914, 1551, 1504, 1442, 1386, 1321, 1073, 1027, 831 cm–1.  
MS (EI) m/z (relative intensity) 309 (65) [M]+, 293 (8), 265 (5), 252 (15), 146 (5), 100 (100). 
HR-MS (ESI): m/z calcd for C23H20N+ [M+H]+ 310.1590, found 310.1592.  
The spectral data were in accordance with those reported in the literature.258  
 
Synthesis of 1-Methyl-3,4-di-n-propylisoquinoline (176ad)  
The representative procedure G was followed using substrate 194a (68 mg, 0.50 
mmol) and oct-4-yne (155d) (110 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 12/1) yielded 176ad (87 mg, 77%) as a yellow 
oil.  
1H NMR (300 MHz, CDCl3): δ = 8.06 (dd, J = 8.5, 0.8 Hz, 1H), 7.94 (dd, J = 8.5, 0.8 
Hz, 1H), 7.3 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.47 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 3.01–2.92 (m, 2H), 
2.92–2.84 (m, 2H), 2.89 (s, 3H), 1.84–1.72 (m, 2H), 1.71–1.58 (m, 2H), 1.07 (t, J = 6.7 Hz, 3H), 1.03 (t, J 
= 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 155.6 (Cq), 151.7 (Cq), 135.4 (Cq), 129.3 (CH), 126.1 (Cq), 126.1 (CH), 
126.0 (Cq), 125.2 (CH), 123.5 (CH), 37.4 (CH2), 29.8 (CH2), 24.2 (CH2), 23.8 (CH2), 22.4 (CH3), 14.6 
(CH3), 14.4 (CH3).  
IR (neat): ṽ = 2957, 2870, 1617, 1568, 1454, 1391, 1333, 1027, 754, 614 cm–1.  
MS (EI) m/z (relative intensity) 227 (40) [M]+, 212 (80), 198 (100), 184 (50), 171 (55), 128 (23), 115 
(16). 
HR-MS (EI): m/z calcd for C16H21N+ [M]+ 227.1669, found 227.1674.  
The spectral data were in accordance with those reported in the literature.255  
 
Synthesis of 4-n-Butyl-3-(4-methoxyphenyl)-1-methylisoquinoline (176ae) 
The representative procedure G was followed using substrate 194a (68 mg, 0.50 
mmol) and 1-(p-tolyl)-1-hexyne (155e) (172 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 12/1) yielded 176ae (70 mg, 46%) as 
an orange oil.  
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Hz, 1H), 7.70 (ddd, J = 8.3, 6.8, 1.3 Hz, 1H), 7.56 (ddd, J = 8.3, 6.8, 1.2 Hz, 1H), 7.39 (d, J = 8.1 Hz, 2H), 
7.25 (d, J = 8.1 Hz, 2H), 3.03–2.91 (m, 2H), 2.95 (s, 3H), 2.41 (s, 3H), 1.70–1.56 (m, 2H), 1.34 (dt, J = 
7.3, 7.3 Hz, 2H), 0.86 (t, J = 7.3 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 155.6 (Cq), 150.9 (Cq), 139.0 (Cq), 136.9 (Cq), 135.4 (Cq), 129.6 (CH), 
129.1 (CH), 128.7 (CH), 127.2 (Cq), 126.5 (Cq), 126.2 (CH), 126.0 (CH), 124.2 (CH), 33.4 (CH2), 28.3 
(CH2), 23.0 (CH2), 22.5 (CH3), 21.2 (CH3), 13.8 (CH3).  
IR (neat): ṽ = 2955, 2923, 2869, 1614, 1563, 1513, 1438, 1391, 1333, 1026, 825, 755 cm–1.  
MS (EI) m/z (relative intensity) 289 (50) [M]+, 260 (70), 246 (100), 231 (30), 216 (8). 
HR-MS (EI): m/z calcd for C21H23NO+ [M]+ 305.1774, found 305.1771. 
 
Synthesis of 4-(4-Chloro-n-butyl)-1-methyl-3-phenylisoquinoline (176af) 
The representative procedure G was followed using substrate 194a (68 
mg, 0.50 mmol) and 6-chloro-1-phenylhexyne (155f) (193 mg, 1.00 
mmol). Purification by column chromatography (n-hexane/EtOAc: 12/1) 
yielded 176af (112 mg, 72%) as a yellow oil.  
1H NMR (300 MHz, CDCl3): δ = 8.16 (ddd, J = 8.4, 1.3, 0.8 Hz, 1H), 8.04 
(dd, J = 8.4, 0.8 Hz, 1H), 7.73 (ddd, J = 8.4, 6.9, 1.3 Hz, 1H), 7.59 (ddd, J = 8.4, 6.9, 1.3 Hz, 1H), 
7.53–7.34 (m, 5H), 3.42 (t, J = 6.2 Hz, 2H), 3.03–2.95 (m, 2H), 2.97 (s, 3H), 1.86–1.68 (m, 4H).  
13C NMR (75 MHz, CDCl3): δ = 156.1 (Cq), 151.1 (Cq), 141.6 (Cq), 135.2 (Cq), 129.9 (CH), 129.2 (CH), 
128.2 (CH), 127.5 (CH), 126.6 (Cq), 126.4 (Cq), 126.3 (CH), 126.2 (CH), 124.0 (CH), 44.4 (CH2), 32.3 
(CH2), 28.1 (CH2), 27.5 (CH2), 22.5 (CH3).  
IR (neat): ṽ = 2953, 1614, 1561, 1504, 1437, 1391, 1331, 1027, 756 cm–1.  
MS (EI) m/z (relative intensity) 311/309 (14/41) [M]+, 246 (95), 232 (100), 217 (16), 202 (6), 189 (6). 
HR-MS (EI): m/z calcd for C20H2035ClN+ [M]+ 309.1279, found 309.1297. 
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AMLA ambiphilic metal-ligand activation 
aq. aqueous 
Ar aryl 
APT attached proton test 
atm atmospheric pressure 


















δ chemical shift 
d doublet 
DCE 1,2-dichloroethane 
dd doublet of doublet 
DFT density functional theory 





DMSO dimethyl sulfoxide 
DMPU 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
DoM directed ortho metalation 
dppbz 1,2-bis(diphenylphosphino)benzene 
List of Abbreviations 





dt doublet of triplet 
E electrophile 
Ed. edition 
EI electron ionization 
equiv equivalent 
ESI electronspray ionization 
Et ethyl 
FG functional group 
g gram 






HPLC high performance liquid chromatography 
HR-MS high resolution mass spectrometry 
Hz Hertz 
i iso 
IES internal electrophilic substitution 
Ile isoleucine 
IR infrared spectroscopy 
J coupling constant 














M. p. melting point 
MPAA monoprotected amino acid 
MPV membrane pump vacuum 
MS mass spectrometry 
List of Abbreviations 
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m/z mass-to-charge ratio 
n normal 
NHC N-heterocyclic carbene 
NMP N-methylpyrrolidinone 











ppm parts per million 
Pr propyl 
Py pyridyl 











Ar electrophilic aromatic substitution 
SET single electron transfer 
SPO secondary phosphine oxides 






TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography 
TMP trimethoxyphenyl 
TM transition metal 
TMS trimethylsilyl 
Ts para-toluenesulfonyl 
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TS transition state 
ṽ absorption 
Val valin 
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